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Abstract 
The South African ostrich industry is under enormous threats due to diseases contracted by the ostriches.  H5N2 
virus (avian influenza) outbreaks the past two years have resulted in thousands of ostriches having to be culled.  
However, the more silent respiratory infectious agents of ostriches are the three ostrich-specific mycoplasmas.  
Named Ms01, Ms02, and Ms03, these three mycoplasmas are responsible for dramatic production losses each 
year, due to their intrusive nature and the fact that no vaccines are currently available to prevent mycoplasma 
infections in ostriches.  The use of antibiotics does not eradicate the disease completely, but only alleviates 
symptoms.  The ostrich industry commissioned investigations into the development of three specific vaccines 
using the relatively novel approach of DNA vaccination. 
The concept of DNA vaccine development is based on the availability of complete genome sequences of the 
pathogen against which the vaccine is to be developed.  This is necessary in order to identify vaccine candidate 
genes through comparative genomic studies.  The Ms02 genome has previously been sequenced, resulting in 
28 large contiguous sequences.  This thesis used the technique of Thermal Asymmetric Interlaced Polymerase 
Chain Reaction (TAIL-PCR) to attempt assembly of these 28 contiguous sequences.  The number was reduced 
to 14 large contiguous sequences, which were then subjected to repetitive sequence analysis and open reading 
frame analysis. Bioinformatic software was also used to predict the origin of replication.  The extent of repeats in 
the Ms02 genome is illustrated, as well as the problems with genome assembly when dealing with repetitive-rich 
and A+T-rich genomes as those of mycoplasmas. 
Previous studies determined the mycoplasma oppA gene to be a good vaccine candidate gene, due to its 
cytadherent properties.  This thesis describes the development of three DNA vaccines containing the Ms02 
oppA gene, and a preliminary attempt to prove expression of one of these vaccines in a cell culture-based 
system.  The DNA vaccine vectors pCI-neo, VR1012, and VR1020 were chosen for the vaccine development.  
The Ms02 oppA gene was also cloned into the prokaryotic expression vector pGEX-4T-1 in order to express the 
OppA protein for purification.  The purified protein may be used in future serological tests in ostrich vaccination 
trials.  In this study the protein was used to elicit anti-OppA rabbit antibodies, which were used to attempt 
detection of the pCI-neo-driven OppA protein expression in an MDA cell line in a transfection study.  However, 
preliminary findings could not detect expression, but did indicate that the currently used colorimetric western blot 
technique may not be sensitive enough.  It is suggested that different cell lines need to be investigated.  Further 
optimisations are also required to decrease the observed non-specific binding.  
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Opsomming 
Die Suid-Afrikaanse volstruisbedryf is onder geweldige druk vanweë siektes wat die volstruise bedreig.  Die 
epidemie van die H5N2 virus (voëlgriep) in die afgelope twee jaar het veroorsaak dat duisende volstruise van 
kant gemaak moes word.  Daar is egter nog ‘n bedreiging wat tot geweldige produksie verliese lei elke jaar: die 
respiratoriese infeksies wat versoorsaak word deur die drie volstruis mikoplasmas, genoem Ms01, Ms02 en 
Ms03.  Geen entstowwe is tans beskibaar om die infeksies te voorkom nie, en behandeling met behulp van 
antibiotikas is nie effektief in die genesing van infeksie nie, maar help net om die simptome te verlig.  Weens die 
erns van die saak, het die Suid-Afrikaanse volstruisbedryf ‘n ondersoek geloods na die ontwikkeling van 
enstowwe teen elkeen van die drie volstruis mikoplasmas.  Die relatiewe nuwe benadering van DNA-entstof 
ontwikkeling was die strategiese keuse. 
Die beginsel van DNA-entstof ontwikkeling berus op die beskikbaarheid van die genoomvolgordes van die 
siekte-veroorsakende organisme waarteen die enstof ontwikkel word.  Geskikte kandidaat entstof gene word so 
opgespoor met behulp van vergelykende studies met ander beskikbare genome.  Die Ms02 genoomvolgorde is 
voorheen bepaal en word verteenwoordig deur 28 groot geenvolgorde fragmente.  Die tegniek van Thermal 
Asymmetric Interlaced Polymerase Chain Reaction (TAIL-PCR) is gebruik om van die 28 fragmente aan mekaar 
te las.  Die aantal fragmente is verminder na 14 groot geenvolgorde fragmente, wat vervolgens gebruik was om 
die omvang van herhalende volgordes in die genoom te bepaal, om nuwe leesrame te ondersoek, asook om die 
oorsprong van DNA replikasie op te spoor met behulp van bioinformatika sagteware.  Die omvang van die 
herhalende aard van die Ms02 genoom word geïllustreer, asook die gepaardgaande probleme met die las van 
geenvolgorde fragmente wanneer met genome van veelvuldige herhalende volgordes, wat boonop A+T-ryk is, 
gewerk word, soos die van mikoplasmas. 
Vorige studies het die mikoplasma oppA geen geïdentifiseer as ‘n geskikte kandidaat entstof geen as gevolg van 
sy selaanhegting-eienskappe.  Hierdie studie behels die invoeging van die Ms02 oppA geen in drie DNA-enstof 
vektore, naamlik pCI-neo, VR1012, en VR1020, asook die voorlopige poging om bewys van uitdrukking van een 
van die entstowwe in ‘n selkultuursisteem te bewerkstellig.  Die geen is ook gekloneer in die prokariotiese 
ekspressie vektor pGEX-4T-1, ten einde die Ms02 OppA proteïen te isoleer.  Die geïsoleerde proteïen kan in 
serologiese toetse in toekomstige volstruis enstof proewe gebruik word.  In hierdie studie is die proteïen gebruik 
om konyn teenliggame teen dit op te wek, wat dan gebruik was om vir die pCI-neo-gedrewe ekspressie van die 
oppA geen te toets in ‘n selkultuur omgewing deur ‘n MDA sellyn te transfekteer.  Die voorlopige resultate toon 
nie ekspressie van die OppA proteïen aan nie, maar het wel uitgelig dat die western blot tegniek wat tans 
gebruik word, dalk nie sensitief genoeg is nie.  Dit kan belowend wees om ander tipes selle te toets.  Verdere 
optimisering is ook nodig om die nie-spesifieke binding wat waargeneem is, te verlaag. 
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Chapter 1 
1.1. INTRODUCTION 
Commercial ostrich farming in South Africa started in the 1850s when pioneering farmers in the Oudtshoorn 
district saw the economic potential in farming for ostrich feathers.  Up until the early 20th century, horse-drawn 
carriages enabled elaborate feather hats to be fashionable and were a sign of the wealthy and elite.  The feather 
industry came to a halt with the mass production of automobiles, the roof making the wearing of feather hats 
impractical.  Soon afterwards, the start of World War I led to the collapse of the feather industry. 
In the 1950s the Oudtshoorn farmers started to rebuild ostrich farming.  Increasing demand for ostrich meat led 
to the first abattoir being erected in the mid-1960s.  After that, the industry boomed with demand for fresh and 
dried ostrich meat locally, as well as demand for ostrich leather internationally, especially in the USA.  Years 
later South Africa is still considered the leader in the ostrich industry, although there are ostrich farms in the USA 
and Australia as well. 
In modern day society, where people are becoming increasingly aware of their health and the nutrient contents 
of their food, ostrich meat has received attention: it tasting similar to lean beef and being regarded as the 
healthiest red meat, with almost no fat, low cholesterol, and high in calcium, protein and iron (Canadian Ostrich 
Association, 2008).  Total ostrich export revenue for 2005 amounted to R1.2 billion, with the Western Cape 
contributing 75% of total ostrich production (SAOBC, 2010).  Furthermore, the industry provides work 
opportunities in rural areas for unskilled workers, amounting to 20 000 jobs (South African Ostrich Industry, 
2004).  Being one of the top agricultural industries in South Africa, the ostrich industry not only has local socio-
economic benefits, but draws international acclaim as well. 
1.2. THREATS TO THE SOUTH AFRICAN OSTRICH INDUSTRY  
Almost all ostrich products are exported, including meat, leather, fertile eggs and even live ostriches (Verwoerd, 
2000). This places a tremendous strain on the industry in terms of quality and disease control, especially for 
export into the European Union (EU), which imports 90% of SA ostrich meat.  This brings to mind the ban in 
August 2004 when the EU banned the import of South African live ostriches, meat and ostrich eggs due to an 
outbreak of avian influenza.  The ban resulted in millions of rands of loss for the industry and was lifted only a 
year later.  The possibility of disease outbreak and resulting trade limitations and quarantine could cripple the 
socio-economic ostrich environment.  In recent times, another outbreak of avian influenza is the biggest threat 
yet to the ostrich industry.  More than 50 000 ostriches have been culled during the last outbreak, and more than 
R60 million has been spent to combat the spread of the virus (Die Burger, 6-9-2012).  Contaminated meat can 
be made safe for human consumption, by heating for only 3 sec at 70°C.  However, the ‘precooked’ meat is not 
as popular and commands only a fraction of the price of raw meat.  In addition to the pressure of avian influenza, 
mycoplasmas cause respiratory diseases in feedlot ostriches and can result in production loss of up to 30% 
(Dr A. Olivier, in personal communication with B. Pretorius, 2009).  The South African Ostrich Industry is as a 
result almost on the brink of collapse. 
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1.3. OSTRICH MYCOPLASMA INFECTION  
There are three mycoplasmas that only infect ostriches.  Infection causes loss in production, downgrading of the 
meat, as well as susceptibility to secondary infections.  The pressure of feedlot farming creates an ideal 
environment for these opportunistic bacteria to infect the ostriches.  Ostriches are especially in danger with 
seasonal changes, when placed under stress when moved or transported, and due to poor hygiene practices.  
Although certain antibiotics mitigate the symptoms of infection, they do not eradicate the infection completely.  
This, together with the fact that there is currently no methods available to prevent infection, impress upon the 
need for vaccine development.  The South African ostrich industry commissioned an investigation into the 
development of vaccines against ostrich mycoplasmas.  A previous study determined that a species-specific 
approach is needed, since existing poultry vaccines do not provide adequate protection.  Thus far a DNA 
vaccine against the ostrich mycoplasma Ms01 was developed (Pretorius, 2009) and tested (Brandt, 2012). 
A similar approach was employed to develop an Ms02 DNA vaccine.  The gene encoding the antigenic OppA 
protein was identified as a candidate gene for DNA vaccine development.  The gene was cloned and modified to 
enable subcloning and expression in the relevant DNA vaccine vectors (Steenmans, 2010). 
1.4. OBJECTIVES OF THE STUDY  
This study focused firstly on filling in the gaps of the previously sequenced Ms02 genome.  In the second part, 
the modified oppA gene was cloned into suitable vectors for protein expression and vaccine development.  This 
is to fulfil the objectives of the study, which are: 
i. To assemble partially the contiguous sequences generated from previous Ms02 genome sequencing 
and to subject the assembled sequence to bioinformatic analysis. 
ii. To subclone the gene into a suitable prokaryotic expression vector in order to express and purify the 
OppA protein to be used as antigen in serological tests. 
iii. To subclone the gene into three different DNA vaccine vectors and test the efficacy of the DNA vaccine 
by evaluating its expression in a eukaryotic cell system. 
To aid in understanding mycoplasmas, Chapter 2 starts with a discussion on the history of mycoplasmas: their 
origin, classification, biochemistry and genomic details.  The second part of Chapter 2 is devoted to the rise and 
development of vaccines, with the focus on DNA vaccines as a next-generation vaccine.  The method of 
Thermal Asymmetric Interlaced Polymerase Chain Reaction (TAIL-PCR) and its use in assembling the 
contiguous sequences (contigs) of the Ms02 genome, followed by bioinformatic analysis of the assembled 
sequence, are discussed in Chapter 3.  The subsequent chapters focus on the DNA vaccine development.  
Firstly, in Chapter 4, cloning of the oppA gene into three suitable DNA vaccine vectors, cloning and expression 
of the gene in a prokaryotic expression vector, as well as antibody production, are discussed.  Thereafter, the 
use and efficacy of one DNA vaccine vector is examined in Chapter 5 to determine if eukaryotic cells will 
transcribe the plasmid in vivo in a tissue culture study.  Chapter 6 covers the possibilities of further research, 
based on the study’s conclusions.  Lastly, a reference list and relevant addenda are attached. 
Stellenbosch University  http://scholar.sun.ac.za
3 
 
Chapter 2 
2.   
In this literature review, an overview of mycoplasmas will be given, including origin, phylogeny, genome features, 
biochemistry and pathogenicity of these organisms.  Ostrich mycoplasmas will be discussed as an integrated 
theme throughout the general discussion on mycoplasmas.  The next section will include a general discussion of 
vaccines, with the focus on DNA vaccine development and strategies.   
2.1. MYCOPLASMAS: FEATURES, METABOLISM AND PATHOGENICITY 
2.1.1. INTRODUCTION 
The name mycoplasma was first coined by Albert Bernhard Frank in 1889, from the Greek mykes (fungus) and 
plasma (formed), due to fungus-like characteristics (Krass and Gardner, 1973).  Later it was discovered that only 
M. mycoides exhibits fungus-like growth.  Since the first successful cultivation in 1898 by Nocord and Roux, 
mycoplasmas have been mostly misunderstood.  Due to their small size, mycoplasmas are able to pass through 
bacteria-retaining filters and were thus thought to be viruses.  In the 1930s the belief arose that mycoplasmas 
are stable L-phase variants of common bacteria.  Genomic analysis in the 1960s and 70s, together with 
advancements in the knowledge of cell structure, genome, and metabolic pathways of mycoplasmas, finally led 
to the current paradigm where mycoplasmas are known to be cell wall-less descendants of Gram-positive 
bacteria. 
Today mycoplasmas are known to be the smallest cellular organisms capable of self-reproduction (Razin, 1987).  
Their lack of a cell wall and lack of many metabolic pathways render mycoplasmas dependent on a host for their 
required nutrients and protection.  Mycoplasmas have been isolated from hosts such as humans, other 
mammals, reptiles, fish, arthropods, and plants, where they cause diseases such as contagious bovine and 
caprine pleuropneumonia in cattle, contagious agalactia in small ruminants, calf pneumonia, enzootic 
pneumonia in pigs, and chronic respiratory diseases in poultry.  Three mycoplasmas specific to ostriches have 
been associated with respiratory diseases in the South African ostrich.  The economic impact of this disease is 
considerable, as respiratory diseases in ostriches have many direct and indirect effects.  Significant production 
losses are caused by the cost of treatment, wearing down of ostriches, downgrading of carcasses and the 
ostriches’ increased susceptibility to opportunistic infections.  Mortality may even occur.  This has far-reaching 
socio-economic implications, since ostrich farming is a significant contributor to agricultural exports and provider 
of job opportunities. 
Despite the severity of the situation in general, with regards to all hosts, few vaccines are available to combat the 
illnesses: mostly whole-cell vaccines, some semi-virulent, that only provide partial immunity and can have 
negative side effects.  Attempts at vaccine development and improvement often lead to exacerbation of 
diseases.  It is becoming even more pertinent to develop reliable vaccines, because antibiotics only control 
mycoplasma infections partially, and their efficacy is decreasing.  In addition to the problems associated with 
vaccine development, the antibodies generated against either ostrich mycoplasma proteins show little or no 
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cross-reactivity with the other ostrich mycoplasma proteins, emphasising the urgent need to develop 
mycoplasma-specific vaccines. 
2.1.2. MYCOPLASMA IDENTIFICATION AND CLASSIFICATION 
2.1.2.1. Taxonomy 
The mycoplasma’s most distinguishing feature is its lack of a cell wall (Razin, 1985).  Mycoplasmas evolved by 
degenerate evolution from low G+C, Gram-positive bacteria, although they stain negative in the Gram test 
(Herrmann, 1992).  In the process they lost the genes encoding for a cell wall and many other metabolic 
processes (Bradbury, 2005; Razin et al., 1998; Weisburg et al., 1989).  Their lack of a cell wall classifies 
mycoplasmas into a distinct class of prokaryotes, the Mollicutes (Latin mollis, soft; cutes, skin), the only class 
within the division Tenericutes (wall-less bacteria) of the kingdom Procaryotae (Freundt, 1973).  Three other 
divisions in the Kingdom exist, namely the Gram-positive bacteria Firmicutes, the Gram-negative bacteria 
Gracilicutes and the archaebacteria Mendosicutes (Razin et al., 1998).  Furthermore, differences in morphology, 
unusually small genome size, low G+C content and nutrient requirements, subdivides the Mollicutes in five 
orders, namely Acholeplasmatales (Acholeplasma), Anaeroplasmatales (Anaeroplasma, Asteroleplasma), 
Entomoplasmatales (Entomoplasma, Mesoplasma, Spiroplasma), Haloplasmatales (Haloplasma) and 
Mycoplasmatales (Mycoplasma, Ureaplasma) (Bradbury, 2005; Razin et al., 1998; Weisburg et al., 1989).  
Currently, six families with a total of twelve genera are recognised in the class Mollicutes (Ludwig et al., 2009).   
2.1.2.2. Origin  
Two schools of thought used to exist on mycoplasma evolution.  One model, as proposed by Neimark and 
London (1982), presumed that mycoplasmas originated by degenerate evolution after the diversification of 
bacteria.  Thus different species of mycoplasmas would have originated from different branches of bacteria and 
would therefore not be phylogenetically related. 
The other model, proposed by Morowitz and Wallace (1973), theorised that mycoplasmas are bacteria 
precursors, because of their small genome size and simplicity.  Thus the assumption is that the small genome 
must have duplicated numerous times to evolve into the ancestral bacteria.  
Today it has been proven that neither of these is correct, but that mycoplasmas originated by degenerate 
evolution from a low G+C content, Gram-positive, walled branch of bacteria.  Firstly, Woese et al. (1980) showed 
a phylogenetic relationship between bacteria and mycoplasmas based on comparative analysis of 16S rRNA 
sequences.  The findings established a relationship between mycoplasmas and a low G+C branch of a clostridial 
phenotype (Clostridium innocuum and C. ramosum) (Razin, 1985; Weisburg et al., 1989).  Woese (1987) also 
proved the mycoplasma phylogenetic tree to be monophyletic, thus disproving the first-mentioned model.  
Secondly, nucleic acid hybridisation and sequencing studies showed that mycoplasmas are related to Gram-
positive bacteria, although they stain negative in the Gram test.  
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2.1.2.3. Phylogeny 
The mycoplasma genus consists of four phylogenetic groups: (a) the anaeroplasma group, (b) the spiroplasma 
group, (c) the pneumonia group, and (d) the hominis group (Dybvig and Voelker, 1996).  In 2005 three distinct 
mycoplasmas were isolated from ostriches in the Klein Karoo, Central Karoo and Garden Route districts (Botes 
et al., 2005a).  Based on 16S rRNA analysis, the mycoplasmas were identified as three unique and ostrich-
specific mycoplasmas that fall within the hominis group.  Mycoplasmas are usually named according to their 
host, and therefore the three mycoplasmas were provisionally named Mycoplasma struthiolus(Ms)01, 02, and 
03, after their host Struthio camelus, until formally described.  Further studies named Ms01 as Mycoplasma 
struthionis sp. nov. and Ms03 as Mycoplasma nasistruthionis sp. nov. (Langer, 2009).  However, for the 
remainder of this thesis, they will be referred to as Ms01 and Ms03.  The three mycoplasmas are 
phylogenetically divergent and fall into two different clades, with Ms01 in a separate clade (Figure 2.1).   
2.1.3. MOLECULAR AND BIOPHYSICAL CHARACTERISTICS 
2.1.3.1. General characteristics of the mycoplasma genome 
At the start of the 1990s the first large scale attempts were made to sequence entire genomes of mycoplasmas 
(Razin et al., 1998).  The mycoplasma cell is typical of prokaryotes, containing a plasma membrane, ribosomes, 
and a circular double-stranded DNA genome.  However, that is where the similarity ends.  Mycoplasma 
genomes are significantly smaller than any other bacteria and have a lower G+C content than typical self-
replicating cellular organisms (Razin, 1985, 1997).  Mycoplasma genome sizes vary between 580 kb for M. 
genitalium and 1 380 kb for M. mycoides subsp. mycoides (Dybvig and Voelker, 1996; Fraser et al., 1995; Lucier 
et al., 1994; Razin et al., 1998).  Genome size may even vary between strains of the same species (Razin et al., 
1998).   
2.1.3.2. Repetitive DNA sequences 
The mycoplasma genome is filled with repetitive elements, thought to be either insertion elements or segments 
of genes that encode for surface antigens, and may be the cause of variability in the genome size of 
mycoplasmas (Razin et al., 1998).  Repetitive DNA sequences are not expected in genomes as small as those 
of mycoplasmas, and the high prevalence of these elements is somewhat surprising.  Many repeats are 
homologous to genes that encode major surface antigens and are also often found in these genes, possibly 
contributing to antigenic variation through DNA rearrangement (Dybvig and Voelker, 1996; Razin et al., 1998).  
Bacteria use repeats to enable gene recombination and to change the number and size of repeats.  This alters 
protein expression (Shapiro, 2002), and some repeats may even encode small proteins themselves (Reed and 
Altman, 1983).  Mycoplasma genome repeats will be further discussed in Chapter 3, Section 3.1.3. 
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 Figure 2.1 A phylogenetic tree of mycoplasmas based on the analysis of 16S rRNA gene sequences.  The tree represents 
one of eight of the shortest trees retrieved by doing a heuristic search (CI = 0.381, RI = 0.696).  The arrows indicate 
branches that collapse in the strict consensus tree.  Branch lengths and bootstrap values are indicated above and below the 
line respectively.  Long arrows point to the three ostrich mycoplasmas.
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2.1.3.3. Base composition and codon usage 
The G+C content of mycoplasma genomes range from 24 – 33 mol%, with the exception of M. pneumoniae, 
which has the highest value of 41% (Bové, 1993; Razin, 1992; Rottem and Barile,1993).  The unique base 
composition is a result of ineffective uracil-DNA glycosylation activity in mycoplasmas, which causes preferential 
usage of adenine- and thymine-rich codons (Dybvig and Voelker, 1996; Razin, 1985).  Up to 90% of codons 
contain an A or T in the third nucleotide (wobble) position.  As a consequence, mycoplasmas employ an 
alternative genetic code, known as the mold mitochondrial code, where the TGA codon encodes for tryptophan 
rather than signalling termination, as in the universal genetic code.  Mycoplasmas utilise the codons UAA and 
UAG as stop codons, with preference given to UAA (Bové, 1993; Marin and Oliver, 2003; Razin et al., 1998).  
This has practical implications when mycoplasma genes are to be expressed in bacteria that employ the 
universal genetic code (Dybvig and Voelker, 1996; Razin et al., 1998, Söll and RajBhandary, 2006).  Due to 
premature truncation caused by the TGA codon, shorter and dysfunctional products will form, hindering 
experimental studies of the gene of interest (Dybvig and Voelker, 1996; Razin et al., 1998).  Codon bias is not 
only apparent in the third nucleotide position, but also in the first and second, with considerable implications for 
the amino acid composition of a protein (Fadiel et al., 2005; Razin et al., 1998).  Compared to Escherichia coli, 
an organism frequently used in laboratory studies, mycoplasmas have fewer GGN, CCN, GCN and CGN codons 
and as a result fewer glycine, proline, alanine and arginine residues in their proteins.  On the other hand, the 
A+T-rich environment of the mycoplasma genome causes a high percentage of AAN, TTY, TAY and ATN 
codons to occur, resulting in an abundance of asparagine, lysine, phenylalanine, tyrosine, and isoleusine amino 
acid residues in their proteins.  Furthermore, highly conserved proteins often have lysine residues (AAA, AAG), 
where the corresponding protein in another organism will have arginine residues (AGA, AGG, CGN) (Dybvig and 
Voelker, 1996). 
2.1.3.4. Rare codons and codon bias in E. coli 
E. coli is a popular heterologous expression system, but due to its high codon bias, genes that contain so-called 
rare codons will cause translational problems when expressed. 
There are 64 codons in the universal genetic code, with three being stop codons.  The amount of anticodons 
(tRNA) seems to be directly proportional to the codon usage frequency (Kane, 1995).  Low-usage codons have a 
usage frequency lower than that of the non-degenerate codons AUG (Met) and UGG (Trp), as well as that of 
optimal codons.  Optimal codons have two or more degenerate codons, each with its own specific tRNA (Chen 
and Texada, 2006).  Rare codons are not only used seldom or infrequently, but also have low-abundant tRNAs 
to decode them.  tRNA availability causes common codons to be more easily translated than rare codons.  Rare 
codons are thus distinguished from low usage codons by the tRNA availability and tend to be in genes 
expressed at a low level, while major codons are used in genes with a high expression level.  Therefore, if a 
gene with many rare codons is desired in high amounts, as is the case with recombinant protein expression, the 
translational machinery may not be able to keep up with production.  This will lead to mistranslation or reduced 
yield (Kane, 1995). 
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Low usage codons, such as the Cys codons UGU and UGC, Thr codons ACU and ACG, or His codons CAC and 
CAU, are not rare codons of E. coli.  However, rare codons are always low usage codons.  E. coli has about 30 
low usage codons, of which 20 are rare codons.  Seven of them (AGG, AGA, CGA, CUA, AUA, CCC and CGG) 
are used at a frequency lower than 0.5% (Chen and Texada, 2006).  The rare arginine codons AGG and AGA 
were the first illustrated to have a detrimental effect on expression (Brinkmann et al., 1989; Spanjaard and Van 
Duin, 1988; Spanjaard et al., 1990).  These codons occur at a frequency of 0.14% and 0.21% respectively.  CUA 
and AUA is the next rare codon pair, with CGG, CGA and CCC codons with frequencies close to those (Kane, 
1995).  Rare codons and rare codon clusters have been shown to cause quantitative and qualitative expression 
problems in E. coli and other organisms, occurring mainly on the translational level (Gurvich et al., 2005; Kane, 
1995; Makrides, 1996). 
2.1.3.5. Gene arrangement 
The structure and organisation of important genes is usually highly conserved between different species.  
Rottem and Barile (1993) found groups of genes conserved within the genomes of different mycoplasma 
species, while Rocha and Blanchard (2002) stated gene order in the genome to be poorly conserved.  This 
finding was supported by Van der Merwe (2006), who found that the genes in the operons encoding cytadhesin 
proteins GapA, CrmA, CrmB and CrmC are found in M. gallisepticum, M. hyopneumoniae and M. pulmonis, but 
that their position in the respective genomes is not conserved. 
Genome reduction can occur either by reducing the amount of genes or clustering genes together.  In 
mycoplasmas, both processes were employed to reduce genome size (Siqueira et al., 2011).  Essential genes 
are generally clustered together, such as those involved in nucleotide transport and metabolism (Souza et al., 
2007).  In twelve studied mycoplasma genomes, glycolysis was found to be the most conserved pathway.  
Genes involved with DNA replication, recombination and repair, and especially ribosomal proteins, are also 
conserved within different clusters.  Although there are numerous conserved genes and clusters among 
mycoplasma genomes, the position of these gene clusters are generally not in the same relative position 
(Yotoko and Bonatto, 2007).  Furthermore, comparison of gene organisation between pathogenic and non-
pathogenic mycoplasmas seems to indicate that gene organisation is not related to pathogenesis (Siqueira et 
al., 2011). 
2.1.3.6. Cell size and shape  
The most distinctive feature of mycoplasmas is the absence of a cell wall.  Their cell size is unusually small, 
ranging from 0.3 – 0.8 µm in diameter (Prescott et al., 2002; Weisburg et al., 1989).  All mycoplasma cultures 
have a basic coccal shape, although elongated and filamentous forms have been observed under certain 
conditions.  The growth medium’s nutritional qualities, osmotic pressure, as well as the growth phase of the 
culture, all have an influence on the cell shape.  The absence of a cell wall means no restrictions are placed on 
the cell shape, since the plasma membrane is not rigid.  As such, mycoplasma cells are pleomorphic and vary in 
shape from spherical, pear-shaped organisms to branched or helical filaments, with a diameter of up to 150 µm 
(Carson et al., 1992; Edward and Fitzgerald, 1951; Klainer and Pollack, 1973; Razin, 1978; Razin et al., 1998).  
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2.1.3.7. Motility 
Although mycoplasmas lack many metabolic pathways, they do have complex systems to enable their parasitic 
lifestyle, for example gliding motility, adhesion to host cells, internalisation into the host cells, membrane 
transport, and antigenic variation (Miyata and Seto, 1999).  Their cell morphology revealed mycoplasmas to be 
grouped as either highly polar or non-polar.  The polar mycoplasmas exhibit a terminal tip structure, shown to 
assist in gliding motility on liquid-covered solid surfaces, as demonstrated in M. pulmonis, M. pneumoniae and 
M. gallisepticum.  It would seem that only the pathogenic mycoplasmas contain the tip structure.  Mycoplasmas 
do not move as a mass, but individually either in a circular pattern or narrow bends (Razin, 1987).  Even so, the 
gliding motility assists in defending the mycoplasma from the host’s defense mechanisms and helps it to reach 
its target (Bradbury, 2005). 
Mycoplasma motility also assists with adherence to host cells.  Not all mycoplasmas are capable of motility.  
Absence of these structures in the non-polar mycoplasmas contributes to the observed irregular and often 
branched morphology (Miyata and Seto, 1999).  Although attachment and adhesion to cell surfaces represent 
the major requirement for pathogenesis, commensal mycoplasmas are also capable of cell adhesion, even in the 
absence of established adhesion proteins.  Rather, adhesion is achieved through specific glycolipid and/or 
glycoprotein receptors on the host cell surface (Razin and Jacobs, 1992).   
2.1.4. METABOLISM  
2.1.4.1. Gene expression 
Gene expression and protein production in mycoplasmas occur mostly as for Gram-positive bacteria.  The only 
difference in mRNA translation between mycoplasmas and Gram-positive bacteria is the TGA codon usage.  
Mycoplasmas use the mold mitochondrial genetic code where TGA codes for tryptophan, whereas Gram-positive 
bacteria employ the universal genetic code where the TGA codon signals termination of translation.  TGG was 
retained as a second tryptophan codon (Jukes and Osawa, 1993).  Most genes in the mycoplasma genome start 
with the usual initiation codon ATG, but GTG and TTG can also serve as alternative start codons (Dybvig and 
Voelker, 1996).  ATG is the preferred start codon in genes that are intermittently expressed, as it interacts more 
strictly with the initiation transcript RNA (tRNA) than the alternative start codons (Sakai et al., 2001). 
2.1.4.2. Protein production and post-translational modifications 
Since mycoplasmas do not have a cell wall and therefore no periplasmic space, proteins are either cytoplasmic, 
membrane-bound or secreted (Dybvig and Voelker, 1996).  Mycoplasmas possess a high amount of lipoproteins, 
many of which possess a consensus signal peptidase II recognition site, followed by a cysteine residue.  
Lipoprotein processing often involves cleavage of the signal peptide in front of the cysteine residue, resulting in 
cysteine being the first amino acid of the lipoprotein. 
The typical eubacterial secretion signal sequence (-4)-VAASC-(+1) that is responsible for directing proteins 
toward a secretory pathway for transport across the plasma membrane, is also present in mycoplasmas (Henrich 
et al., 1999).  In Figure 2.2, a comparison of the conserved sequence that forms part of the OppA protein is 
shown for M. hominis (M. hom), Ms01, Ms02 and Ms03.  The signal peptide directs the protein to the outside of 
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the membrane, where the protein then attaches via the cysteine amino acid.  A signal peptidase II enzyme is 
responsible for the cleavage of the signal peptide form the lipoprotein precursor. 
M. hom 22' LVAASCKIDPA 32' 
Ms01 23' LVAAACNSKSA 33' 
Ms02 23' SVAVSCANNVS 33' 
Ms03 18' ALALSCKWTSS 28' 
Figure 2.2 Signal peptidase II recognition site of the OppA protein.  Comparison of the typical secretion signal amino 
sequence of the signal peptidase II recognition sequence as part of the OppA protein amino sequence between M. hominis 
(M. hom) and the three ostrich mycoplasmas.  Underlined is the conserved sequence, where the C represents the cysteine 
amino acid responsible for the attachment of the protein to the membrane. 
Although simpler than eukaryotic proteins, prokaryotic proteins do require certain post-translational 
modifications, such as phosphorylation, acylation and isoprenylation in mycoplasmas.  Data about post-
translational modification of bacterial proteins remain scarce, and especially little is known about glycosylation 
(Demina et al., 2011).  Proteins have a cysteine residue in a position that is susceptible to covalent fatty acid 
modifications.  Mycoplasmas are known for their large amount of membrane proteins that contain bound fatty 
acids (Demina et al., 2011). 
Covalent modifications to proteins are a major pathway of control and regulation in many important cellular 
processes, for instance protein phosphorylation is a known regulatory switch involved in intracellular signalling.  
It is possible that phosphorylation of cytoskeletal proteins in mycoplasmas may regulate cellular activities such 
as cytadherence, gliding motility and cell division. 
The function and mechanism of action of isoprenylation is not entirely clear (Dybvig and Voelker, 1996, Razin et 
al., 1998).  Isoprenylation refers to the addition of an isoprenoid group to a cysteine residue at the C-terminal of 
a protein.  It has been well recognised that the incorporation of isoprenoids to proteins as a post-translational 
method is an important process for facilitating protein-protein and protein-membrane interactions through 
specialised prenyl binding domains (Kloog and Cox, 2004; Marshal, 1993; Novelli and D’Apice, 2012).  It is 
generally assumed that the isoprenyl groups enable attachment to the cell membrane, even though direct proof 
is lacking.  Studies have shown that certain proteins, such as G-proteins whose function is critically dependant 
on their localisation, require this post-translational modification in order to anchor the protein to the membrane 
(Magee and Marshall, 1999).  Thus prenylation is seen as necessary for regulating the localisation and function 
of proteins.  Even though there are numerous studies on protein prenylation, there is still a lot to discover and 
this remains a field of active investigation (McTaggart, 2006). 
2.1.4.3. Biosynthetic pathways 
Mycoplasmas have not only lost the genes for cell wall synthesis during evolution, but also many genes involved 
in catabolic pathways and metabolite transport.  This reduction in metabolic genes accounts for the 
mycoplasma’s obligatory parasitic lifestyle.  Their diminutive gene reservoir renders mycoplasmas dependant on 
their hosts for a variety of nutrients, such as fatty acids, cholesterol, some amino acids, and purines and 
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pyrimidines (Dybvig and Voelker, 1996; Henrich et al., 1999; Prescott et al., 2002).  Mycoplasmas are unable to 
synthesise sterols, the same as other prokaryotes.  However, unlike other prokaryotes, most mycoplasmas are 
dependent on exogenous cholesterol for growth and incorporate large quantities into their cell membranes 
(Razin, 1975, 1982; Rottem, 2002).   
The fermentative mycoplasmas generate ATP through glycolysis and the pyruvate dehydrogenase pathway, 
producing lactic acid.  Non-fermentative species, such as M. hominis and M. arthritidis, and some fermentative 
species, produce ATP, ammonia, ornithine and CO2 through the arginine dihydrolase pathway (Dybvig and 
Voelker, 1996; Prescott et al., 2002; Razin et al., 1998).  Mycoplasmas have no cytochromes or quinones and 
lack complete tricarboxylic acid (TCA) cycle enzymes, therefore ATP is synthesised by substrate level 
phosphorylation where the electron transport chain is terminated by flavin (Pollack, 2002).  This is a less 
effective mechanism than oxidative phosphorylation, an unfortunate consequence of gene reduction.  In some 
mycoplasmas at least, the pentose phosphate pathway seems functional (Dybvig and Voelker, 1996; Prescott et 
al., 2002; Schuster et al., 2002).  
2.1.4.4. ABC transporters 
Due to the genome reduction and accompanied loss of genes, the mycoplasma is dependent on its host for a 
variety of nutrients and metabolites.  Therefore, it is not surprising that a substantial number of genes in the 
mycoplasma genome encode for transport proteins.  There are three types of membrane transport systems in 
mycoplasmas, namely the ATP-binding cassette (ABC) transport system, the phosphotransferase transport 
system, and facilitated diffusion by transmembrane proteins that function as specific carriers.  The ABC 
transporter is involved in the import and export of a large number of substances including sugars, peptides, 
proteins and toxins, and due to its broad functionality, mycoplasmas depend the most on this transporter system 
(Razin et al., 1998).  ABC transporters are found in prokaryotes and eukaryotes, although eukaryotes only have 
the ABC exporter and not importer.  A possible reason for this could be that the function was attributed to a 
different organelle, due to the sub-cellular compartmentalisation of eukaryotes. 
The ABC transporters can be differentiated into different classes, families and subfamilies, based on their 
phylogenetic analysis (Garmory and Titball, 2004).  ABC transporters are one of the largest protein families in 
living organisms.  In bacteria, the number of ABC transporters correlates with the genome size and the 
physiological niche of residence.  This is due to their importance regarding the competitive growth of bacteria in 
these various niches (Nicolás et al., 2007).  Thus, the combination of transporters in a given organism can allow 
one to predict its lifestyle (Ren and Paulsen, 2005).  An understanding and in-depth knowledge of the transport 
proteins of an organism can greatly improve the understanding of its metabolic capabilities.  Completely 
sequenced mycoplasma genomes have indicated that more than 50% of all membrane transporters are 
ATP-dependent, and of these, 59% to 92% are ABC transporters (Nicolás et al., 2007).  The interest in ABC 
transporters increased after realising their potential to be targets in the development of antitumor agents, 
antibacterial vaccines and antimicrobials.  Studies have demonstrated the ABC transporters’ role in drug 
resistance due to its associated outer membrane proteins in Gram-negative bacteria, as well as direct or indirect 
roles in the virulence of the bacteria, for instance virulence associated with the uptake of nutrients and metal 
ions (Garmory and Titball, 2004). 
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2.1.4.5. The oligopeptide permease system of M. hominis as an example of an ABC transporter 
The oligopeptide permease (Opp) system is one of the ABC transporters in bacteria and is responsible for the 
import of oligopeptides (Henrich et al., 1999).  To discuss the structure and functionality of this system, the 
mycoplasma M. hominis will be used as an example.  For a visual demonstration, refer to Figure 2.3.  Four core 
domains (OppBCDF), together with a cytadherence-associated lipoprotein known as the P100 protein in 
M. hominis, comprise the Opp system.  The species-specific P100 protein is a cysteine-anchored lipoprotein, 
expressed as a precursor polypeptide that functions as a substrate-binding site, also known as the OppA 
domain.  The OppB and OppC subunits each contain six membrane-spanning α-helices, which together form the 
integral membrane-spanning domain for the transport of oligopeptides across the membrane.  These two 
subunits possess the conserved hydrophobic motif that is characteristic to bacterial permeases: 
RTAKKGLXXXI/VZXXHZLR in the OppB domain and AAXXZGAXXXRXIFXHILP in the OppC domain.  The 
OppD and OppF subunits form the peripheral ATPase domains: binding and hydrolysing ATP, to provide energy 
for the active transport of an oligopeptide (Henrich et al., 1999; Hopfe and Henrich, 2004).  The OppA domain of 
M. hominis contains the highly conserved Walker A and Walker B motifs, usually associated with the OppD and 
OppF ATP-binding domains.  Thus it can be deduced that the OppA domain is also associated with ATP 
hydrolysis.  As such, the OppA domain of M. hominis is sometimes described as the ecto-ATPase domain.  
However, due to the vague understanding of its specific function, a number of hypotheses arose to explain its 
physiological function.  Firstly, it is possible that it hydrolyses extracellular ATP to protect the cell against the 
cytolytic effect of extracellular ATP (Redegeld et al., 1991).  It might also regulate the ecto-kinase substrate 
concentration (Plesner, 1995).  Another hypothesis speculates as to its involvement in signal transduction 
(Clifford et al., 1997; Margolis et al., 1990; Najjar et al., 1993), and lastly it could also be involved in cell-
adhesion (Kirley, 1997; Knowles, 1995; Stout et al., 1995).  Hopfe et al. (2011) recently demonstrated that the 
OppA-mediated cytadherence of M. hominis depends on the functionality of the ecto-ATPase activity.  No 
mutants without this domain have been identified.  This suggests that the domain does play an essential role in 
the survival of the organism (Hopfe and Henrich, 2004). 
 
 
 
 
Figure 2.3 Schematic illustration of the basic components of the oligopeptide permease system of M. hominis (Doeven et al., 
2008). 
2.1.5. MYCOPLASMA PATHOGENICITY 
Despite their small and rudimentary nature, many mycoplasmas cause adverse effects in their hosts.  The 
virulence and pathogenicity of mycoplasmas is still poorly understood, but is sure to entail a complex and multi-
factorial process (Kleven, 2008; Lockaby et al., 1998).  Different factors influence the pathogenicity of an 
P100/OppA 
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organism, such as virulence, tropism, number of organisms (dosage) and route of infection (Jordan, 1979).  
Pathogenesis may also result from the nutrient uptake and substrate sequestering (Garmory and Titball, 2004). 
2.1.5.1. Distribution 
Not all mycoplasmas are parasites.  Some live in nature as saphrophytes, growing on and obtaining nutrients 
from decaying organic matter.  Others are commensals, living in or on another organism without any effect on 
the host.  The parasitic mycoplasmas have been isolated from a broad range of hosts (Razin and Freundt, 1984; 
Razin et al., 1998).  Mycoplasmas are quite host-specific, even organ- and tissue-specific, possibly a reflection 
on their nutritionally fastidious nature and parasitic lifestyle (Kleven, 1997; Razin et al.,1998).  However, there 
are numerous reports of isolation from sites other than their normal specified niches and of mycoplasmas 
crossing species barriers.  This demonstrates their ability to adapt to different environments (Dybvig and 
Voelker, 1996; Erickson et al., 1988; Pitcher and Nicholas, 2005; Razin et al., 1998; Tully, 1993).  Despite these 
reports, mycoplasmas are still considered to be very specific to their hosts.  They are found mostly in mucous 
surfaces such as the respiratory and urogenital tract, the eyes, alimentary canal, mammary glands, as well as 
joints (Razin et al., 1998; Rocha and Blanchard, 2002). 
In a study done by Botes et al. (2005b), the three ostrich mycoplasmas were found to be mostly located in the 
upper respiratory system.  In addition to tissue specificity, the ostrich mycoplasmas are also seasonal, with a 
higher occurrence during the change of the seasons.  Ms01 was detected at the start of the winter months and 
again at the start of summer.  Ms02 and Ms03 were found to occur throughout the year, although Ms02 at much 
lower incidence.  Ms03 had the highest occurrence, followed by Ms01.  Of all the samples that tested positive, 
Ms02 occurred only at a frequency of 11.6%, with Ms03 the highest at 57.4%, not taking into account 
simultaneous mycoplasma infections (Botes et al., 2005b). 
2.1.5.2. Host cell attachment 
Adherence of the mycoplasma to the host cell is the foremost and critical step in pathogenesis.  It is a complex, 
multifactorial process that involves the adhesins of the pathogen, the host cell receptors, extracellular matrix 
components (EMC) and host cell molecules that act as a bridge between the pathogen and the host receptors 
(DeBey and Ross, 1994; Duensing et al., 1999; Zhang et al., 1994, 1995). 
Most of the pathogenic mycoplasmas possess a specialised attachment tip structure that mediates attachment to 
and interaction with the host cell (Dybvig and Voelker, 1996; Henrich et al., 1993; Razin et al., 1998).  The 
attachment and colonisation of mycoplasmas to the epithelial cells of the host is regarded as the first critical step 
in pathogenesis (Razin et al., 1998), especially where the mycoplasma is confined to the mucosal surfaces of 
the host (Kleven, 2008).  The mycoplasma cytadherence proteins are large integral membrane proteins with 
regions that are exposed on the cell surface (Dybvig and Voelker, 1996; Evans et al., 2005; Henrich et al., 1993; 
Razin et al., 1998).  Loss of cytadherence prevents colonisation, and consequently infection and disease.  
Therefore, membrane cytadherent proteins are deemed crucial regarding mycoplasma pathogenicity.  One of the 
most abundant transporters in prokaryotes, the ABC transporter, is located on the outside of the cell membrane.  
Since the cell membrane of the mycoplasma is the outer barrier, ABC transporters may possibly play a role in 
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the pathogenicity of a mycoplasma and represent an immunogenic target to exploit in vaccine development 
(Henrich et al., 1993; Lockaby et al., 1998). 
The attachment tip structure contains a network of interactive proteins, adhesins, and adherence-accessory 
proteins (Baseman, 1993; Baseman et al., 1996).  It could also have a motile function: certain mycoplasmas can 
glide along plastic and glass surfaces if the tip is pointed in the right direction (refer to Motility, Section 2.1.3.7).  
Mycoplasmas that do not have this tip are still able to attach to the host cell (Dybvig and Voelker, 1996; Henrich 
et al., 1993).  For instance, M. hominis and M. fermentans lack such a tip structure.  However, M. hominis is able 
to adhere via two cytadhesins: the membrane proteins P50 and P100 (Henrich et al., 1993).  M. penetrans has a 
tip structure containing a 65 kDa fibronectin-binding protein that is able to bind selectively to immobilised 
fibronectin, forming a molecular bridge (so to speak) between the mycoplasma and the host cell’s surface 
proteins (Giron et al., 1996).  This is followed by internalisation of the mycoplasma (Dimitrov et al., 1993; 
Duensing et al., 1999).  After adherence, some mycoplasmas are able to enter the host cell.  Refer to 
Intracellular location, Section 2.2.3.2 for more information. 
Well-known cytadhesins include the cell surface-exposed P1 and P30 proteins of M. pneumoniae (Dybvig and 
Voelker, 1996), both clustered together at the attachment organelle (Krause, 1998).  Without P1, M. pneumoniae 
would be unable to attach to its host and would thereby lose its virulence (Chaudhry et al., 2005; Krause, 1998; 
Krause and Balish, 2001; Razin and Jacobs, 1992; Razin et al., 1998).  Other well-known adhesins include the 
MgPa adhesin of M. genitalium: an analogue of P1 with apparent similar roles; the GapA adhesin and 
cytadherence-related molecule CrmA of M. gallisepticum; and a P1-like adhesin in M. pirum (Papazisi et al., 
2000). 
Attachment is not only dependent on the mycoplasma, but also on receptors on the host cell surface.  Razin et 
al. (1998) demonstrated the involvement of two different types of receptors in ligand-receptor interactions, 
namely sialoglycoproteins and sulfated glycolipids.  Sialoglycoconjugates are the receptors for M. pneumoniae, 
M. genitalium, M. gallisepticum, and M. synoviae (Razin and Jacobs, 1992).  Some mycoplasmas, such as 
M. pneumoniae, have more than one type of receptor (Razin, 1999; Rottem, 2003). Sometimes the receptors 
function as a directional infection point.  For instance, at the primary site of M. pneumoniae infection, i.e. the 
optical micro-villar border and cilia, sialoglycoconjugates function as the receptors, while the secretory cells and 
mucus lack them.  Thus attachment of M. pneumoniae to the ciliated cells is favoured (Loveless and Feizi, 
1989).  M. hyopneumoniae, in turn, binds to glycosaminoglycans, plasminogen, fibronectin, and glycolipid 
receptors on respiratory ciliated cells (Zhang et al., 1994).   
In addition to receptors on the host cell surface, the basal membrane (BM) surrounding the host cells also 
present attractive targets for microorganisms to adhere to.  The BM contains the EMC laminin and collagen, 
which are targeted by microorganisms to adhere to and invade the host tissue (Diacovich and Gorvel, 2010).  
Some microorganisms may then further damage the tissue with their secretory or membrane-bound proteases, 
and the damaged and exposed EMC present an expanded target for adhering microorganisms (Vanlaere and 
Libert, 2009). 
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2.1.5.3. Virulence causal factors   
In addition to the cytadherence and internalisation of the mycoplasma, other factors may also contribute to the 
pathogenicity of mycoplasma infections.  Possible factors include cell damage and disruption due to oxidative 
stress, concurrent infections and environmental factors.  Mycoplasma infection often causes opportunistic 
infections to occur as well.  Thus, in many cases, two or more simultaneous infections may exist within the same 
host, exacerbating the effect of one another and leading to aggravated infections and severe illness (Kleven, 
1998).  Concurrent infections caused by bacteria such as E. coli, Pseudomonas aeruginosa, Avibacterium 
paragallinarum, Bordetella avium and Pasteurella species have been associated with mycoplasmal clinical 
conditions in South African feedlot ostriches (Pretorius, 2009).  As such, even mild mycoplasma infections pose 
a serious risk.  Kleven (1998) also reported synergism between different mycoplasmas, such as M. synoviae 
with M. gallisepticum or M. meleagridis. 
Respiratory diseases are known to be aggravated by environmental factors.  Mycoplasma infections associated 
with respiratory disease often arise as a result of the temperature fluctuations that occur with seasonal change.  
Respiratory diseases are also exacerbated by stress (transportation and handling, change in feed, increase in 
population density) and environmental conditions (dust, high levels of ammonia, temperature, ventilation) 
(Allwright, 1995).  These environmental factors greatly increase the severity of the infection (Kleven, 1998).  
Infections may lie dormant until any of these debilitating factors occur. 
2.1.5.4. Interaction with the host organism  
Mycoplasma infections are rarely of the fulminant type, but rather follow a chronic course (Razin, 1992).  That 
these cell wall-less, fragile and simple organisms can resist the host immune response and cause chronic 
infection, seems surprising.  Although the molecular basis of mycoplasma pathogenicity still remains largely 
unknown, the mycoplasma has developed numerous ways in which it is able to avoid the immune attacks of its 
host, leading to chronic infection and resistance to treatment.  In addition to evasion, the clinical symptoms 
associated with mycoplasma diseases are often more indicative of damage to the immune and inflammatory 
responses of the host, rather than to the direct toxic effects of the mycoplasma cell components (Bradbury, 
2005; Razin et al., 1998). 
2.1.5.4.1. Competition for precursors 
Mycoplasmas depend on their host to supply amino acids, fatty acids, co-factors and vitamins, competing with 
the host for these biological precursors (Pollack et al., 1997; Rottem and Barile, 1993).  This presents a danger 
to the host cell’s integrity and function, due to the depletion of these critical biochemicals (Baseman and Tully, 
1997; Simecka et al., 1992).  Non-fermentative mycoplasmas rapidly deplete the host’s arginine reserves to 
generate ATP, adversely affecting the host’s protein synthesis, cell division and growth (Rottem and Barile, 
1993).  Arginine utilisation by the mycoplasmas is suggested to inhibit histone synthesis and cause 
chromosomal damage of the host, due to the arginine-rich nature of histones.  Certain strains cause further 
chromosomal abnormalities such as breakage, multiple translocations, reduction in chromosome number and 
possible new chromosome varieties (Rottem and Barile, 1993).  
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2.1.5.4.2. Damage due to cytadherence  
Cytadherence of the mycoplasma to the host cell and fusion with its membrane may interfere with the membrane 
receptors and transport mechanisms of the host cell (Rottem, 2003).  Adhering mycoplasmas also release toxic 
materials and the close proximity of the two cells may result in the hydrolysis of host cell phospholipids, caused 
by phospholipases present in many mycoplasma cell membranes (Shibata et al., 1995). 
2.1.5.4.3. Damage due to fusion  
Fusion implies the transference of the mycoplasma’s cellular components to the host cell, such as hydrolytic 
enzymes (Razin et al., 1998; Shibata et al., 1995) and nucleases that may degrade the host cell’s DNA 
(Paddenberg et al., 1996, 1998).  Mycoplasma membrane compounds will be introduced to the host cell 
membrane, possibly altering receptor recognition sites and thus affecting induction and expression of cytokines, 
influencing cross-talk between the cells in the infected tissue (Rottem, 2003). 
2.1.5.4.4. Damage due to internalisation 
Internalisation of the mycoplasma into the host cell may disrupt its normal cellular function, causing cell damage, 
disruption and death.  Cell damage is thought to occur due to the toxic effects of metabolic byproducts, such as 
hydrogen peroxide and superoxide radicals, as well as toxic components on the mycoplasma’s cell surface 
(Lockaby et al., 1998).  The oxidative stress damages the cell membrane and disrupts cellular function (Rottem 
and Naot, 1998; Rottem. 2003). 
2.1.5.5. Clinical signs and symptoms  
Mycoplasma infection in the South African ostrich is associated with respiratory disease in feedlot birds.  Rhino-
tracheatis (inflammation of the upper respiratory tract) and airsacculitis (an extension of nasal infection) are 
observed as a result of infection (Huchzermeyer, 1994).  Other symptoms include nasal exudates (rhinitis), 
swollen sinuses (may be filled with thick yellow-white exudates), foamy eyes (conjunctivitis), rattling sounds of 
the throat due to post-nasal drip (sinusitis), shaking of the head and excessive swallowing.  Laboured breathing 
may indicate air sac infection.  The air sacs have a wet appearance and clear to white foamy exudates.  
Although growth is retarded, the ostrich’s appetite generally remains unaffected, causing an increase in the cost 
of feeding (Allwright, 1995; Huchzermeyer, 1994).  In the case of concurrent infections, the ostrich may exhibit 
increased pus in the sinuses and air sacs, fever, pneumonia and septic infection (Botes et al., 2005a). 
2.1.5.6. Diagnosis 
The variety of clinical symptoms, especially those that overlap, complicates the diagnosis of specific 
mycoplasmas.  The clinical signs and lesions are not pathognomonic for any one mycoplasma, but can only be 
regarded as an indication of general mycoplasma infection (Jordan, 1990).  Mycoplasma infections can be 
diagnosed using in vitro cultivation methods.  Due to the different places of infection and maturity level, 
mycoplasmas can be isolated from different tissues.  Tracheal swabs, and to a lesser extent, air sac -, sinus - or 
conjunctival swabs, are taken from the ostrich and introduced directly onto a suitable medium, either agar or 
broth.  Different techniques are available to identify and confirm the presence of a mycoplasma, for example 
PCR-based methods and antibody-based procedures (Ley and Yoder, 1997). 
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2.1.5.7. Prevention 
The first step in keeping a flock free of infection should always be prevention.  Currently, the only way to prevent 
ostrich mycoplasma infections is with good farming and bio-security practises.  However, this is complicated by 
the fact that ostrich carrier conditions exist without any clinical signs.  Mycoplasmas have also developed ways 
of evading the host’s immune system, further contributing to the difficulty of their eradication. 
Bio-security programs are the most effective, but with the increase in population density of feedlot farming, this 
has become problematic to maintain (Kleven, 2008).  Further methods of prevention for breeding stock are listed 
below: 
i. Minimum contact between the host and the pathogen (Jordan, 1979). 
ii. Hatching eggs can be treated to reduce transmission, by manual injection into the air sac or by dipping 
them in a suitable drug solution (Jordan, 1990, 1996; Ley and Yoder, 1997). 
iii. Isolate the progeny in flocks of smaller groups, separated from the other flocks (Jordan, 1990; Ley and 
Yoder, 1997; Yoder, 1984). 
iv. Frequent monitoring of the flock for infection and eradication of the whole group if a member shows 
signs of infection (Jordan, 1990). 
Vaccination presents another method of prevention, but an important requirement for effective vaccination is that 
the flock has to be vaccinated before the field challenge occurs. 
2.1.5.8. Treatment and control 
Since mycoplasmas do not have a cell-wall, they are unaffected by antibiotics that target cell-wall synthesis, for 
example penicillin.  They are, however, susceptible to antibiotics such as fluoroquinolones, macrolides and 
tetracyclines (Levisohn and Kleven, 2000).  Fluoroquinolones target DNA gyrase, blocking DNA replication 
(Roberts, 1992).  It kills bacteria quite rapidly, but when mycoplasmas are present at high concentrations, a 
decrease in killing is observed.  Tetracyclines are broad-spectrum antibiotics, effective against almost all of the 
mycoplasma species, and work by binding to ribosomes and preventing their normal functioning. 
Even though antibiotics are widely used to reduce the severity of mycoplasma diseases, it is still preferable to 
keep the flock disease free.  Antibiotics such as tylosin, oxytetracycline, doxycycline and danofloxacin are used 
to control infection, but these antibiotics are not effective in eradicating the infection, they only manage the 
clinical symptoms (Dr. A. Olivier, in personal communication with B. Pretorius, 2009).  Tylosin is a mycoplasma-
specific antibiotic that can be administrated orally, either through the feed, dosed, or by injection (Botes et al., 
2005b).  Unfortunately tylosin is one of the antibiotics that have been banned by the European Union since 
1999, in addition to bacitracin, spiramycin, and virginiamycin (Casewell et al., 2003).  Antibiotics cannot be used 
for young birds and their usage should in general be kept to an absolute minimum (Huchzermeyer, 1998). 
If used as a long term solution against microbial infections, resistance may build up in the pathogenic organism, 
and they predispose birds to fungal infections of the mouth and digestive tract (Perelman, 1999).  Resistance 
against antibiotic treatment has led to more and more focus being placed on effective vaccine development.  
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There are no commercially available vaccines for ostrich inoculation and the need for such vaccines is 
imperative. 
2.1.5.9. Current poultry vaccines  
There are numerous live attenuated M. gallisepticum (MG) and M. synoviae (MS) vaccines commercially 
available that show a high degree of protection against the spread of MG or MS infection.  There are also 
commercially available inactivated, oil-emulsified bacterins against MG and MS.  Bacterins have been 
demonstrated to cause a consistent and reliable immune response (Droual et al., 1990).  Oil-emulsified bacterins 
often cause tissue damage and cause abscesses to form under the skin, making it an unfeasible approach to 
follow for ostriches. 
Van der Merwe (2006) demonstrated that MS and MG vaccines elicit an immune response in ostrich chicks, but 
protection against challenge was not assessed.  Pretorius (2009) tested the hypothesis that MS and MG 
vaccines could provide protection against mycoplasma infections in ostriches.  In chickens and turkeys, the MS 
and MG vaccines only provided protection against MS and MG respectively, indicating that cross-reactivity 
between these two mycoplasmas is too low to provide simultaneous protection.  Pretorius (2009) noted the same 
result in ostriches, where the antibodies elicited by the MS and MG vaccines were specific to the MS and MG 
antigen and did not provide protection against the three ostrich specific mycoplasmas. This demonstrates the 
need to develop species-specific vaccines for each of the three ostrich mycoplasmas.  Preliminary investigations 
into a DNA vaccine against Ms01 showed promising results, although these were compromised by co-infection 
with avian influenza (Brandt, 2012). 
2.2. MYCOPLASMA VACCINE DEVELOPMENT 
Different types of mycoplasmas vaccines exist, as well as different administrating routes, but none of these have 
been developed for ostrich-specific mycoplasmas.  Due to the high antibody specificity towards individual 
mycoplasma species and the low cross-reactivity between different mycoplasmas, the need to develop a vaccine 
for each ostrich mycoplasma is imperative.  To follow is an introduction to immunology, as well as a discussion 
of the immune responses elicited by mycoplasmas and their immune-response evasion mechanisms.  This is 
followed by a series of discussions of the history of vaccines and their current applications.  These discussions 
will focus on DNA vaccines: the immune responses that they elicit; their advantages; a vaccine development 
strategy, and its promise and application in ostrich-specific mycoplasma vaccine development. 
2.2.1. INTRODUCTION TO VACCINES AND IMMUNOLOGY 
Vaccines could possibly be regarded as one of the greatest achievements of medicine.  The first illustration of 
the principle of vaccination was in 1798 when Edward Jenner discovered that prior exposure to cow pox could 
prevent later infection of small pox (Stern and Markel, 2005).  In less than 200 years later, the World Health 
Organization launched a campaign that led to the complete eradication of the pox virus.  Jenner’s experiments 
formed the basis on which vaccines against almost all infectious agents were developed, many of which today 
have been successfully controlled or even eliminated altogether (Babiuk, 2002; Gurunathan et al., 2000; Oshop 
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et al., 2002).  Despite the success, there are still many infections hazardous to human and animal health, where 
an effective vaccination is unattainable, mostly because of the need for cellular immunity.  Traditional vaccines 
have been successful due to the extended time of antibody response, but only live attenuated vaccines provide 
the much-needed cellular response.  Due to manufacturing and safety implications, the use of live attenuated 
organisms is restricted.  However, these traditional methods provide insufficient protection against cell-invading 
pathogens such as Plasmodium, Ehrlichia ruminantium, and possibly mycoplasmas.  These organisms require a 
comprehensive immune response in order to protect the host.  The need for long lasting cellular immunity 
instigated the research on DNA vaccination, as DNA vaccines elicit both humoral and cellular immunity (Oshop 
et al., 2002). 
2.2.2. BASIC PRINCIPLES OF IMMUNOLOGY 
2.2.2.1. Immunology and the immune response 
To understand how a vaccine works, it is important to understand the immune system and its defence 
mechanisms.  The immune system consists of innate and specific acquired immunity.  Innate immunity refers to 
an existing immunity, not requiring prior exposure, which is present before the contact to the infectious agent. 
Due to the focus on vaccination, only specific acquired immunity will be discussed further.  Specific acquired 
immunity requires contact with the live pathogenic organism or a vaccine against this organism.  The immune 
response launched is a delayed response, but provides long term protection.  Actively acquired immunity 
consists of two branches: antibody-mediated immunity (humoral (B cells) immunity) and cell-mediated immunity 
(cellular (T cells) immunity).  The humoral branch of the immune system produces antibodies to protect the host 
against extracellular pathogens, while the cellular branch protects against intracellular pathogens by killing the 
infected cells (cytotoxic T cells) or helping the cells to recover (helper T cells).  Different types of helper T (Th) 
cells have different effects on the immune response that is launched through the effect of secreted cytokines and 
lymphokines.  Th-1 cells secrete lymphokines that activate macrophages, while Th-2 cells stimulate B cell 
development and activate cytotoxic T (Tc) cells (Rabson et al., 2005). 
Foreign molecules are recognised in the external environment by naive B-cells and dendritic cells.  These 
antigen-presenting cells (APCs) have surface receptors that internalise proteins and digest them.  Some of the 
resulting fragments are then exposed on the cell surface of the APCs the major histo-compatibility complex 
(MHC) class II.  All cells of the body can process intracellular organisms such as viruses and present peptide 
fragments on MHC I.  MHC class I presentation is recognised by the cytotoxic CD8+ T cells, which proceed to 
attack the relevant infected cell (cellular immunity), killing it before the pathogen replicates.  Class II is 
recognised by helper CD4+ T cells that induce differentiation and proliferation of pre-B cells to produce 
antibodies, as well as release a variety of cytokines that in some cases activate macrophages, enabling them to 
kill intracellular parasites (Rabson et al., 2005). 
The pre-B cells mature into antibody-secreting cells, replicating and eventually resulting in the production of 
long-lived memory B cells (humoral immunity).  The maturation of B-cells is important when looking at immunity; 
it is responsible for producing high-affinity antibodies and creating memory of the initial exposure.  When the 
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memory B cell is then re-exposed to the antigen, it quickly transforms into an antibody-secreting plasma cell 
(Rabson et al., 2005). 
2.2.2.2. Vaccination and the immune response 
In the first response, B cells are activated by the interaction of the antibodies they express on the cell surface 
and other activation signals.  The antigen binds to the antibody, activating a process that results in the formation 
of memory B cells, known as priming.  When the host is exposed to the pathogen for a second time, known as 
the secondary or memory response, the response is far quicker and greater in magnitude.  This is the basis for 
the success of vaccination: by priming the immune response, vaccination presents a harmless method to 
prepare the host for eventual infection (Rabson et al., 2005). 
Vaccination works on the principle that exogenous antigens provided by the inactivated or killed pathogens, or 
protein from live vaccines, are taken up by the APCs and presented on the MHC class II, stimulating CD4+ T 
cells.  The MHC class I is used when antigens that are produced in the cell’s cytoplasm are presented, a 
response generally elicited by live or DNA vaccines (Rabson et al., 2005).  Immunologically, live vaccines 
provide the most effective protection through their wide range of effects, but from a safety point of view, the use 
of live vaccines raises many concerns (Babiuk, 2002).  This emphasises the advantage of DNA vaccines: 
eliciting both types of immunity in the same manner as live vaccines, but without the associated risks. 
2.2.2.3. Mucosal immunity 
The surface of the respiratory system, eyes, intestinal and urinary tract are exposed to the external pathogen-
containing environment.  These tissues are covered by epithelial cells that provide a protective barrier against 
this environment (Jeurissen et al., 1989).  The first line of defence is non-specific mechanisms (epithelial cells, 
mucus, and extreme pH) that prevent pathogens from adhering to the surface (Neutra et al., 1996).  The 
epithelial cells contain lymphoid tissue that is able to respond specifically to invading pathogens (Jeurissen et al., 
1989).  Mucosal immunisation has two major advantages: ease of administration and induction of local immunity.  
The mucosal surfaces are the target tissues of the ostrich-specific mycoplasmas, demonstrated by the fact that 
the majority of the mycoplasmas were isolated from the ostriches’ trachea (Botes et al., 2005b).  Mucosal 
surfaces represent the primary portal of entry for animal pathogens (Oshop, 2002).  Inducing local mucosal 
immunity is of particular importance in the case of respiratory pathogen infections. 
2.2.2.4. Immune responses elicited by mycoplasmas 
Mycoplasma infections cause specific responses in the host, including production of local and systemic 
antibodies and stimulation of cellular phagocytosis of the organism.  Unfortunately, as necessary as these 
protective mechanisms are, they also play a role in exacerbating issue damage and mycoplasma-induced 
illnesses.  This contributes to the mycoplasma’s pathogenicity and enables it to avoid the host’s immune 
defences, leading to chronic infection (Razin, 1992b; Razin et al., 1998). 
Immune effects caused by mycoplasma infections include either suppression or stimulation of B and T 
lymphocytes, induction of cytokine production, cytotoxicity of macrophages, natural killer cells (NKC) and T cells, 
as well as enhanced expression of cell receptors and complement activation.  Mycoplasmas are able to avoid 
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phagocytosis, but still interact with mononuclear and polymorphonuclear phagocytes to stimulate the synthesis 
of pro-inflammatory cytokines (Rottem and Naot, 1998; Salman et al., 1994).  Mycoplasmas can have a 
synergistic or antagonistic influence on immune cells (Rottem, 2003).  Different mycoplasmas are able to 
stimulate either B cells or T cells, or both.  They can be potent stimulators of T cell-derived cytokines interleukin 
(IL)-2, interferon (IFN)-α and IL-4.  Mycoplasmas have an effect on phagocytes and lymphocytes, thus 
influencing the balance between Th1 and Th2 populations of CD4+ T cells, and also enhancing NKC activity of 
the innate immune system (Razin et al., 1998; Rottem and Naot, 1998). 
Although the precise mechanism by which mycoplasmas elicit immune responses is not completely understood, 
it is accepted that the transfection and presentation by dentritic cells (DC) plays a significant role in the 
development of immunity brought about by DNA vaccines (Casares et al., 1997; Porgador et al., 1998; Condon 
et al., 1996).  DC presentation may also occur by uptake of secreted protein from other transfected cells, or 
uptake of the antigen, known as cross-presentation (Corr et al., 1996). 
2.2.3. MYCOPLASMA EVASIVE TECHNIQUES 
2.2.3.1. Lipoproteins and antigenic variation 
Antigenic variation contributes to the pathogenicity of mycoplasmas by enabling the mycoplasma to evade the 
host immunity and adapt to the environment.  By generating a versatile surface coat that constantly changes via 
high frequency phenotypic switching, the antigenic profile is modified too often for the host to recognise it and 
synthesise antibodies (Dybvig and Voelker, 1996).  Antigenic variation is thought to occur primarily in the 
lipoproteins.  Bacterial lipoproteins are potent modulators of the immune system and lipoproteins represent the 
preferential target of the humoral immune response in mycoplasma infections (Chambaud et al., 1999).  Studies 
with M. gallisepticum, M. mycoides subsp. mycoides and M. bovis have demonstrated that lipoproteins are the 
most active immunogens in experimental chicken and cattle infections (Abdo et al., 1998; Behrens et al., 1996; 
Jan et al., 1995).  The P53 lipoprotein of M. penetrans is the preferentially recognised antigen of the host’s 
humoral immune system (Grau et al., 1995; Neyrolles et al., 1999).  Mycoplasmas have an unusually high 
number of lipoproteins with unknown function, often expressing several at once.  Lipoproteins account for a 
significant portion of the membrane-protein mass (Chambaud et al., 1999).  The lipoproteins are fixed in the cell 
membrane via a lipid moiety or hydrophobic amino acids, with part of the protein exposed to the outer surface of 
the cell.  Mycoplasmas are able to modify the expression of these immunogenic surface lipoproteins and so 
avoid antibody attacks (Tryon and Baseman, 1992). 
Two methods of lipoprotein variation in mycoplasmas have been described.  In the first method, the number of 
tandem repeats at the carboxy terminal is varied, creating lipoproteins of different sizes, and in the second 
method, phase variation is employed, which entails the reversible and inheritable switching between two 
phenotypes.  Certain gene families contain multiple copies of a gene, and by varying expression of these 
alternative genes, different antigenic moieties are encoded (Dybvig and Voelker, 1996; Kleven, 1998).  Another 
advantage of phase variation entails masking the epitope accessibility of another surface antigen.  Known as 
differential masking, this increases the possible variation even further (Theiss et al., 1996).  Genes that encode 
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surface antigens are often found to contain repetitive elements, which further contribute to antigenic variation, 
based on sequence variation (Dybvig and Voelker, 1996; Razin et al.,1998). 
It should be noted that although the repertoire of lipoprotein variation is vast, it does not necessarily change 
during infection.  A long-term study on M. hominis infected patients showed no antigenic variation on the 
mycoplasma isolates over time in the same patient (Jensen et al., 1998).  However, when isolates from different 
patients were compared, a high degree of antigenic variation was observed.  The study concluded that antigenic 
variation in M. hominis is a result of the specific host, rather than a reaction to the development of an immune 
response.  Bergonier et al. (1996) demonstrated that geographical differences may also account for lipoprotein 
variation.  They found different epitopes between M. agalactiae isolates from Europe and those from Africa.  
Taking all this into account, surface variation of mycoplasmas can be considered more of a general mechanism 
that allows the organism to adapt to its fluctuating environment.  This is further supported by the fact that 
microorganisms that are not exposed to host immune systems also have surface variation (Deitsch et al., 1997). 
2.2.3.2. Intracellular location 
Although most mycoplasmas are non-invasive surface pathogens, species such as M. fermentans, 
M. genitalium, M. hominis and M. penetrans have the ability to infiltrate and survive inside their host’s cells 
(Evans et al., 2005; Razin et al., 1998; Rottem, 2003).  M. penetrans and M. genitalium both contain tip 
structures that enable penetration into the host cell, while other mycoplasmas, such as M. fermentans and 
M. hominis, enter via internalisation, where the mycoplasma is engulfed by the cell membrane.  M. penetrans 
localises in the cytoplasm and perinuclear regions (Borovsky et al., 1998; Giron et al., 1996).  M. fermentans, 
M. pneumoniae, M. genitalium and M. gallisepticum are surface pathogens, but under certain circumstances are 
able to reside in non-phagocytic cells (Rottem, 2003).  Inside the cell the mycoplasmas can exist freely or inside 
a vesicle.  The intracellular location of mycoplasmas not only protects them against the humoral immune 
response of the host, but also against antibiotic exposure.  This contributes to the difficulty with which 
mycoplasmas are eradicated, thus promoting chronic infection (Kleven, 2008; Razin et al., 1998).  The process 
of invasion is based on the ability of bacteria to bind to fibronectin (adhesive glycoprotein) or sulfated 
polysaccharides (Duensing et al., 1999; Dziewanowska et al., 1999).  Some mycoplasmas have fusogenic 
activity due to the absence of a cell wall, as well as the close proximity of the mycoplasma membrane and the 
cytoplasmic membrane of the host.  Rottem and Naot (1998) showed that mycoplasmas that require unesterified 
cholesterol for growth have fusogenic activity.  To illustrate the importance of unesterified cholesterol in 
fusogenic activity: M. capricolum adapted to survive in the absence of cholesterol, and with the dramatic 
reduction of cholesterol in its membrane, the organism lost its fusogenic activity (Tarshis et al., 1993).  The 
ability of mycoplasmas to multiply within the host cell has not been proven completely (Rottem, 2003). 
2.2.3.3. Immunomodulins 
Henderson et al. (1996) proposed the term ‘modulin’ to describe molecular moieties that induce cytokine 
production with pathological consequences.  Mycoplasmas produce at least three of the 16 classes of modulins 
currently listed: lipoproteins and lipids (Razin et al., 1998; Rottem and Naot, 1998), as well as a polypeptide 
super-antigen only produced in M. arthritidis (Cole et al., 1996).  The role of lipoproteins in antigenic variation 
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has been discussed (refer to Lipoproteins and antigenic variation, Section 2.2.3.1), but lipoproteins also 
stimulate monocytes and induce the secretion of pro-inflammatory cytokines (Rawadi and Roman-Roman, 1996; 
Razin et al., 1998).  All membrane-anchored lipoproteins contain a lipoylated amino-terminal cysteinyl residue, 
which is responsible for the modulin activity (Brenner et al., 1997).  In some cases this residue can be 
N-acylated.  Lack of this terminal acylation of specific mycoplasma lipoproteins, such as the 2 kDa macrophage 
activating lipopeptide 2 (MALP-2) from M. fermentans, stimulates macrophages considerably more than 
triacylated lipoproteins (Mühlradt et al., 1997, 1998).  Interestingly, mycoplasma infections are not necessarily 
associated with a strong inflammatory response, demonstrated by the fact that some mycoplasmas colonise 
respiratory and urogenital tracts without any clinical symptoms.  Indeed, it has been shown that lipoproteins of 
M. fermentans induce IL-10 in isolated human monocytes, which is one of the cytokines that down-regulates the 
inflammatory response (Rawadi et al., 1996).  There is still much to learn about the nature and kinetics of 
cytokine production following mycoplasmas infection, but it appears that cross-talk between cytokines 
determines the intensity of inflammatory reactions (Chambaud et al., 1999). 
2.2.3.4. Molecular mimicry and phenotypic plasticity 
Another immune evasion tactic that hinders the host’s recognition of mycoplasmas involves molecular mimicry 
and phenotypic plasticity.  Some antigenic epitopes are shared between different mycoplasmas and their host 
cells, referred to as molecular mimicry.  In addition to evasion of the host immune system, auto-antibodies have 
been observed during certain mycoplasma infections (Rottem, 2003).  Phenotypic plasticity refers to the ability of 
a single genotype to produce more than one morphology, physiological state and/or behaviour, either due to 
environmental signals or random changes in the expression profile of single or multiple genes (Rottem, 2003).  
Surface compounds such as flagella, pilli, outer membranes or capsules, are major immune targets.  Lacking 
most of these, mycoplasmas’ major source of antigenic variation falls on membrane proteins (refer to 
Lipoproteins and antigenic variation, Section 2.2.3.1). 
2.2.4. VACCINES 
The ideal vaccine has many specific characteristics and requirements.  Firstly, a vaccine must be immunogenic, 
which is characterised by Ada (1994) as: 
i. activation of APCs to stimulate antigen processing and interleukin production, 
ii. activation of B and T cells to yield memory cells, 
iii. generation of Th and Tc cells to several epitopes, thus overcoming MHC polymorphism in populations, 
iv. and continuous presence of antibodies. 
Furthermore, other factors that should be noted when developing a vaccine are cost-effectiveness, safety, ease 
of manufacturing and administration.  In the case of a live vaccine, it should be genetically and phenotypically 
stable and should not cause disease, nor should it spread to neighbouring populations and cause disease there.  
The vaccine itself should not cause any toxic reactions or negative immune effects (Ellison et al., 1992).  Ideally, 
a single dose would provide life-long immunity (Whithear, 1996). 
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2.2.4.1. Conventional approaches 
Conventional vaccines are known as first generation vaccines.  First generation vaccines refer to whole-
organism vaccines, which can either be killed (chemical or heat inactivation), attenuated (live organism with 
disabled virulence) or a close relative of the pathogenic strain without the virulence.  Live attenuated vaccines 
are able to elicit Tc and Th cell responses, as well as antibody immunity.  Live vaccines have the advantage of 
providing long-lasting cellular and humoral immunity, due to their close resemblance to natural infection.  
However, the possibility of reverting back to its virulent form and causing disease in the immune-compromised 
inoculated host does remain a concern and one of the biggest disadvantages.   
Killed vaccines, also called bacterins, provide a high and extended level of immunity.  In comparison with live 
vaccines, however, they have a lower immunogenic effect and are unable to generate specific Tc cell responses 
(Lechmann and Liang, 2000).  Bacterins are non-infectious, an advantage over live vaccines, since there is no 
risk of reverting back to virulence or risk of cross-infection.  Certain disadvantages make this a non-ideal vaccine 
approach for ostriches.  Firstly, the vaccine is quite expensive and the birds need to be vaccinated individually.  
In addition, oil emulsion adjuvants cause large abscesses and granulomas beneath the skin in ostriches.  With 
reference to mycoplasmas, synergistic effects may occur between the mycoplasma and another infectious 
agent, possibly causing several diseases, especially if the bird is vulnerable due to environmental and 
physiological stress (Whithear, 1996). 
2.2.4.2. Novel approaches 
The availability of bioinformatic tools enabled in silico analysis of genome sequences and identification of active 
proteins, leading to more innovative approaches to vaccine development.  Possible antigenic proteins can be 
identified, regardless of their abundance, and the genes encoding biologically active proteins can be cloned, 
expressed and analysed under controlled conditions.  Vaccine development that starts with in silico analysis of 
the genomic information, in contrast with the conventional approach that starts by cultivating the pathogen, is 
termed reverse vaccinology (Rappuoli, 2000).  These novel and innovative approaches include conjugate and 
recombinant approaches.  Conjugate vaccines contain a bacterial capsular polysaccharide, generally a poor 
antigen, joined to a carrier protein to enhance the immunogenicity.  Some immunogenic compounds, such as the 
surface polysaccharides of encapsulated bacteria, are immunogenic but not able to induce immune memory.  
Protein antigens are conjugated to these components to improve elicitation of the T cell response.  The 
immunological properties of the carrier proteins are thereby conferred to the attached antigen.  The technique is 
mostly applied to provide protection against invasive bacterial disease. 
There are three categories of recombinant vectors, as discussed below (Ellis, 1999). 
i. Live genetically modified organisms 
Live genetically modified organisms have one or more genes deleted, usually a double knock-out to prevent 
regression (Uzzau et al., 2005).  The vaccine can also be an organism that is transfected with a gene from 
the pathogen, thus functioning as a vaccine vector.  This requires knowledge of the pathogenic organism’s 
genes and care should be taken that the gene(s) or resultant protien(s) do not harm the viability or 
immunogenicity of the organism. 
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ii. Recombinant inactivated vaccines 
Recombinant inactivated vaccines include subunit vaccines (containing part of a whole organism), synthetic 
peptides (representing the most basic part of the immunogenic protein), virus-like particles (which look like 
a virus on the outside but do not contain genetic material and thus cannot replicate) and whole proteins 
extracted or expressed from cloned genes.  Subunit vaccines are injected with an adjuvant; a substance 
that stimulates the immune system, enhances response by protecting the vaccine from degradation, attracts 
APCs (which process and present the antigen to the immune system), stimulates immune cells directly, 
stimulates cytokine secretion, or any combination of these.  These are known as second generation 
vaccines.  Second generation vaccines are able to elicit the humoral and helper T cell responses, but not 
cytotoxic T cell responses.  They overcome the risks and problems associated with first generation 
vaccines; however, they too have limitations.  In vivo immunogenic proteins are not necessarily protective 
antigens.  They may also be too variable in their coding sequence, difficult to express, and have high 
production costs.  In addition, only the most abundant antigens can be identified and as such there are 
many diseases for which vaccines cannot be developed (Mora et al., 2003). 
iii. Genetic vaccines 
Genetic vaccines are known as the third generation vaccines and are currently one of the largest growing 
fields in vaccine development.  A DNA vaccine consists of a plasmid vector, carrying a foreign gene that 
encodes for an immunogenic (or pathogenic) protein.  The plasmids are multiplied and maintained in a 
bacterial host, usually E. coli, before it is purified and injected directly into the host as ‘naked DNA’.  The 
host will then express the proteins and an immune response is launched against the foreign protein. 
2.2.4.3. Comparison of the essential steps of the conventional vaccine approach and reverse 
vaccinology 
Conventional vaccine development requires the pathogen to be cultivated on a large scale.  The steps involved 
are cumbersome and time-consuming: first the pathogen is grown in laboratory conditions to search for 
protective antigens using biochemical, serological and microbial methods; then it needs to be mass produced.  
This approach works well for organisms with abundant antigens, but fails to provide a solution for pathogens that 
do not have obvious immunodominant protective antigens.  With reverse vaccinology, all that is required is the 
genome sequence.  Computer analyses are used to predict possible antigens without relying on their expression 
profiles or on the cultivation of the pathogen.  The concept of DNA vaccines will now be discussed in greater 
detail, focussing on the development strategy. 
2.2.4.4. DNA vaccines 
The concept of DNA vaccination were originally illustrated by Wolff et al. (1990), when they inoculated mice with 
a plasmid that expressed the human growth hormone.  Instead of causing growth as they predicted, antibodies 
were produced against the hormone.  Thus they demonstrated that direct immunisation with naked DNA resulted 
in the in vivo expression of the protein within the muscle cells of mice.  Their unexpected results sparked interest 
in the use of DNA plasmids that encode for an antigenic protein as a means of inducing immune responses, a 
principle known as DNA immunisation. 
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Today, DNA immunisation is employed in a wide range of animal models to provide antibody and cell-mediated 
protection against different bacterial, fungal and parasitic diseases (Dhama et al., 2008; Donnelly et al., 1997).  
Traditional vaccines make use of whole organisms, either killed, attenuated or a close non-pathogenic relative of 
the pathogen, whereas DNA vaccines circumvent the associated problems by employing a gene encoding for 
the immunogenic protein of the pathogen.  The DNA vaccine provides the gene(s) for encoding the antigen, 
rather than consisting of the antigen itself.  Recombinant DNA technology and bioinformatic tools are used to 
develop and construct a DNA vaccine.  A typical DNA vaccine consists of a bacterial plasmid backbone that 
provides the frame for inserting the gene(s) of interest (GOI).  Since the plasmid does not contain an origin of 
replication that is active in eukaryotic cells, it will not be able to replicate itself or integrate into the chromosomal 
DNA of the host (Garmory et al., 2003; Webster and Robinson, 1997). 
2.2.4.4.1. Principle and mechanism of DNA vaccination 
In order to develop a DNA vaccine against the selected pathogen, a gene or genes must be identified that will 
possibly evoke an immune response.  For a schematic illustration of the process of DNA vaccine development, 
refer to Figure 2.4 (Dufour, 2001).  Sequence analysis and gene comparison between the genomes of different 
pathogenic organisms may be used to identify immunogenic proteins.  When an appropriate gene is identified, it 
is then isolated and cloned into a suitable eukaryotic expression vector.  The vector has to contain a bacterial 
origin of replication to allow mass production of the plasmid in a bacterial host, such as E. coli.  After large-scale 
production and purification, the plasmid (DNA vaccine) can be inoculated directly into the host animal, usually by 
intramuscular (IM) injection.  The host cell will then internalise the plasmid and produce the encoded protein.  
Following the process of antigen production and processing, the foreign protein or derived peptides are 
suggested to be presented on both MHC class I and MHC class II molecules of local APCs, activating CD8+ 
T cells and CD4+ T cells, inducing both humoral and cellular immunity (Gurunathan et al., 2000). 
The precise mechanism by which the antigen is produced, processed and presented, is less clear.  The two 
hypotheses entail firstly that the in vivo uptake of DNA occurs through specific receptors (Bennet et al., 1985), 
and secondly, rather non-specifically, similar to phago- or pinocytosis (Lewis and Babiuk, 1999).  The amount of 
antigen produced is only up to the nanogram range, but despite the low quantity, a broad, sustained immune 
response is induced.  Presentation of the foreign peptides mimics natural infection, because they are presented 
in their native form, similar to the presentation that occurs during natural infection.  The basic immune responses 
are thought to occur similarly in avian hosts as in mammals, although unique organs in the avian lymphatic 
system, such as the bursa of Fabricius and the Harderian gland, may account for some of the differences in the 
early immune responses to DNA vaccination (Oshop et al., 2002). 
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Figure 2.4 The principle of DNA vaccination (Dufour, 2001).  A candidate gene is identified and isolated from the pathogenic 
organism’s DNA.  The gene is cloned into a eukaryotic DNA expression vector.  After large-scale production and purification, 
the DNA vaccine is then delivered directly into the host animal.  The host animal will produce, process and present the 
antigenic peptides to the immune system on MHC I and MHC II molecules, inducing both cellular and humoral immune 
responses. 
2.2.4.4.2. Immune responses elicited by DNA vaccination 
Different features will have an effect on the efficacy of the DNA vaccine, including the choice of expression 
vector, the method of DNA delivery, and even the DNA itself.  Certain bacterial DNA motifs, such as 
unmethylated cytidine-phosphate-guanosine (CpG) motifs, have been shown to be immunogenic, and 
polynucleotides are known for their ability to induce cytokines (Krieg et al., 1994).  These motifs activate 
monocytes, NKC, as well as DC and B cells, by acting as an adjuvant and enhancing the immune response 
when added into the plasmid (Weeratna et al., 1998).  The presence of a well-known consensus sequence, 
known as the Kozak sequence, influences the recognition of the start codon by eukaryotic ribosomes, thus 
influencing translation efficiency.  The method of delivery, as well as the delivery site, will influence the type of 
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immune response launched: for example Th1 helper cells are activated following IM injection, but when DNA is 
delivered by the gene-gun method, the emphasis shifts to Th2 helper cell responses (Donnelly et al., 1997).  The 
reason for this is that with needle injection the plasmid DNA is taken up by dendritic cells in the extracellular 
space, proceeding to differentiate for Th1 cytokine production, while gene-gun delivery bypasses this 
mechanism with direct entry into the cell (Jakob et al., 1998). 
The immune response raised by a DNA vaccine can be divided into three different sections:  
i. Humoral immune responses 
Antibody responses induced by DNA vaccination have been demonstrated for a wide array of proteins, 
in some cases detectable years afterwards, thereby providing a continued antigen stimulus.  Humoral 
immune responses were launched against various viral, bacterial, parasitic, tumour and eukaryotic 
proteins (Donnelly et al., 1997). 
ii. Cytotoxic T cell responses 
MHC class I-restricted CD8+ cytotoxic T lymphocyte (CTL) responses have been demonstrated in mice 
that have been inoculated previously.  Antigens and viral infections have been used to challenge the 
mice lymph node or spleen cells both in vitro and in vivo.  In some cases, the CTL responses persisted 
for up to 15 weeks after the final immunisation (Donnelly et al., 1997). 
iii. Helper T cell responses 
Following antigen activation, the helper T cells secrete cytokines, signalling macrophages and B and 
T lymphocytes to facilitate the differentiation and development of memory cells.  Mice, humans, 
chickens, ferrets and many more animal models have been shown to launch helper T cell responses to a 
wide variety of antigens.  The comprehensive results suggest that the generation of helper T cells may 
be a general characteristic of DNA vaccines (Donnelly et al., 1997). 
These responses constitute one of the many advantages of DNA vaccination: its ability to evoke both branches 
of the immune system, the cellular and humoral response. 
2.2.4.4.3. Administration / delivery methods  
Many different methods of delivery into the animal tissue are available, namely: IM, intradermal (ID), 
subcutaneous (SC), ocular, intrabursally (IB), intravenous (IV), intraperitoneal (IP), oral, vaginal, intranasal (IN), 
or by gene-gun delivery to the skin.  The route of administration of the vaccine is believed to influence the cells 
involved with protein production.  For example, following IM injection, the plasmid can occur in the monocytes or 
in the muscle cells (Babiuk et al., 2000), while for intra-dermal injection, it is believed that the skin is important in 
generating an immune response (Bos, 1997).  Babiuk et al. (2003) established that gene-gun delivery delivers 
the DNA directly into the cell and appears to be more efficient in transfecting Langerhans cells or dendritic APCs.  
The skin is known to contain these cells, which can induce MHC class II responses, thus inducing strong CD4+ 
T cell responses (Akbari et al., 1999).  Recently several new methods have been explored to increase the 
transfection efficiency of DNA vaccines, such as high-pressure delivery, dermal patches, forming DNA in 
particles such as liposomes, and electroporation.  A variety of enhancing agents can be co-administrated with 
the DNA vaccine, such as sucrose, cardiotoxin, bupivacaine, hypertonic solutions or adjuvants such as calcium 
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phosphate, lipids, CpG oligonucleotides and cytokines (Oshop et al., 2002).  Most often IM and ID is the 
preferred delivery choice, often formulated without any adjuvants, due to their simplicity and effectiveness 
(Oshop et al., 2002).  Other methods include aerosol delivery onto mucosal surfaces and topical administration 
to the eye and vaginal mucosa (Lewis and Babiuk, 1999). 
Another possibility of DNA vaccine delivery is the use of carriers.  DNA vaccines can be delivered in attenuated 
intracellular bacteria such as Salmonella, Shigella and Listeria (Du and Wang, 2005; Fairweather et al., 1990; 
Yang et al., 2009).  Non-viable strains are employed as carriers of the DNA vaccine plasmid and administrated 
orally.  Success has been achieved against Newcastle Disease virus, hepatitis B virus and human 
immunodeficiency virus (HIV).  Fagan et al. (2001) demonstrated oral immune responses in pigs against a 
number of genes of M. hyopneumoniae.  Numerous other studies demonstrated oral immunity when 
recombinant plasmids transformed in Salmonella typhimurium aroA SL3261 were used as a delivery system 
(Chen et al., 2003, 2006, 2008; Fagan et al., 2001).  The results indicated that using Salmonella carriers as a 
way of inoculation should be considered as a means of evoking immune responses in ostriches against the 
ostrich mycoplasmas.  It is suspected that the three ostrich-specific mycoplasmas might be combated with 
mucosal immunity, as would be provided with oral administration.  Eliciting mucosal immunity may prevent 
infection altogether, instead of preventing disease after infection.  Another advantage of using a carrier as 
delivery method is that it provides protection against degradation of the DNA by extracellular 
deoxyribonucleases (Gurunathan et al., 2000). 
2.2.4.4.4. The effect of the route of delivery on dosage requirements 
The dosage is dependent on the particular antigen and model system that is used, as well as the method of 
administration.  Intramuscular or subcutaneous injection usually requires 100 - 200 µg of plasmid DNA, while 
gene-gun immunisation requires 250 to 2 500 times less DNA to induce antibody or CTL responses (Fynan et 
al., 1993).  Fynan et al. (1993) demonstrated that gene-gun immunisation achieved similar protection with up to 
2 500 times less DNA than used with saline DNA injections.  As a dose example, IM/ID immunisation of mice 
requires between 1 and 100 µg DNA, while monkeys and calves require between 10 µg and 1 mg to provide the 
same level of immune response.  If mice are inoculated using the gene-gun delivery system, the amount falls to 
between 10 ng and 10 µg (Robinson and Pertmer, 2000).  Some are of the opinion that the dose required is 
independent of the host animal size (Cox et al., 1993), even though others argue, as an example, that mice 
require a tenth of the DNA than primates do (Robinson and Pertmer, 2000).  In poultry, a single ballistic injection 
delivery required from 0.25 µg DNA to induce a measurable immune response (Kodihalli et al., 1997), while an 
IM injection required at least 750 µg (Triyatni et al., 1998).  Different doses resulted in a clear difference in 
immune responses (Kodihalli et al., 1997; Song et al., 2000; Suarez and Schultz-Cherry, 2000). 
2.2.4.5. Advantages of DNA vaccination 
DNA vaccines have several advantages over the use of conventional vaccines, including mimicry of live 
vaccination, but without the possibility of reverting back to virulence and causing disease.  DNA vaccines induce 
cytotoxic T cell responses, an advantage over protein vaccines, which elicit a poor T cell response when 
immunised without adjuvants (Donnelly et al., 1997).  Although live vaccines also generate both types of immune 
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responses, they have the disadvantage of having a risk of infection if reverting back to their virulent form.  DNA 
vaccines do not pose this security risk (Gurunathan et al., 2000; Robinson and Torres, 1997).  Recombinant-
based vaccines are costly to produce and difficult to purify, they could cause incorrect folding of the antigen and 
poor induction of CD8+ T cells, all of which DNA vaccines do not suffer from.  It is also possible to direct the type 
of immune response, either toward a Th1 cell or Th2 cell response (Robinson and Pertmer, 2000).  With DNA 
vaccination concurrent administering is possible, the plasmid is genetically stable and the immune response can 
be modified by manipulation of the genetic sequence (Oshop et al., 2002; Webster, 1998). 
DNA vaccines obviate the need for peptide synthesis, expression and purification of recombinant proteins, and 
eliminate the need for toxic adjuvants (Sedegah et al., 1994).  The need for pathogen cultivation is 
circumvented, making it possible to develop vaccines against difficult-to-cultivate pathogens, as well as for 
pathogens that are dangerous to work with.  This makes DNA vaccination a feasible approach for mycoplasma 
vaccine development, due to the latter’s notoriously difficult cultivation properties.  DNA vaccines also present a 
tool to identify protective antigens without knowing the function of the protein. 
2.2.4.6. Limitations of DNA vaccination 
Concerns regarding DNA vaccines include the possibility of tolerance to the antigen produced, host genome 
integration, induction of auto-immunity and anti-DNA antibodies, as well as the risk of affecting the genes that 
control cell-growth (Oshop et al., 2002; Webster, 1998).  A limitation of the DNA vaccine approach is the inability 
to detect and therefore utilise any non-protein antigens.  For instance, bacterial polysaccharides represent 
potent vaccine targets, due to their extracellular exposure, and are an important component of many successful 
vaccines.  CD1-restricted antigens such as glycolipids may be also present promising vaccine candidate targets, 
but will not be detected using the reverse vaccinology approach (Rappuoli, 2001).  Another limitation is the 
possibility of atypical processing of bacterial and parasitic proteins, since the expression occurs in a eukaryotic 
organism (Robinson and Pertmer, 2000). 
2.2.4.7. Safety of DNA vaccines 
In contrast with conventional vaccines, DNA vaccines are stable.  Originally it was feared that the plasmid could 
potentially integrate into the host’s genome, and possibly lead to the development of anti-DNA immune 
responses.  The DNA vaccine is non-live, non-replicating and non-spreading, adding to their list of advantages.  
Research into these safety concerns found little evidence of genomic integration, with a significantly lower risk 
for integration than the risk associated with natural mutations (Ledwith et al., 2000; Sheets et al., 2006; Wang et 
al., 2004).  Numerous studies and clinical trials were done to monitor for possible anti-DNA responses, but no 
evidence was found (Tavel et al., 2007).  It seems that the platform of DNA vaccination is safe and well-tolerated 
in hosts (Ferraro et al., 2011). 
There are already licensed DNA vaccines available for commercial use (Table 2.1), such as for the West Nile 
virus that causes encephalitis in horses, infectious haematopoietic necrosis virus that affects salmonid fish, and 
melanoma in dogs (Bergman et al., 2006). 
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Table 2.1 Currently licensed DNA therapies (Kutzler and Weiner, 2008). 
Vaccine target Product name Date licensed and country Target organisms 
West Nile virus West Nile Innovator 2005, USA Horses 
Infectious haematopoietic 
necrosis virus 
Apex-IHN 2005, Canada Salmon 
Growth hormone releasing 
hormone 
Life-Tide-SW5 2007, Australia Swine and food animals 
Melanoma Canine Melanoma Vaccine 2007, USA, conditional 
license 
Dogs 
2.2.4.8. Candidate genes for DNA vaccine development 
Vaccine candidate genes are genes encoding for proteins with good immunogenic properties, such as the 
proteins involved in pathogen attachment and interaction with the host, as well as those associated with the 
virulence of the pathogen (Henrich et al. 1993).  The membrane proteins of mycoplasmas that mediate the 
adherence to the host cells, as well as ABC transporters that are essential for nutrient uptake, are thus 
considered candidate genes (Garmory and Titball, 2004).  Proteins that are secreted or located on the outer 
membrane surface are more accessible to the antibodies produced by the host than those inside the cell. 
In order to identify such a gene, the genome sequence of the pathogen is required.  Publicly available genetic 
databases, such as GenBank, provide genetic information on an ever-increasing list of organisms.  Partial or 
whole genomes are annotated and can be used in similarity searches to identify possible antigenic genes.  
Similarity searches were applied on the whole genome, using bioinformatic tools, to identify the oppA gene as a 
vaccine candidate gene for Ms01.  The decision was based on the high homology of the putative protein with the 
M. hominis P100 protein, also coded by the oppA gene.  In a similar manner, Steenmans (2010) identified the 
Ms02 oppA gene as a candidate gene for an Ms02 DNA vaccine. 
This study will reduce the 28 contiguous sequences of the Ms02 genome, produced in a previous round of 
genome sequencing, through linkage of the contigs using a technique called Thermal Asymmetric Interlaced 
Polymerase Chain Reaction (TAIL-PCR).  This, together with bioinformatic analysis on the Ms02 genome, such 
as repetitive sequence analysis, will be described in Chapter 3. 
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Chapter 3 
3.   
This chapter is presented as a short review on TAIL-PCR, the technique used to assemble the Ms02 genome 
partially, and on mycoplasma genomes in general: their repetitive sequences; how this influences the assembly 
of mycoplasma genomes; the order and arrangement of genes; and also gene distribution on the leading and 
lagging strands of the genome.  The experimental procedures and results specific to Ms02 follow thereafter in an 
article format. 
3.1. INVESTIGATION INTO MYCOPLASMA GENOME REPEATS, GENE 
ARRANGEMENT, ASSEMBLY AND ANNOTATION 
3.1.1. INTRODUCTION 
Genome sequencing methods have improved rapidly in recent years, reaching a point where genome analysis 
and annotation cannot keep up with the amount of newly released sequences.  In order to understand and use 
the raw information contained in the genome sequence, it is necessary to identify and annotate genes, the 
proteins they code for, and the metabolic pathways the proteins form part of.  Understanding the genetic 
information contained in the genomes of bacteria could lead to the development of novel vaccines, identification 
of drug targets to develop antimicrobial compounds, and modification of the bacteria for bioremediation 
applications (Barker, 2006; Binnewies et al., 2006; Stothard and Wishart, 2006). 
In order to develop a DNA vaccine, it is necessary to have the DNA sequence of a vaccine candidate gene of 
the pathogenic organism.  Advances in molecular genetics and bioinformatics resulted in a large number of 
genomes that have either been sequenced completely or for which contiguous sequences exist.  The genome 
sequence of an organism provides insight about possible proteins, without having to clone and express every 
hypothetical gene of interest.  Comparisons between different genomes can lead to the identification of 
conserved domains, thus identifying vaccine candidate genes through in silico analysis of the genome, 
circumventing laborious and time-consuming experiments.  Identification of essential genes in mycoplasmas not 
only contributed to the discovery of the minimal set of genes required for self-replicating life, but also aid in drug 
development, because essential genes represent attractive targets for developing antibiotics and DNA vaccines.  
Identification of essential genes will also enable quicker annotation of unknown genome sequences by using 
homology searches and genome comparative studies (Lin and Zhang, 2011).  The comparative genomic 
approach is thus limited by the availability of annotated, complete genomes of close and distantly related sets of 
species. 
3.1.2. THERMAL ASYMMETRIC INTERLACED POLYMERASE CHAIN REACTION 
In 1995, Liu and Whittier developed a simple, powerful technique to recover unknown genome sequences 
adjacent to known sequences.  Based on the strategy that primers of different lengths and base pair 
compositions will have different annealing temperatures, Thermal Asymmetric Interlaced Polymerase Chain 
Reaction (TAIL-PCR) employs cycles with interlaced high and low temperatures, thus favouring both long and 
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short primers to function with near equal annealing efficiency.  Three long, specific, nested primers are designed 
on the known DNA sequence, and the DNA is amplified in three consecutive PCRs with a non-specific, shorter, 
arbitrary degenerate (AD) primer.  Because of the difference in annealing temperatures, the relative amplification 
of products can be controlled to favour the target product over the non-specific products.  Performing three 
consecutive TAIL-PCRs dilutes non-specific products to negligible concentrations so that predominantly only the 
target product remains (Figure 3.1). 
In the primary reaction three types of product may form.  Firstly, the target product primed by the specific forward 
and degenerate reverse primer will form (type I).  A detectable amount of product amplified by the specific primer 
alone will also form (type II), but is usually diluted out by the secondary reaction due to the nested effect of the 
specific primers.  Due to the indiscriminate nature of the degenerate primers, fragments amplified on both sides 
by these primers will also form (type III) and constitutes the major source of background, since they cannot be 
diluted out by the nested specific primers during normal PCR cycling.  The strategy of TAIL-PCR is designed to 
favour the amplification of the target product (type I) and suppress formation of type III product.  An initial low 
stringency cycle creates the binding sites for the AD primer by facilitating initial base miss-match annealing.  In 
the following high stringency cycle only the long specific primer can effectively anneal, and type I product is 
amplified, while little or no type III product will form.  A reduced stringency cycle then ensures annealing of both 
primers, replicating the single stranded DNA product produced in the high stringency cycle.  Thus the template of 
type I is greatly increased.  Cycling of the high and reduced stringency cycles are then used to increase the 
target product, while suppressing the formation of non-specific products.  Unfortunately, the high stringency 
cycle also favours mispriming of the specific primer, and the product primed on both ends by the specific primer 
will also be amplified with even higher efficiency.  However, due to the use of nested primers, the effect of such 
mispriming is diluted out in the second reaction.  The third reaction usually does not require further TAIL-cycling 
and only serves to amplify the target sequence. 
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Figure 3.1 Schematic diagram of TAIL-PCR indicating the preferential amplification of the target sequence over non-target 
sequences.  (a) indicates the primary PCR, (b) the secondary PCR, and (c) the tertiary PCR.  Analyses of the PCR products 
are performed with (d) agarose gel analysis, a simple and cost-effective method.  Specific primers are denoted by SP and 
arbitrary degenerate primers denoted by AD. 
Non-target sequence 
AD 
Known sequence Unknown target 
sequence 
SP1 SP2 SP3 
1:500 dilution of PCR product 
to serve as template 
Non-target type II 
SP1 
SP1 
High, detectable 
AD 
AD 
Non-target type III 
Low, undetectable 
Target product type I 
SP1 
AD 
Moderate, undetectable 
1:500 dilution of PCR 
product to serve as template 
Target product type I 
SP2 
AD 
High, detectable 
AD 
AD 
Non-target type III 
Very low, undetectable 
a) Primary  PCR with SP1 & AD 
Cycling high and low stringency annealing 
temperatures  
 
b) Secondary  PCR with SP2 & AD 
           25 reduced stringency cycles  
 
c)    Tertiary PCR with SP3 and AD 
         30 normal cycles 
d)     Agarose gel analysis 
Target product type I 
SP3 
AD 
Very high, detectable 
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3.1.2.1. Advantages of TAIL-PCR 
TAIL-PCR has proven effective in a wide range of genomes, including the hexaploid wheat genome, a genome 
about five times larger than the human genome (Liu and Whittier, 1995).  TAIL-PCR is a method that can be 
used for chromosome walking, genome physical mapping, developing sequence-tagged sites, serial gene-
walking, as well as analysis of genomic sequences that flank T-DNA, transposon or retrovirus insertions (Liu and 
Whittier, 1995).  It is especially useful when dealing with a large number of samples.  The advantages include: 
i. Simplicity: TAIL-PCR does not require complex DNA manipulations, either prior or post PCR.  The 
resultant DNA can be analysed easily on an agarose gel.  After a simple purification step, the DNA can 
be used directly in sequencing reactions. 
ii. Sensitivity: Only nanogram quantities of DNA are required and crude DNA or cell lysate can be used.  
Thus TAIL-PCR is an effective, sensitive method to use when only a small amount of template is 
available. 
iii. Specificity: Due to the cycling process and consecutive PCR reactions, the amount of non-specific 
product is so low that the TAIL-PCR products can be used as a sequencing template or as hybridisation 
probes without any complicated preparation steps. 
iv. Efficiency: Using four different AD primers, it is almost certain to obtain a specific product with very little 
background.  Product sizes range from 100 to 2 000 bp. 
v. Speed: The three reactions, together with agarose gel analysis, can all be completed in one day.  Due to 
the direct sequencing of the template, the process from amplification to sequencing data is streamlined. 
3.1.2.2. Limitations of TAIL-PCR 
Although TAIL-PCR is easy to optimise and generally has a high success rate, it is dependent upon the quality 
of the specific primers and the nature of the genome.  The specific primer needs to bind to a unique site in the 
target sequence of the genome.  In certain cases, such as genomes with high numbers of repeats, one specific 
product is not amplified, but rather an array of different products.  The high background prevents purification and 
sequencing of a specific product. 
Genomes that contain multiple runs, or that are A+T-rich such as mycoplasmas, make the design of optimal 
specific primers difficult.  It is generally difficult to obtain a long specific primer that adheres to the primer 
guidelines, i.e. no secondary structures or base pair runs, and a certain TM (melting temperature), to prevent 
non-specific binding.  AD primers with too high a degree of degeneracy will also result in too many small 
undesirable products.  TAIL-PCR has proved inefficient when applied to complex genomes such as rice, with 
lower efficiencies and amplification products that rarely exceeded 600 bp (Nakazaki et al., 2000; Sato et al., 
2001). 
3.1.3. REPETITIVE SEQUENCES IN MYCOPLASMA GENOMES 
Repetitive elements are most often found in eukaryotes and to a lesser extent in prokaryotes, but the prevalence 
of these elements are unexpected in genomes as small as those of mycoplasmas.  Repetitive elements present 
a problem in sequence alignments and assembly by creating ambiguities, which in turn produces biases and 
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errors when the results are interpreted.  While it is tempting to just ignore repeats, this leads to further problems 
and may cause important biological information to be missed.  If the repeats are longer than the read lengths 
generated by the sequencing method, gaps will be created during de novo assembly (Treangen and Salzberg, 
2012).  Worse than gaps, the repeats may be collapsed on top of one another, resulting in a lower 
representation of repeats than what actually occurs in the genome, as well as misassembly (Treangen and 
Salzberg, 2012).  The main problem with repeats is that the assembler cannot recognise and distinguish 
between them, leading to a common error where two chromosomal regions are joined that do not belong 
together.  At first glance, the partially assembled genome would seem almost complete with very few gaps, but 
when attempts are made to complete the assembly using chromosome walking techniques, or bioinformatic 
analysis is performed on the partial genome, it is very quickly realised that the presence of repeats caused 
missassembly and complicated further down-stream processes. 
3.1.3.1. Simple sequence repeats  
Simple sequence repeats (SSRs) refer to perfect, uninterrupted tandem repeats of a single nucleotide or a short 
oligomer in a DNA sequence, also called microsatellites, and have been found in all eukaryotic and prokaryotic 
genomes that have been studied (Katti et al., 2001).  They are powerful genetic markers that have become 
useful tools for high density genetic mapping, molecular tagging of genes, phenotype mapping and genetic 
diversity studies (Jewell et al., 2006).  These repeats are caused by DNA polymerase slippage during replication, 
causing insertion or deletion of base pairs and are therefore quite diverse with respect to their lengths (Kashi 
and King, 2006; Toth et al., 2000).  This is seen as a common source of phase variation in bacteria and 
antigenic variation in pathogens, aiding the pathogenic organism in evasion of the host immune system, by 
increasing the genetic diversity of the population (Groisman and Casadesus, 2005; Rocha, 2003; Van der 
Woude and Baumler, 2004). 
3.1.3.1.1. SSRs and their function and gene associations 
Long SSRs are generally rare in prokaryotes and mostly restricted to host-adapted pathogens that do not readily 
survive outside of their host (Mrázek et al., 2007).  Mrázek (2006) investigated SSRs in mycoplasma genomes 
and found that they are not just involved in phase variation, but also in the organisation of the chromosome, as 
well as protein structure and function.  Depending on their length, sequence, and location, various functions 
have been attributed to SSRs in the genome.  This include involvement in gene expression, gene regulation and 
function, as well as significance even when present in non-coding regions (Gupta et al., 1994; Kashi et al., 
1997).  They provide recombination hot-spots, facilitate genome rearrangements, have been found to bind 
nuclear proteins, and function as transcriptional activating elements (Li et al., 2002).  They may also affect 
protein structure and thus protein-protein interactions (Mrázek, 2006).  Some of the repeats act as contingency 
loci that are associated with surface antigens.  Obligate parasites benefit from this due to the mutations that aid 
in avoidance of the host immune response, or in general the adaptive mutations promote the survival of the 
microbes that live in rapidly changing environments (Moxon et al., 1994). 
Analysis of over 300 prokaryotic species showed a large variance in the SSR content (Mrázek et al., 2007).  
Trivedi (2010) concluded that the highest amount of SSRs in the 13 mycoplasmas she studied, are found in 
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methylase genes, followed by DNA polymerase, exonuclease and topoisomerase genes.  Guo and Mrázek 
(2008) detected SSRs that are associated with housekeeping genes such as ribosomal protein genes, RNA 
genes and chaperones.  This is somewhat surprising, since these genes are essential for the survival of the 
organism, and inactivation due to DNA polymerase slippage and recombination could be lethal. 
M. capricolum and M. mycoides contain two SSR-associated genes for ABC transporters (Guo and Mrázek, 
2008).  Both the genes in M. mycoides have a 14 bp run of T-nucleotides (Tn) in the upstream flanking regions.  
Taking into account that components of mycoplasma ABC transporters can be recognised as antigens, this is 
consistent with the role of SSRs in antigenic variation.  Some SSRs in M. capricolum encode for putative 
membrane proteins that include three ABC transporters, five genes of the vmc cluster, and several proteins of 
the Lpp family.  The vmc cluster contains TAn repeats in the promoter regions, thus possibly influencing 
expression of these phase variable genes (Wise et al., 2006).  In M. pulmonis there are five SSR-associated 
genes encoding DNA methylases, which might indirectly contribute to antigenic variation by changing the 
methylation patterns in distant chromosome regions and influencing the expression levels of other genes (Rocha 
and Blanchard, 2002).  Approximately 16% of M. gallisepticum’s genome seems to be a reservoir of sequences 
that exists for the variation of a single haemagglutinin antigen (Baseggio et al., 1996). 
3.1.3.1.2. SSRs and immune evasion 
One of the mechanisms of adaptive immune evasion in M. pulmonis concerns phase variation in the Vsa 
proteins.  These are surface-bound lipoproteins that are both phase and size variable (Denison et al., 2005).  
A tandem repeat region of 40 or more repeat units confers resistance to complement lysis of the mycoplasma, 
while those with a repeat of 5 or fewer are readily killed when dispersed, but able to form a bio-film.  This led to 
the development of the shield hypothesis: the Vsa protein with many repeats may shield the surface of the 
mycoplasma and prevent the complement membrane attack complex from inserting into the mycoplasma 
membrane (Simmons et al., 2007).  Shaw et al. (2012) showed the VsaA protein to be the major protein involved 
in this phenomenon.  Irrespective of the Vsa isotype, mycoplasmas that produce a long VsaA protein are able to 
resist binding to macrophages (in this case specifically alveolar macrophages), and once bound, are then able to 
resist being killed. 
The above-mentioned findings were also observed in other mycoplasmas.  Proteins with extensive repeats that 
are similar to the Vsa proteins were found in M. hominis, M. agalactiae, M. arthritidis, M. bovis and M. hyorhinis 
(Citti et al., 1997; Flitman-Tene et al., 2003; Glew et al., 2002; Jensen et al., 1995; Sachse et al., 2000; 
Washburn et al., 1998; Yogev et al., 1991).  In M. hyorhinis, the tandem repeats of Vlp proteins protect the 
mycoplasma from serum antibodies (Citti et al., 1997).  M. hominis produces a Lmp1 protein containing tandem 
repeats, which has been shown to protect the organism from antibodies (Jensen et al., 1995). 
3.1.3.1.3. SSRs and antibiotic resistance 
It is possible that SSRs aid the mycoplasma in evading or resisting antibiotics.  Guo and Mrázek (2008) have 
reported antigenic variations in host-adapted pathogens that are facilitated by SSRs.  This is supported by the 
increasing resistance of prokaryotes, including mycoplasmas, to the broad-spectrum fluoroquinolones that target 
proteins in the topoisomerase II family, DNA gyrase, and topoisomerase IV.  The resistance of some prokaryotes 
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is mediated by mutations that occurred in the target regions of these enzymes (Bébéar et al., 1998).  As such, 
enzymes that target two or more proteins or genes would be more effective, since the odds of a mutation 
occurring in both of these targeted proteins/genes would be rare, as shown by studies on Staphylococcus 
aureus (Fournier et al., 2000).  Antibiotics that target ribosomes have also proved ineffective against certain 
mutants (Pereyre et al., 2002).  SSRs in the rRNA genes may provide the genetic variability that enables the 
mycoplasma to survive in the altered environment, living with the antibiotics that target their ribosomes (Guo and 
Mrázek, 2008). 
The focus thus far has been on the ability of SSRs to enable the mycoplasma to avoid attacks by its host, as well 
as avoid the workings of antibiotics, therefore it should be noted that the pathogenic mycoplasma 
M. hyopneumoniae have fewer repeats when compared to other mycoplasmas.  How this mycoplasma then 
evades the host immune system and is able to lead to chronic infection even in the absence of the help of these 
repeats, remains an open question (Minion et al., 2004).  Even the repeats that do exist, mainly An and Tn 
repeats as discovered between three different strains, may rarely be involved with genome rearrangements 
(Mrázek, 2006). 
3.1.3.2. Repetitive elements in different mycoplasma species 
A large number of close repeats were found in M. pneumoniae.  Ten of these have well-conserved motifs, and 
most of these repeats are associated with lipoproteins, UFOs or RMSs.  Complete analysis of the 
M. pneumoniae genome revealed multiple copies of four large repetitive elements, designated RepMP2/3, 
RepMP4 and RepMP5, with homology to large repeats also found in M. gallisepticum and M. genitalium 
(Musatovova et al., 2012).  In contrast with this, the repeat sequence designated RepMP1 seems to be 
M. pneumoniae specific, with no homologues found in other sequenced mycoplasma species, and with 
numerous copies in its own genome (Musatovova et al., 2012).  These repeats vary in size from 0.3 kb to 2.2 kb, 
and illustrate the extent to which repeats are present in bacterial genomes. 
M. pulmonis contains three sets of large repeats, corresponding to sets of lipoproteins, restriction and 
modification systems (RMSs) and unknown function open reading frames (UFOs).  In addition, 33% of the direct 
or inverse two-copy repeats were found within UFOs, followed by 25% in lipoproteins, and 11% in intergenic 
positions (Rocha and Blanchard, 2002).  The most relevant large repeats found in M. genitalium represent 
multiple copies of fragments of the gene in the mgpABC operon that encode for an adhesin.  Only one of M. 
genitalium’s lipoproteins has been shown to contain a clearly defined close repeat (Rocha and Blanchard, 2002).  
This might be due to its small genome, it being the smallest of the mycoplasmas identified thus far. 
Parts of the P1, P40, P90 and P110 proteins in M. pneumoniae and M. genitalium are subjected to homologous 
recombination due to repetitive sequences such as RepMP and MgPar (Sluijter et al., 2009).  M. synoviae 
contains amino acid repeats in its haemaglutinins that may affect the antigenic response.  Haemaglutinins are 
highly immunogenic, variably expressed, surface proteins (Bencina, 2002).  Repetitive sequences (DR-1 and 
DR-2) in the putative cytadhesin gene pvpA of M. gallisepticum, consisting of 30 or more proline residue repeats 
and 7-10 repeats of the tetrapeptide motif, affect the functionality of the gene (Jiang et al., 2009).  M. bovis 
contains insertion sequences, IS3, IS4, and IS30, whereas M. hyopneumoniae, M. agalactiae and M. mycoides 
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subsp. mycoides contain variable number tandem repeats (VNTRs), which are associated with coding 
sequences and may provide genetic diversity.  The insertion sequences and VNTRs possibly code for amino 
acid residues that affect interaction with the host immune system, as well as host cell attachments (de Castro et 
al., 2006; McAuliffe et al., 2007, McAuliffe et al., 2008).  Tandem amino acid repeats in the genes of 
M. pneumoniae that contain the RepMP1 repeat, and Vsa proteins of M. pulmonis, may have certain regulatory 
functions (Musatovova et al., 2008; Simmons and Dybvig, 2007).  Almost 9% of the genes of a Californian strain 
of M. capricolum subsp. capricolum contain repeats, just under M. pulmonis with 9.3% of its genes, and above 
M. synoviae with 8.3% of its genes (Trivedi, 2010). 
3.1.4. PROKARYOTIC GENE ARRANGEMENT 
Mycoplasma genomes exhibit a poor conservation of gene order.  Exceptions are the more recently diverged 
M. pneumoniae and M. genitalium, whose gene order tends to be more conserved (Glass et al., 2000).  In 
general, enzymatic pathways are the most conserved and are often organised in gene clusters to better regulate 
and optimise protein production.  An example is the arginine deiminase pathway (ADI) of M. penetrans, which 
consists of three enzymes and a specific membrane-associated arginine permease that is organised in a gene 
cluster.  The most conserved pathway is that of glycolysis, followed by the genes involved with DNA replication, 
recombination, repair, and ribosomal proteins, all conserved within clusters (Souza et al., 2007).  Essential 
genes are generally clustered together, such as those involved with nucleotide transport and metabolism (Souza 
et al., 2007).  Gene order and localisation tend to become fixed over time and occur in such an order and 
position to best support the fitness of the organism (Képès et al., 2012). 
3.1.5. STRAND BIAS, BACTERIAL ORIGIN OF REPLICATION AND RELATED SURROUNDING GENES 
It is generally accepted that bacterial chromosomes have a bias of Gn towards their leading strands, leading to 
the so-called G+C skew, but for some genomes, including many Firmicutes, there is also a weaker A+T strand 
bias, with the leading strand containing more Tn than An (Rocha et al., 2000).  G+C content has been related to 
numerous properties, such as genome size, oxygen and nitrogen exposure, and specific habitats.  On that note, 
intracellular bacteria on average have smaller genomes and are more A+T-rich (Wassenaar et al., 2009).  The 
higher A+T content in small, intracellular bacteria has been attributed to a loss of repair genes, leading to an 
increase in the mutation rates from cytosine to thymine (Moran, 2002; Rocha and Danchin, 2002). 
Bacterial chromosome replication starts from a single origin, the origin of replication (ori).  Most bacteria show 
G+C and A+T skews around the origin of replication.  However, two mycoplasma species were shown to be 
C+T-rich in the third codon position (McLean et al., 1998).  Uneven distribution of nucleotides on the leading and 
lagging strands cannot always be reduced to a nucleotide skew.  Circular chromosomes tend to have the ori and 
terminus of replication on exact opposite sides, which evens out the G+C skew to the extent that the bias is 
filtered out to near zero, resulting in the number of Gn being equal on both strands (Bohlin et al., 2010).  
Replication mechanisms may influence the strand’s symmetry patterns, and as such, a lot can be learned by the 
examination thereof.  However, horizontally transferred genes may also influence the strand symmetry, leading 
to changes in the polarity of skew plots (Xia, 2012). 
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The direction of the nucleotide skew switches at the origin of replication, so that the leading strand contains 
more Gn than Cn.  However, in M. genitalium and M. pneumoniae, the direction of the skew was found to be 
opposite to the direction for codon position 3 (McLean et al., 1998).  Their genes are also arranged in such a 
way resulting in the transcriptional and replicational directions to be the same, a tendency that is more 
pronounced for highly expressed genes such as ribosomal protein genes (Brewer and Fangman, 1988).  
According to Karlin et al. (2003) most bacterial genomes contain a large cluster close to the ori that contains 
between 20% and 40% of all ribosomal protein genes.  Many bacterial genomes’ rRNA operons are in the same 
direction as replication (Price et al., 2005; Rocha, 2002).  Other genes that are involved in protein synthesis are 
encoded within or proximal to this large cluster, such as the tuf, fus, rpoA, rpoB and rpoC genes. 
All of the replication origins that have been experimentally confirmed occur in intergenic regions (Gao and 
Zhang, 2008; Mackiewicz et al., 2004).  The position of the ori is conserved among bacterial species, mostly 
found in close proximity to the dnaA gene.  The dnaA gene encodes for the universally conserved DNA 
replication initiation protein DnaA (Ogasawara et al., 1991).  The gene cluster rnpA-rpmH-dnaA-dnaN-recF-gyrB-
gyrA that surrounds the ori and the dnaA gene is often conserved, with the ori located adjacent to the dnaA gene 
in an intergenic region (Briggs et al., 2012).  The ori of M. genitalium and M. pneumoniae reside in an A+T-rich 
area between the dnaA and dnaN genes.  The low G+C content Firmicutes generally have two unique essential 
genes, the dnaD and dnaB genes, in addition to the dnaA gene (Leonard and Grimwade, 2011; Soultanas, 
2011).  Several Mollicutes have only a single gene, the dnaD-like gene, combining both of the functions of the 
dnaD and dnaB genes (Briggs et al., 2012).  Genomes with more An than Tn were shown to contain both a polC 
and dnaE homologue, while the other genomes lack the polC homologue (Worning et al., 2006).  The direction 
of the A+T skew is determined by the DNA polymerase-α subunit that replicates the leading strand (Worning et 
al., 2006). 
3.1.6. DEFINITION OF ESSENTIAL GENES AND THE MINIMAL GENOME 
Essential genes (EG) form one of the three groups of functional genes, with highly expressed genes (HEG) and 
horizontally transferred genes (HGT) being the other two, that play an important role in the survival and 
infectious ability of pathogens (Gao and Chen, 2010).  EG represent the minimal gene set that is required for 
sustaining life of the simplest, self-reproducing bacteria.  For some researchers they represent the gene set 
absolutely required for cell viability, under any conditions.  Others use EG to refer to the gene set that 
contributes to the fitness of the organism and its competitive growth under favourable conditions, for instance in 
the absence of environmental stress and in the presence of essential nutrients (Mushegian and Koonin, 1996a).  
Most of the metabolic genes’ essentiality is relative to the metabolic context or specific conditions (Gerdes et al., 
2003; Koonin, 2003).  These genes therefore represent the part of the bacterial genome that one would suspect 
to be relatively constant, since a change in the expression profile or change in the phase variability would cause 
functional differences and lead to a loss of essentiality.  Some of the known functional genes are drug targets, 
therefore further identification and investigation into important EG might provide further drug targets, lead to 
development of broad-spectrum antibiotics, and aid in developing species-specific antibiotics (Gao and Chen, 
2010).  It will further enable quicker annotation of unknown genome sequences through comparative studies and 
homology searches (Lin and Zhang, 2011). 
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One would expect EG to be conserved, as is the case in bacteria (Gerdes et al., 2003; Jordan et al., 2002).  
EG are more conserved than non-EG, however, conserved genes are not necessarily essential (Fang et al., 
2005).  In addition to this, the fact that certain genes are conserved among bacteria, does not necessarily imply 
that the genes’ essentiality is also conserved, i.e. extrapolation of essentiality is not possible among bacteria 
(Zalacain et al., 2003). 
3.1.7. GENOME STRAND GENE DISTRIBUTION AND REPLICATION 
Mycoplasmas indicate extreme strand distribution, with 80% of genes occurring on the leading strand, compared 
to the more evenly spread 55% of E. coli (Rocha and Blanchard, 2002).  Due to the nature of replication, where 
the leading strand is continuously replicated while the lagging strand is replicated in fragments, bacterial 
chromosomes exhibit strong strand-specific bias, both in terms of oligonucleotide sequence and gene orientation 
(Rocha, 2004).  For Firmicutes, the PolC polymerase and the dnaE gene are responsible for replication in the 
leading and lagging strand respectively (Dervyn et al., 2001; le Chatelier et al., 2004).  In addition, for Firmicutes 
in general, the polymerase that replicates the leading strand with proof-reading capacity resides in one 
polypeptide chain, while the proof-reading capabilities resides in a complex of two polypeptides for the lagging 
strand. 
Necşulea and Lobry (2007) found that all rRNA genes and most of the ribosomal protein coding genes are 
transcribed more often than not in the same direction as DNA replication, this being the leading strand.  The 
same is true for most of the EG, such as those involved with transport and metabolism.  Using this information, 
one would expect to be able to predict the leading and lagging strands in an incomplete and partially annotated 
genome.  An annotated contiguous sequence can be studied to determine if most of the genes, especially EG, 
occur in one direction, thus predicted to be the leading strand. 
3.1.8. GENOME ANNOTATION 
Annotation refers to the extraction of biological information from raw nucleotide sequences (Médigue and 
Moszer, 2007).  Two different methods of genome annotation currently preside: first, the static level and second, 
the dynamic level.  While the static level is only concerned with the basic, automatic annotation that predicts the 
location and function of genes and proteins, including such features as the chemical and structural properties, 
subcellular location, and modular organisation, the dynamic level includes the biological context, by taking into 
account the interactions between the genomic components (Médigue and Moszer, 2007).  These interactions 
refer mainly to protein-protein interactions, regulatory interactions and metabolite transformations.  The dynamic 
level is more focussed on the networks and the biological contexts, using the information obtained from the first, 
static round of annotation.  This leads to a more complex interpretation of the dimensions of annotation (Reed et 
al., 2006). 
Correct, successful annotation relies on similarity analysis, which requires numerous data collections, archives 
and correctly annotated genomes.  Different databases exist for this purpose, including DNA, RNA and protein 
databases.  Protein domains are used to determine the function of predicted genes.  A problem that arose with 
the expanding number of databases available is the issue of integration.  One solution is the Interpro project that 
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integrates different domain signatures to create a unique characterisation for a given protein family, domain or 
functional site (Apweiler et al., 2000).  Annotation and comparison between large numbers of genomes require a 
practical, user-friendly interface in order to make sense of and organise the currents of data.  Therefore, in 
addition to the annotation software available, there are also different software solutions from which to present 
the annotation results visually. 
In the not too distant past, annotation was done manually; a cumbersome and time-consuming process requiring 
careful curation and review.  However, today with high-throughput and low-cost sequencing methods, such 
attention to individual sequences is not feasible.  Thus, the focus shifted to automated annotation, with very little 
‘human’ influence.  The upshot is that some genomes remain poorly, or incorrectly, annotated.  Reannotation 
provides a solution to this: genomes need to be updated regularly.  As manual curation is still performed, albeit 
on a much smaller scale, certain putative proteins or other proteins with unfamiliar functions may be incorporated 
into the automatic database, thus integrating experimental and predicted data.  In support to this feature, 
integrated databases will provide even better annotation.  Armengaurd (2009) indicated that an alliance between 
proteomics and genomics, which can be carried out in the earliest phase of genome sequencing, produces 
almost complete and accurate gene catalogues for small microbial genomes, as has been illustrated with the 
M. mobile and Deinococcus deserti genomes.  Proteomics, transcriptomics, metabolomics and interactomics 
present the opportunity to integrate genomic and functional information.  Integration is important in more than 
one aspect: it enables standardisation of experimental results, simultaneous and complex correlations between 
different pieces of information and coordinated data mining is possible, and genes and proteins that behave 
similarly under various conditions can be grouped (Swertz and Jansen, 2007). 
3.2. THE PARTIAL ASSEMBLY, REPETITIVE SEQUENCE AND BIOINFORMATIC 
ANALYSIS OF THE CONTIGUOUS SEQUENCES OF THE Ms02 GENOME 
3.2.1. INTRODUCTION 
By January 2012, the number of complete bacterial genome sequences deposited into the National Center for 
Biotechnology Information (NCBI) reached 1743.  This rapid increase in the availability of numerous prokaryotic 
sequences has revolutionised new fields of research: that of comparative genomics.  We are able to scrutinise 
pathogenic organisms based on their genome sequence alone.  Comparative studies between different 
annotated genomes enable identification of possible pathogenic proteins, immunogenic targets, and other 
important metabolic features of prokaryotes in general.  The advantage of this bioinformatic approach is 
especially relevant to pathogens.  Different approaches regarding vaccines and other immune therapies against 
pathogens can be investigated, without having to cultivate these dangerous organisms.  The role and 
importance of bioinformatics thus lies in it enabling the extraction of meaningful biological information from the 
flood of sequence data.  Raw sequence data need to be interpreted, which involves the identification and 
annotation of genes, proteins, and regulatory and metabolic pathways, in order to exploit fully the enormous 
possibilities therein.  Genomes also need to be reprocessed or reannotated on a regular basis to incorporate 
newly characterised functions. 
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Liu and Whittier (1995) developed a PCR strategy using interlaced cycles of high and low stringency in a 
multistep thermal cycling program, called TAIL-PCR.  This strategy enables the isolation of flanking regions of 
unknown DNA to a known DNA sequence, irrespective of whether it is a coding sequence or not, as is the case 
with library screening methods.  Mazars et al. (1991) devised the first PCR strategy based on thermal 
asymmetry.  However, the concept of interlaced cycles was illustrated by Liu and Whittier (1995).  Instead of just 
having low and high stringency cycles, their concept is based on intertwining the thermal asymmetric cycles: as 
such allowing for better formation of specific product, as well as amplifying longer products. 
Mycoplasma species represent an interesting organismal group to study from an evolutionary viewpoint, given 
their adaptation to parasitic lifestyles and interaction with their host cells.  In order to explore the organism to its 
full extent, it is necessary to obtain the genome sequence.  The genome sequence of an organism may reveal 
novel biological information.  With the fast expanding availability of bioinformatic tools, the amount of information 
that can be extracted by purely investigating the DNA sequence of an organism is remarkable.  Knowledge 
about its lifestyle, adaptive capabilities, metabolism, evolution and phylogenetics is just the tip of the iceberg.  
The Ms02 genome was previously sequenced using GS FLX 454 sequencing technology, which generated read 
lengths of an average 300 bp.  The short sequences were assembled into 28 larger contiguous sequences, 
amounting to an estimated size of 900 kbp (895 119 bp).  In the present study, an attempt was made to 
decrease the number of contigs using TAIL-PCR.  After assembling a certain amount of the initial contiguous 
sequences, the newly generated consensus sequence was subjected to bioinformatic analysis, including 
repetitive sequence analysis and predicting the location of the origin of replication. 
3.2.2. EXPERIMENTAL PROCEDURES 
3.2.2.1. Genomic DNA isolation 
Ms02 cultures were cultivated by Mr. Johan Gouws at the Veterinary Institute in Onderstepoort, Pretoria.  
Mycoplasma colonies were routinely visible after 72 hours’ growth on modified Hayflick’s medium plates, 
although it tends to vary, especially between species.  The genomic DNA was isolated from a phosphate 
buffered saline (PBS) suspension of the colonies, using a slightly modified method that was first described by 
Hempstead (1990).  In short, 25 ml Ms02 culture was centrifuged at 12 000 x g (4°C) in a sterile JA-20 centrifuge 
tube for 60 min (Avanti J-E Centrifuge; Beckman Coultier, USA).  Care was taken to decant the supernatant as 
completely as possible, after which the pellet was resuspended in 1 ml TE buffer (50 mM Tris-HCl and 10 mM 
EDTA, pH 7.5), followed by centrifugation at 16 000 x g (4°C) for 30 min in a microcentrifuge (Spectrafuge, 24D, 
Labnet International, Inc.).  After resuspending the pellet in 100 µl TE buffer, the sample was stored overnight at 
-20°C.  The frozen cell suspension was incubated at 55°C until just thawed, after which 1 ml TE buffer, 
containing 1% (v/v) SDS, was added.  To this, 44 µl proteinase K (20 mg/ml, Roche) was added and incubated 
for 30 min in a 55°C water bath with occasional mixing.  Thereafter, 14.3 µl pancreatic RNase A (20 mg/ml) was 
added and incubated for 1 h at 37°C.  To precipitate the SDS (indicated by the clearing of the suspension), 
100 µl (5 M) potassium acetate (untitrated) was added and incubated on ice for 30 min.  After centrifuging the 
sample at 16 000 x g (room temperature, RT) for 10 min, the supernatant was transferred to two sterile 2 ml 
microcentrifuge tubes.  An equal volume of chloroform:isoamylalcohol (24:1) was added and the samples mixed 
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by inverting the tubes by hand for 15 min at RT.  After 2 min centrifugation at 16 000 x g (RT), the upper phase 
was removed and the process repeated twice more.  After the third centrifugation, the supernatant was briefly 
mixed with a tenth volume of 3 M sodium acetate (pH 4.8), before adding 2 volumes 95% ethanol.  The tubes 
were then inverted a number of times to ensure a homogenous mixture.  Overnight incubation at -20°C was 
performed to allow for maximum precipitation of the DNA.  Centrifugation for up to 40 min at 16 000 x g was 
performed to maximise pellet formation, after which the pellet was washed twice with 70% ethanol.  To ensure 
complete evaporation of the ethanol, the pellet was air-dried overnight at room temperature.  When the pellet 
was completely dry, it was resuspended in 50 µl TE buffer (10 mM Tris-HCl and 1 mM EDTA, pH 8.0) and left 
overnight at 4°C to dissolve the DNA. 
3.2.2.2. Quantity and quality determination of the genomic DNA 
The concentration and quality of the isolated Ms02 genomic DNA samples were analysed spectrophotometrically 
with the Novell® Nanodrop ND-1000 (v 3.5.1) at 260 nm.  Concentration (ng/µl) and purity (A260/A230 and 
A260/A280) were measured. 
3.2.2.3. Confirmation of Ms02 genomic DNA identity 
To ensure the culture was free from contamination from Ms01 and Ms03, and to confirm the identity of the DNA 
preparations that were isolated from the Ms02 culture, a standardised mycoplasma PCR was performed using 
species-specific primer pairs (Botes et al., 2005a), given in Table 3.1. 
Table 3.1 Nucleotide sequences of the species-specific primer pairs to confirm the purity of the isolated Ms02 DNA. 
Primer pair Primer name Primer sequence (5'→3') Bp-position Tm (°C) 
Ms01 Ms01Z (F) 5'-AACATTAGTTAATGCCGGATACGC-3' 114 75 
Ms01D (R) 5'-GCCAGTATCCAAAGCGAGCC-3' 613 75 
Ms02 Ms02H (F) 5'-AATATAAAAGGAGCGTTTGC-3' 160 70 
Ms02A (R) 5'-AAGGCAATAGCATTTCCTCTACT-3' 447 70 
Ms03 Ms03A (F) 5'-AGTGCTAATGCCGGATACTTATAC-3' 118 70 
  Ms03C (R) 5'-CGTTAACCTCTATACAATTCTAGCG-3' 639 70 
Three positive control reactions were performed; each mycoplasma DNA with its own primer set.  The Ms02 
DNA was tested with each of the three primer pairs.  Briefly, the reaction contained 2 µl of 10x reaction buffer 
(RB; JMR-Holdings, USA), 0.8 µl of 5 mM of each deoxynucleotide (dATP, dCTP, dGTP and dTTP; Advanced 
Biotechnologies Ltd., UK), 0.4 µl of each primer (20 pmol/µl), 1.6 µl of 25 mM MgCl2, 0.1 µl of Taq DNA 
polymerase (5 U/µl Super-Therm Taq polymerase, JMR-Holdings), 12.7 µl Milli-Q® water and 2 µl of purified 
DNA. 
The amplifications were carried out in a 2720 Thermal Cycler (Applied Biosystems Ltd., Warrington, UK).  The 
program consisted of 30 cycles of 30 s at 94°C, 15 s at 57°C, and 1 min at 72°C, followed by a final extension 
reaction for 6 min at 72°C.  The amplified DNA was subsequently cooled and analysed by gel electrophoresis.   
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3.2.2.4. PCR product agarose gel analysis 
Ten microliters of the PCR product, mixed with 1 µl of gel loading buffer (50% (v/v) glycerol, 0.1% (v/v) 
bromophenol blue, 50 mM EDTA, and 100 mM Tris-acetate, pH 8.0), were electrophoresed (100 V,~60 min) on 
a 1% (w/v) agarose gel (Molecular Grade Agarose D1-LE, Whitehead Scientific) in 1 x TAE buffer (40mM Tris-
acetate and 2 mM EDTA, pH 8.0).  GelRedTM Nucleic Acid Gel Stain (Cat #41003, Biotium, Hayward, CA) (0.1 
µl/ml) was included in the gel for ultraviolet (UV) visualisation of the DNA. 
3.2.2.5. Assembly of the Ms02 contiguous sequences by TAIL-PCR 
3.2.2.5.1. Oligonucleotide primer design 
All primers were designed using the computer software package Primer Designer Version 1.01, and synthesised 
by Integrated DNA Technologies (IDT), Iowa City, USA.  Four arbitrary degenerate primers were synthesised, 
according to Liu and Whittier (1995).  These primers have an average Tm of 47-48°C, as calculated by the 
method of Liu and Whittier (1995).  Contiguous sequences were chosen at random and three long, sequence-
specific nested primers were designed on the 3’ end of a contig.  All the primers were either 26 or 28 bp long.  
These three primers were designed to have a Tm within 5°C of one another and to range between 68°C and 
76°C.  The Tm of the specific primers was calculated by the Primer Designer software.  Where deemed 
necessary, further primer pairs were designed to confirm results obtained with the TAIL-PCRs.  These primers 
were designed to be 24 bp in length. 
3.2.2.5.2. TAIL-PCR procedure 
Three rounds of TAIL-PCRs were carried out, using a VeritiTM 96-well Thermal Cycler (Applied Biosystems Ltd.).  
The product of the previous PCR served as the template for the next.  The PCR conditions for all three 
procedures can be seen in Table 3.2.  The PCR mixture for the primary TAIL-PCR contained 4 µl of a 5x RB, 
0.4 µl of 10 mM of each deoxynucleotide (dATP, dCTP, dGTP, dTTP), 0.8 µl of 25 mM MgCl2, 0.2 µl of the 
forward primer (primer a) (20 pmol/µl), 2 µl of the degenerate primer (primer AD) (20 pmol/µl), 0.1 µl of 5 U/µl 
Kapa2G Robust Taq DNA polymerase, all from Kapa Biosystems (South Africa), approximately 1 ng purified 
DNA, and Milli-Q® water up to 20 µl.  The reaction mixture for the secondary TAIL-PCR contained 2 µl of 
10x RB, 0.8 µl of 5 mM of each deoxynucleotide (dATP, dCTP, dGTP and dTTP), 0.2 µl of the forward primer 
(primer b) (20 pmol/µl), 2 µl of the degenerate primer (primer AD) (20 pmol/µl), 2 µl of 25 mM MgCl2, 0.1 µl of 
Taq DNA polymerase (5 U/µl; Super-Therm Taq polymerase), 11.9 µl Milli-Q® water and 1 µl of DNA (1:500 
diluted from the primary reaction).  For the final tertiary PCR reaction, the mixture contained the same final 
concentrations as for the secondary reaction, except for equal amounts of the specific and arbitrary primer: 
1 µl (20 pmol/µl) each.  The reactions were scaled up to 50 µl to ensure ample amount of DNA was available for 
down-stream use.  
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Table 3.2 TAIL-PCR procedures for the three reactions. 
Reaction Number of cycles Thermal settings 
Primary 
5 94°C-30s; 68°C-30s 
1 
94°C-30s; 25°C-1s; 10.4% ramp rate  to 68°C; 
68°C-30s 
24 
94°C-30s; 68°C-30s; 94°C-30s; 68°C-30s; 94°C-
30s;  
(AD1)41°C/(AD2)39°C/(AD3,4)45°C-30s; 68°C-
30s 
1 68°C-5min; 15°C-hold 
Secondary 
25 
94°C-30s; 68°C-30s; 94°C-30s; 68°C-30s; 94°C-
30s;  
(AD1)41°C/(AD2)39°C/(AD3,4)45°C-30s; 68°C-
30s 
1 68°C-5min; 15°C-hold 
Tertiary 30 
94°C-30s; (AD1)41°C/(AD2)39°C/(AD3,4)45°C-
15s; 68°C-15s 
 1 68°C-5min; 15°C-hold 
The amplified PCR products were analysed on a 1% (w/v) agarose gel as previously discussed in Section 
3.2.2.4.  Only 10 µl of the 50 µl were loaded onto the gel.  Fragments were selected based on their size and 
concentration (degree of visibility).  Those with only one fragment visible on the gel were purified directly from 
the PCR product, while the PCR reactions with more than one fragment were again loaded completely on a gel 
and the chosen band excised.  Prior to sequencing, the generated products were purified with illustra GFXTM 
PCR DNA and Gel Band Purification kit (GE Healthcare, UK), according to the manufacturer’s instruction, but 
with one difference: the elution of the DNA was performed with 10-50 µl pre-heated (60°C) Milli-Q® water.  
Concentration of the purified DNA fragments was determined spectrophotometrically as discussed in Section 
3.2.2.2. 
3.2.2.5.3. Sequencing and analysis of PCR products 
Sequencing of the TAIL-PCR products was done with the ABI BigDye® Terminator v3.1 Cycle Sequencing kit 
(Applied Biosystems, UK).  Each sequencing reaction consisted of 5 µl of 5x Sequencing buffer, 2 µl Terminator 
mix, 1 µl (8 pmol/µl) primer (primer c), purified DNA (amount as determined by the ABI BigDye® Terminator 
instructions), and Milli-Q® water to add up to a final volume of 10 µl.  Amplifications were performed in a 2720 
Thermal Cycler programmed to perform 35 cycles of 10 s at 96°C, 30 s at 52°C, 4 min at 60°C, and a final 
extension of 10 min at 60°C. 
The sequencing PCR products were sequenced and analysed with an ABI® 3130 Genetic Analyser (Applied 
Biosystems) at the Central Analytical Facility (CAF), the DNA sequencing facility of the University of 
Stellenbosch.  The resulting sequences were used as a query sequence in a Basic Local Alignment Search 
(BLAST) against a database containing all the contigs of the Ms02 genome in CLC Combined Workbench 
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(v. 4.0.1).  The contigs with significant hits were then manually aligned in BioEdit® Sequence Alignment Editor 
(v 7.0.5.2, Hall), with the generated sequence, as well as with the sequence the specific primers were originally 
designed on. 
3.2.2.6. Investigation of the Ms02 genome repeats  
3.2.2.6.1. Large repetitive sequences in the Ms02 genome 
Large repetitive units were defined as being at least 80 bp long and occurring at least twice in the genome with 
80% and higher identity (based on the definition by Koressaar and Remm, 2012).  To find these repetitive 
sequences, a BLAST was performed on all of the Ms02 contigs.  Each contig was used as a query sequence in 
a BLASTn (nucleotide BLAST) against all 28 large Ms02 contigs using the 4-mold mitochondrial code with the 
word size set at 7 and a match:mismatch setting of 1:-3, all performed in CLC Combined Workbench.  All the hits 
above 80 bp and with 80% or higher identity were investigated to determine whether the repeats were involved 
in coding sequences as annotated previously (Steenmans, 2010).  If one copy of the repeat falls within an ORF, 
the repeat was regarded as gene-associated.   
3.2.2.6.2. Simple sequence repeats in the Ms02 genome 
In order to search for SSRs, the contigs of the Ms02 genome were subjected to the repeat search program 
SPUTNIK (http://espressosoftware.com/sputnik/index.html).  It searches for di-, tri-, tetra- and penta-nucleotide 
repeats, using its own scoring mechanism.  Insertions, mismatches and deletions were tolerated, although they 
affected the overall score.  The program does not search against a library of known microsatellites, but instead 
reads through the provided DNA sequence, assuming the existence of a repeat at every nucleotide, comparing 
subsequent nucleotides and allocating a score to the significance.  If the score rises above a preset threshold 
value, the repeat is accepted.  If it remains below the threshold, the search is abandoned and a new search 
started at the next nucleotide.  Nucleotides that match the predicted value, assuming a repeat, add to the score, 
while those that do not match, subtracts from the score.  Three possible kinds of error exist: insertions, deletions, 
or mismatches.  These are revisited and comparisons may result in a score above the cutoff threshold, and the 
best score of the three may be accepted. 
The length of an SSR was measured in base pairs, rather than as the number of repetitive units.  This allows for 
detection of partial copies and also facilitates comparison among SSRs of different lengths.  In addition, a repeat 
that formed part of more than one oligomer, was deemed to be the shortest SSR and counted as such.  This 
means that a sequence such as ATATATATATAT qualifies as a dinucleotide (AT), as well as a tetranucleotide 
(ATAT) and a hexanucelotide (ATATAT), but is counted as a dinucleotide. 
3.2.2.6.3. Tandem repeats in the Ms02 genome 
The Tandem Repeat Finder (TRF) software available at http://tandem.bu.edu/trf/trf.html was used to identify 
tandem repeats (Benson, 1999).  The program uses the technique of independent Bernoulli trials (coin-tosses) 
to compare the alignment of two tandem copies of a pattern of length n, by a sequence of n independent “coin-
tosses”.  Each head then represents a match between the aligned nucleotides, while tails represent a mismatch, 
insertion or deletion.  It also calculates the probability which specifies the average percentage of insertions and 
deletions between the aligned copies.  Two components are employed in the process of repeat finding: detection 
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and analysis.  First the detection component finds candidate repeats based on a set of criteria.  Following this, 
the analysis component attempts to produce an alignment for each candidate tandem repeat.  Successful 
alignments are further analysed to determine statistics about the alignment, such as percentage identity and 
indels (insertions and deletions), and the nucleotide sequence, including the nucleotide composition and entropy 
measure.  The period size is the pattern size of the tandem repeat.  If the repeat contained numerous copies, 
then this repeat will be detected at various period sizes.  The software noted the period size and the three best 
scoring sizes were chosen.  The following parameters were chosen: match (2), mismatch (-3), indel (-5), 
a minimum alignment score of 50 to report a repeat, and a maximum period size of 2 000.  These represent the 
least stringent parameters available on the program.  To analyse the repeats, the 28 contigs were linked to one 
another numerically.  This enabled ease of assessment of the repeats, without having to search manually 
between contigs. 
3.2.2.6.4. Single base pair runs in the Ms02 genome 
In order to determine the amount and extent of single nucleotide repeats in the Ms02 genome, the contigs were 
searched manually as individual sequences for base pair runs of A, T, C and G.  The contigs were imported into 
the BioEdit® Sequence Alignment Editor and searched for base pair runs of 6 bp and higher (Gur-Arie et al., 
2000). 
3.2.2.7. Bioinformatic analysis of the Ms02 contiguous sequences 
The sequences that were newly assembled, as well as the sequences that could not be assembled, were first 
subjected to a series of analyses to improve the preliminary annotation.  This meant taking into account the 
orientation and grouping of essential genes to decide in which direction a contig is probably positioned, as well 
as using the genes located on the ends of the contigs to try and predict whether certain contigs can be 
provisionally linked to one another.  In this study the terms ‘plus’ and ‘minus’ are not necessarily used to indicate 
leading or lagging, but rather indicative of the direction of the genes on the specific contig, as well as to 
distinguish between the orientation of a contig after being linked to another, from its original orientation. 
3.2.2.7.1. Directional orientation of contiguous sequences based on predicted gene orientation 
Using the preliminary annotations (Steenmans, 2010), the contigs were organised to be orientated in a specific 
direction.  This was determined by arranging the individual contigs according to their annotated gene content.  
The plus strand was predicted to contain the majority of essential genes and also predicted to contain the most 
ORFs.  The rRNA genes and ribosomal genes were analysed in order to determine their direction, since they are 
mostly transcribed in the direction of DNA replication, i.e. the leading strand. 
3.2.2.7.2. Provisional linkage of contigs based on the gene content on the contig ends 
The non-linked contigs were investigated to determine if the genes occurring on their ends could be used to 
predict whether specific contigs could be linked by using a focused PCR.  The genes that occur on the ends of 
the contigs were noted and the contigs analysed, resulting in a prediction as to which other contig it likely occurs 
next to.  Specific primers were then designed to test the prediction.  The PCR was performed as for the Ms02 
identity confirmation (refer to Section 3.2.2.3). 
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3.2.2.7.3. Assembling the single contigs into one large contiguous sequence 
The contigs that were linked with the PCR-based methods, the contigs with the additional sequences that did not 
align with another contig, as well as the rest of the contigs, were used to generate one large contiguous 
sequence.  The information of the directional predictions, based on the gene distribution and gene orientation on 
the individual contigs, and the provisional linkage based on the gene content on the ends of the contigs, were 
used to link the individual contigs in one single sequence. 
3.2.2.7.4. Searching for the origin of replication 
Different programs were used to search for the ori, but only after the contigs were aligned and orientated in their 
respective predicted directions. 
Ori-Finder (http://tubic.tju.edu.cn/Ori-Finder/) finds oris in bacterial genomes based on an integrated method that 
comprises the analysis of base composition symmetry (using the Z-curve method), the analysis of the 
distribution of DnaA boxes, and the occurrence of genes that occur frequently close to oris (Gao and Zhang, 
2008).  Unannotated genome sequences’ ori is routinely found by using the integration of the gene-finding 
program ZCURVE (v. 1.02).  The Z-curve constitutes a unique representation of a DNA sequence, shown as a 
3D curve, commonly used for replication origin identification (Worning et al., 2006; Zhang and Zhang, 2005), 
gene-prediction (Guo et al., 2003), isochore identification (Zhang and Zhang, 2004a), genomic island 
identification (Zhang and Zhang, 2004b), and comparative genomics (Zhang et al., 2003). 
DoriC (v. 5.0) (http://tubic.tju.edu.cn/doric/blast1.html) is an updated database of bacterial replication origins, 
allowing one to search against known oris.  The software’s default settings were used to search the Ms02 
genome, namely the BLOSUM62 matrix, with an Expect value (e-value) of 1.0e-10.  The genome was also 
analysed in GraphDNA (http://athena.bioc.uvic.ca/virology-ca-tools/graphdna/), a DNA Skew Graphing tool that 
allows the user to generate graphical representations of raw DNA sequences (Thomas et al., 2007).  The G+C 
skew is calculated as (C-G)/(C+G) and changes sign when crossing the ori region (Lobry, 1996a; Lobry 1996b).  
The A+T skew [(A-T)/(A+T)], keto-amino skew [(A+C)-(G+T)] and purine-pyrimidine [(A+G)-(C+T)] skew were 
also calculated.  A sliding window size of 70 bp was chosen, based on the software’s recommendation. 
3.2.2.7.5. Gene prediction of the Ms02 genome 
The TAIL-PCR assembled contigs, together with the findings on the genome strand analysis and the provisional 
linkage of the contigs, were used to create one large contiguous sequence.  The contiguous sequence was then 
submitted to four different automatic gene prediction programs (Table 3.3), the results compared, with the most 
likely ORFs identified.  The lower limit cutoff size used for ORFs was 70 bp.  This was decided based upon the 
previous annotations, where the smallest group of genes were the tRNA genes, falling in the range of 70-90 bp.  
In NCBI, the ORF Finder is limited to 50 bp as the smallest ORF.  The 4-mold, mitochondrial and mycoplasma 
code was chosen as the genetic code used to identify the open reading frames.  Another gene prediction 
program available from the NCBI website, GLIMMER, was also used.  GLIMMER (Gene Locator and 
Interpolated Markov ModelER) (v. 3.02), uses interpolated Markov models to identify coding regions in the 
genomes of bacteria and archaea (Delcher et al., 1999; Salzberg et al., 1998).  The Ms02 genome was run 
through the algorithm with the (4) mycoplasma/spiroplasma genetic code.  The final software used, GeneMark, 
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required a reference genome, because the Ms02 genome is too short for self-training.  For this purpose the 
genome of M. synoviae 53 was chosen, because it is the closest to Ms02 phylogenetically in comparison with 
other available genomes.  GeneMark.hmm 2.4 (v. 2.10f) was run using the genetic code 4.  The program 
integrates the GeneMark models into a hidden Markov model framework, where gene boundaries are modeled 
as transitions between hidden states, using the ribosome binding site model to make the gene-start predictions 
more accurate.  Protein-coding potential is analysed within a sliding window using species-specific parameters of 
the Markov models of coding and non-coding regions.  The final application used to predict ORFs (the earlier 
introduced ZCURVE), utilises the Z-curve, a bioinformatics algorithm widely used in genome analysis, including 
ab initio gene prediction (Guo et al., 2003). 
The ORFs that were identified to overlap the linked contigs, i.e. new ORFs that did not occur in the previous 
annotations, were submitted to a BLASTx search (where a translated nucleotide query is searched against the 
protein database) to determine the identity of the ORF.  The mold mitochondrial (4) genetic code was chosen for 
translation to search the mycoplasma (taxid: 31969) organism database.  Significant hits were chosen based on 
the E-value (an indication of the statistical significance of the alignment between the query and the target 
sequence), and the bit score values.  The bit score is an indication of how good the alignment is: a higher score 
means a better alignment. 
Table 3.3  Software applications and databases that were used to search for open reading frames in the Ms02 genome. 
Name Comments URL/Availability 
BLAST Software for sequence database searching http://www.ncbi.nlm.nih.gov/blast/ 
GenBank 
Annotated collection of publicly available DNA 
sequences 
http://www.ncbi.nlm.nih.gov/GenBank/ 
GLIMMER 
Protein gene prediction software for microbial 
genomes 
www.ncbi.nlm.nih.gov/genomes/MICROBES/-
glimmer_3.cgi 
GeneMark Self-training protein gene prediction software  http://exon.gatech.edu/-gmhmm2_prok.cgi 
ORF Finder 
Finds open reading frames of selectable 
minimum size 
http://www.ncbi.nlm.nih.gov/projects/gorf/ 
ZCURVE Genome analysis that includes gene prediction http://tubic.tju.edu.cn/Zcurve_B/ 
3.2.2.7.6. PCR of the linkages between the predicted contig alignments 
A standard mycoplasma PCR was performed on the contigs as they were linked, where primers were available 
to test the alignments (Section 3.2.2.3).  The reactions were scaled down to contain only 10 µl final reaction 
volume.  The products were separated on a 1% agarose gel (Section 3.2.2.4). 
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3.2.3. RESULTS 
3.2.3.1. Isolation of Ms02 genomic DNA 
Genomic DNA was isolated successfully with the modified Hempstead method and was free of contamination 
from Ms01 or Ms03.  The quality and quantity of the DNA were sufficient to use it as a DNA template for the 
TAIL-PCRs.  The DNA was confirmed to be Ms02, producing a product of the correct size in the Ms02 DNA 
sample, and the absence of any product in the DNA sample tested with the Ms01 and Ms03 primer sets.  
This indicated that there was no Ms01 or Ms03 DNA present. 
3.2.3.2. Linkage of contiguous sequences by TAIL-PCR 
Contigs were chosen at random and three specific primers were designed on the 3’ end.  It was found that 
primers designed on the 5’ end tended to result in band sizes of insufficient length to justify sequencing.  Certain 
cases required optimisation: in these cases the annealing temperatures were adjusted to be approximately 
5°C above the Tm of each individual specific primer.  When the sequenced PCR product proved linkage between 
two contigs, a new set of primers was designed on the 3’ end of the linked contig.  In this manner, a total of 
22 sets of specific TAIL primers on 16 contigs were designed.  This resulted in 15 linkages (Table 3.4).  Another 
four contigs were linked (contig 3 with contig 16 and contig 7 with contig 17), but this was not done using TAIL-
PCR and will be discussed later.  The net result was the linkage of 19 contigs in four separate contiguous 
sequences, named A, B, C and D for ease of further reference.  Thus the initial 28 contigs of the Ms02 genome 
was reduced to 14.  However, it was soon realised that the sequencing results were not always reliable, and it 
was necessary to design specific forward and reverse primers, to corroborate the linkage sequence.  In addition, 
the presence of repetitive units in the genome hindered the definite linkage of the sequences.   
In Figure 3.2, an image of a typical TAIL-PCR agarose gel can be seen, following electrophoretic separation and 
UV visualisation of the DNA.  In this instance, specific primers were designed on the 3’ end of contig 15.  
The nested effect due to the use of three specific primers in the three consecutive PCR reactions is clearly 
visible in the image.  Also prevalent is the absence of any visible product in the primary TAIL reaction, as can be 
seen for AD1.  The degenerate primers AD3 and AD4 did not result in any usable products.  This was found to be 
the norm rather than the exception for the TAIL-PCRs.  As can be seen in Table 3.4, 76% of the products that 
were used in successful sequencing resulted from the AD1 and AD2 primer mixes.  An exception was the linkage 
sequence between contigs 32 and 1, and contigs 32 and 33.   
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Table 3.4 The TAIL-PCR linked contigs, additional base pairs that were added and the 
E-values of the linkage. 
Contig alignment AD primer Additional base pairs E-value 
1_32 AD4 71 6.57e-123 
4_38 AD1 173 7.04e-21 
17_31 AD1 10 0 
31_37 AD1 374 5.84e-153 
32_33 AD4 8 0 
33_34 AD1 0 2.35e-72 
34_33 AD1 & AD2 8 0 
37_39 AD1 & AD2 214 4.89e-24 
37_7 AD1 370 1.08e-49 
38_15 AD2 0 4.20e-86 
26_1 AD2 overlap 5 bp 1.02e-85 
15_8 AD2 430 1.86e-31 
41_4 AD1 171 2.56e-43 
10_41 AD1 & AD2 160 0 
8_33 AD2 50 0 
The linkage between contigs 1 and 32 was first detected using a focused PCR, after which a TAIL-PCR product 
was also sequenced.  The linkage between contigs 32 and 33 was sequenced a few times afterwards with the 
other AD primers as well, to confirm the sequence alignments.  In general, the resulting sequences produced a 
surprisingly large number of additional sequences.  Also evident in Table 3.4, is the linkage of one contig to 
more than two other contigs (contig 37 links to contig 7, contig 31, and contig 39).  This in itself is an indication of 
the presence of repeats, although it was not expected for the repetitive sequences to be amplified, when doing a 
nested PCR such as with a TAIL-PCR. Contig 33 and contig 34 also present ambiguous results.  The 3’ end of 
contig 33 linked with the 5’ end of contig 34, whose 3’ end in turn linked with the 5’ end of contig 33, effectively 
forming a circle.  Numerous attempts were made to try and establish which of these linkages are correct, but 
definitive results remained elusive.  Another interesting observation was that the additional base pairs between 
these three contig linkages represent the largest amount of extra sequences that were produced during any 
contig linkage.  The only other (largest) additional sequence is the linkage between contig 15 and contig 8.  
TAIL-PCRs performed on the 3’ end of contig 15 did not produce a long enough sequence to enable linkage to 
another contig.  It necessitated the design of a new set of specific primers on the generated sequence from the 
first TAIL-PCR, on the 3’ end of the contig 15-generated sequence, before a linkage was established with 
contig 8.   
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 Figure 3.2 Image of the TAIL-PCR products 
separated on a 1% (w/v) agarose gel with 
1: 1 KB DNA GeneRulerTM DNA ladder mix (Fermentas)
10: TAIL 1-3 with AD3.  Lane 11-13: TAIL 1
product of TAIL 3 from AD2 was loaded onto a gel, excised, purified and sequenced.
3.2.3.2.1. Linkage of Ms02 contig A
With a test PCR, the primers contig_3d and contig_39x produced a band of approximately 400 bp.  Although the 
general appearance of the agarose gel was poor, it was decided to purify the PCR product and subject it to 
sequencing from both ends.  However, sequenc
align with contig 39.  In this instance, the 39x sequence aligned with contig 3, together with the 3d sequence, but 
unexpectedly did not align with contig 39
a CTn repeat.  In Table 3.5, the results of the local BLAST with the 3d sequence and the 39x sequence can be 
seen.  Thus contig 3 (3’ end) was linked with contig 16 (5’ end).
Table 3.5 Local BLAST performed on the sequences 3d and 39x.  The result was that contig 3 links to contig 16, but no hits 
were achieved with contig 39. 
Contig hit Contig length (bp) 
Contig 16 809 
Contig 3 1204 
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Sequence E-value Hit range Query range
3d 1.04e-114 17-296 98-376
39x 2.38e-99 17-271 266-14
3d 3.90e-15 1147-1202 10-64 
39x 3.70e-43 1110-1202 392-300
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 255 
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 3.2.3.2.2. Linkage of the Ms02 contig B
Contig B consisted of 5 linked contigs in the following sequence: 7
7 and contig 31 also linked contig 7 with contig 37.
aligned for approximately 120 bp, causing the confusing alignment results.  
determine the correct linkage resulted in unrepeatable, numerous different results.  Finally, i
based on the E-values (Table 3.4), the linkage was finalised as described above.  
contig 7 aligned perfectly for 130 bp with the 5’ end of contig 17
contig 17.  In order to confirm whether it is a feasible assumption, a standard PCR was performed.  It has
noted that the binding site for primer 7c 
7a and primer 7b were sequenced (Figure 
 
Figure 3.3 Image of the PCR products 
products were separated on a 1% (w/v) 
the DNA.  Lane 1: 1 KB DNA GeneRuler
contig_17R.  Lane 3: product formed with the 
pair contig_7c and contig_17R.  The products that resulted
contig_17R were purified and subjected to sequencing.
3.2.3.2.3. Linkage of the Ms02 contig
Named contig C, this newly generated sequence consisted
Assembling these contigs was accomplished 
designed to confirm the linkages.  The linkage between contig 4 and contig 41 represent
using reverse primers in the TAIL-PCRs.  Three specific primers for use in a TAIL
end of contig 10.  The resultant sequence had a BLAST hit of 1
10 000 
3 000 
1 000 
500 
100 
 
-17-31-37-39.  A large repeat between contig 
  Sequences from contig 7 and sequences from contig 31 
Primers that were designed to 
.  It is therefore possible that contig 7 links to 
is located inside the repeat, so only the two products formed by primer 
3.3). 
 
between contigs 7 and 17 obtained after electrophoretic separation
agarose gel with 0.1 µl/ml GelRedTM Nucleic Acid Gel Stain
TM
 DNA ladder mix.  Lane 2: product formed with the
primer pair contig_7b and contig_17R.  Lane 4: product f
 from primer pairs contig_7a and contig_
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significant throughout.  Although numerous attempts were made, it was not possible to establish a link between 
contig 10 and contig 39.  It was decided that the linkage was not correct. 
For contig 15, three specific primers were designed on the 3’ end for use in TAIL-PCR, which resulted in a clear 
sequence of over 500 bp, but in spite of the length, did not align to another contig.  To address this problem, 
three more specific primers were designed on the generated sequence.  This resulted in a large enough 
sequence (total 680 bp) and aligned with the 5’ end of contig 8, with an overlap of 70 bp and an additional 
430 bp sequence in between.  Three specific primers were also designed on the 3’ end of contig 8 and the 
resultant sequences aligned perfectly with contig 33.  This will be discussed further together with contig D, since 
the presence of a repeat on contig 33 hindered a confident prediction of the alignments.  
3.2.3.2.4. Linkage of the Ms02 contig D 
Contig D was one of the most difficult sequences to assemble, consisting of the following contigs: 34-33-32-1-
26.  While at first every contig aligned perfectly with long overhangs with the next contig, later the presence of a 
large repetitive unit was detected.  This enabled a linkage with perfect alignments of contig 32, contig 34, as well 
as contig 8, with the 5’ end of contig 33 (Figure 4.3).  A series of nested and specific PCRs finally indicated that 
contig 8 did not link to contig 33: although bands formed in each PCR reaction, the bands were of incorrect size.  
However, the formation of products was erratic between contig 32 and contig 33: a number of times the product 
size was extremely large (in excess of 3 000 bp). 
The additional base pairs between these contigs and contig 33 are runs of An (refer to Section 3.2.3.3.4 for more 
information on this matter).  For none of these contigs are there other possibilities of alternative linkages.  
For this reason, it was decided that contig 33 links to the 5’ end of contig 34, and that contig 32 links to the 
5’ end of contig 33.  Further support for this decision resides in the reannotation of contig 8 linked to contig 33, 
which was established in the course of an Honours project in this laboratory (Bezuidenhout, 2012).  
No difference in the ORF distribution was detected, especially near the connected ends. 
 
contig 33    
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~AAAAAAATAACCCTCCGTGGGTTTTGATCTTTGAAAACTGAATAGT 
32c_contig32 
TAAGTTCTGTAAATTAAGTTTATGCACTAAAAAATAA......~....................................... 
 
8C_contig8 
CCTTAAGGTGTTAATTAGGAATGCATCAAAAAAATAA.............................................. 
 
34c_contig34 
AGTTAACTTTTTTGAGTATTTTAACGTTGAAAAAATA.............................................. 
 
Figure 3.4 Alignment of contig 33 with the sequences that were generated from contig 32, contig 8, and contig 34 
respectively.  Alignment was done manually in BioEdit® Sequence Alignment Editor (v 7.0.5.2, Hall). 
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3.2.3.3. Investigation into the Ms02 genome repetitive elements 
3.2.3.3.1. Large genome repeats 
The single contigs were used as query sequences in a local BLAST against all of the Ms02 genome contigs.  
Repeats were noted only when the identity was 80% or higher.  Sizes ranged from 18 to 396 bp.  The total size 
of these repetitive sequences amounted to 11 310 bp.  This is not an indication of the total amount and extent of 
the repeats, since the true number of copies was not determined, but rather just the presence of a repeat.  The 
repeats accumulated to 116 different units, i.e. not taking into account the number of times a single repeat 
occurs in the genome. 
Repeats of 80 bp or more in length, with 80% or more identity to at least one other copy in the genome, were 
defined as being “large”.  Only 17 such large repeats were found, ranging from 82 to 396 bp in length.  The 
repeats were found to be mostly gene duplications.  Only one repeat was not associated with any coding 
sequence, and one repeat was associated with a hypothetical protein coding sequence.  The repeats appear to 
be mostly aminopeptidases and Type I Restriction Modification systems (RMS).  Only one large repeat is 
associated with a tRNA gene (Table 3.6). 
Reasons for the small number of large repeats include the mechanism of analysis.  Numerous repeats were 
found to occur adjacent to one another.  The program recognised these repeats as single segments, while the 
large comprehensive repetitive sequence is a more correct representation of the repeats.  Manual analysis of 
these regions identified repeats of more than 1 000 kb.  Generally, large repeats are associated with 
lipoproteins, RMSs, and unknown function open reading frames (UFOs).  The Ms02 genome adheres to this 
generalisation, with five of the genes associated with large repeats being Type I Restriction Modification System 
genes. 
3.2.3.3.2. Simple sequence repeat searches using SPUTNIK 
Simple sequence repeats (SSRs) are defined as being repeating units of 2-6 bp in length, also known as 
microsatellites, and are a type of variable number tandem repeat (VNTR).  Thirteen contigs were found to 
contain microsatellites using the SPUTNIK program.  Each SSR was treated as a separate repeat, i.e. the 
complements were not grouped together.  For instance, CA was not grouped with GT repeats.  Each repeat was 
also treated separately per contig.  In Table 3.7, the type of SSRs is indicated, together with their respective 
lengths.  In the first group, the di-nucleotide repeats, the microsatellites TA and GA occur on two different contigs 
with different lengths, and they are therefore treated separately.  There are 30 different types of SSRs in the 
Ms02 genome, distributed as follows: two di-nucleotides, twelve tri-nucleotides, seven tetra-nucleotides and nine 
penta-nucleotides.  The total number of these repeats is 39, with a total length of 545 nucleotides, ranging from 
11 to 21 bp. 
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Table 3.6 Large repetitive sequences occurring in the Ms02 genome and their gene association. 
Contig Repeat contig Size (bp) E-value % Identity Gene association 
3 10 108 1.02e-15 84 HsdS 
44 99 9.82e-13 84 / 
4 30 115 1.14e-53 98 tRNA-Gly-TCC 
7 17 131 1.25e-55 95 Cellobiose-related proteins 
30 152 8.58e-26 85 Aminopeptidase 
30 141 3.15e-19 84 Aminopeptidase 
30 103 2.89e-20 87 Aminopeptidase 
12 114 1.85e-03 80 ATP synthase alpha chain 
8 14 88 2.78e-09 84 Aminopeptidase 
9 44 359 7.56e-48 82 Type I restriction modification system 
11 341 2.88e-44 82 Type I restriction modification system 
11 82 8.44e-05 82 Type I restriction modification system 
11 44 396 1.92e-70 83 Type I restriction modification system 
39 116 2.99e-32 90 Type I restriction modification system 
13 1 194 1.62e-17 81 Hypothetical protein 
30 41 92 4.48e-16 87 DNA-cytosine methyltransferase 
41 87 2.56e-08 84 DNA-cytosine methyltransferase 
 
Table 3.7 The sequences, distribution and lengths of Ms02 genome simple sequence repeats. 
Repeat type 
Di Tri Tetra Penta 
Repeat 
group 
Repeat 
length 
Repeat 
group 
Repeat 
length 
Repeat 
group 
Repeat 
length 
Repeat 
group 
Repeat 
length 
GA 20 + 11 TTC 12 + 12 + 13 ACAA 13 CTTTT 14 
TA 20 + 17 TCC 13 TTAT 13 TTTTG 21 + 14 
  ACC 12 TTTG 13 ATGAA 14 
  TAA 12 + 12 TAAA 13 ATAAT 12 
 
  GTT 12 TATT 13 TTGTT 14 
  CTG 12 TTGA 14 AAATG 15 + 14 
  GCT 13 + 15 AATT 21 TGTTT 14 
  TGT 13     AGAAA 15 
  ACT 15     AAAAT 14 
  AAT 12 + 12     
  GAA 12     
  CAG 12     
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3.2.3.3.3. Tandem Repeat Finder 
Tandem repeats are patterns of two or more nucleotides that form a series of repetitions adjacent to one 
another.  Tandem repeats shorter than 10 nucleotides are called microsatellites, while repeats between 10 and 
60 nucleotides are known as minisatellites.  The Tandem Repeat Finder (TRF) was used to detect these repeats 
in the Ms02 genome.  Doing the analysis on all of the contigs at once by linking them numerically resulted in a 
total of 1 218 repeats over the 900 kbp sequence.  Copy numbers of individual repeats range from 1.9 to 34.8, 
and the sizes of the repeats range from 14 to 99 bp.  Although the definition of a repeat implies at least two 
copies of a given sequence, this program did not work on absolute values.  The possibility of insertions and 
deletions was also analysed and taken into account, and as such, the lowest copy number found was 1.9.  All of 
the repeats have an alignment score of 50 or higher.  The size of the repeats represents 8.2% of the genome.  
The distribution of nucleotides in the repeats supports the A+T-rich nature of mycoplasma genomes: 39% of the 
repetitive sequence are Tn, 35% are An, and Cn and Gn are 13% each. 
3.2.3.3.4. Single base pair runs in the Ms02 genome 
The contiguous sequences of the Ms02 genome were subjected to manual searches for single nucleotide 
repeats.  A minimum starting value of 6 bp was used (Gur-Arie et al., 2000), but due to the A+T-richness of the 
mycoplasma genome, this was increased to 8 bp for An and Tn repeats.  True to the A+T-rich nature of 
mycoplasma genomes, G and C runs are underrepresented.  There are only two repeats of Gn6 (6 repeating 
guanine nucleotides), and 3 repeats of Cn6.  This is in sharp contrast with An and Tn runs. 
There are a total of 50 repeats of An runs of 8 bp or more.  The Ms02 genome contains 5 repeat sequences with 
more than 8 bp An runs: An9, An12, An17, and two An16.  The repeat sequence of the two 16 bp runs is similar, 
excluding one base pair (AGCAAAAAAAAAAAAAAAACA-A/G).  In addition to these repeats on the single 
contigs, the linkage of contig 32, 33, 34, and 8 also exposed An runs, which is suspected to contribute to the 
difficulty of finalising these linkages.  Between the contigs 8 and 33 part of the additional sequence that was 
produced, an An7 run occurred, i.e. AAAAAAATAA.  This sequence was directly followed by the 5’ end of contig 
33, which contained the exact repeat.  However, the additionally produced sequence contained one less A both 
before and after the Tn, between the alignment of contig 32 with 33, i.e. AAAAAATA.  The same occured on the 
alignment between contigs 34 and 33. 
The Tn nucleotide repeats of 8 bp or more amounted to 57, with two Tn15, one Tn13, three Tn9, and four Tn14.  
Many of the larger repeats contained the same three base pairs at the end of the run, and differed only in the 
number of Tn (as well as An, as mentioned above).  The following sequence serves to demonstrate the extent of 
the runs, and reminds one of the problems when attempting to assemble the genome: 
CTGTTTTTTTTTTTTTTGTTTTTTGCAGTTTTTTT.  Runs such as these complicate the assembly of reads 
during de novo sequencing, as well as complicate primer design for use in PCR-based chromosome walking 
techniques, such as TAIL-PCR, to assemble individual contigs. 
The repeats that were 9 bp or higher were investigated to determine their gene association.  Most were found to 
occur in intergenic regions, some close to the genes, both upstream and downstream.  Two repeats are 
associated with hypothetical proteins (Tn9 and An17), one repeat occurs in a 5S RNA gene (Tn9), and one occurs 
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near the end of a maltodextrin ABC transporter permease protein MalC (An9).  According to Guo and Mrázek 
(2008), both M. mycoides and M. capricolum contain Tn runs upstream from their SSR-associated ABC 
transporter genes.  The Ms02 genome contains five Tn runs upstream from ABC transporter genes, located 
between 190 and 534 bp upstream, and one Tn run inside an ABC transporter gene, the ABC transporter xylose-
binding lipoprotein. 
3.2.3.4. Bioinformatic analysis of the contiguous sequences 
The gene predictions were performed on contigs A, B, C, and D (that resulted from the TAIL-PCRs), as well as 
on the sequences that were force-linked by analysis of their gene distribution patterns.  Thus the gene prediction 
was only done after  the linkage of the contigs.  First, the contigs were assembled into one contiguous 
sequence, based on this information.  The contiguous sequence was then submitted to gene prediction 
programs.  Only the ORFs that were located across two contigs were subjected to identity searches using the 
BLASTx tool. 
3.2.3.4.1. Directional orientation of contigs based on predicted gene orientation 
The individual contiguous sequences were analysed based on the previous ORF predictions and annotation 
results (Steenmans, 2010).  The total amount of ORFs, the location of essential genes, and the gene distribution 
on the plus and minus strand, were taken into consideration in order to predict the direction of the contig.  
The essential gene categories (as shown in Table 3.8) were chosen based on the essential gene analysis of 
twelve mollicute genomes, as done by Souza et al. (2007).  To categorise the contigs, both essential genes and 
total ORFs were taken into account (Addendum A).  Only contigs with 10 or more ORFs were considered.  
From these, if the percentage genes on each strand were too close to one another, and if the comparison 
between essential gene and total gene percentages cancelled out, it was deemed that not enough information 
existed to make a reasonably confident prediction of the orientation of the contig.  Of the 25 annotated contigs, 
only 11 contigs’ direction could be predicted confidently.  Contigs 16, 37, and 39 were not annotated previously, 
because of their small size.  Three of the 11 contigs remained in the current direction, the other 8 were predicted 
to occur in the opposite direction.  However, this method of prediction is not infallible, and to test its validity, the 
contigs that were already linked were investigated.  Three sets of newly generated sequences, categorically 
named contig B (linked contig 7-17-31-37-39), contig C (linked contig 8-15-38-4-41-10), and contig D (linked 
contig 34-33-32-1-26), were analysed to determine if there was any merit in the predictions.  Contig A was 
deemed too short to be of significance (2 027 bp).  Of contig C, all of the individual contigs were linked in the 
same direction as their respective predictions.  Certain other factors were taken into account, such as the 
orientation of specific genes.  The Opp operon, containing the OppA protein, occurs on the negative strand of 
contig 8.  The analysis of total genes and essential genes with regard to their direction predicted contig 8 to be in 
the opposite direction.  Thus, this was taken as enough evidence to orientate the contig opposite to what it was, 
currently correctly indicated in Section 3.2.3.2.3.  In addition, contig 8 is part of a linked contig, where the total 
direction of the combined contig also indicated the validity of the prediction.  Contig B could not be validated, 
since 2 of the linked contigs were not annotated, due to their small size, and the other 3 could not be predicted 
as there was not enough information available.  Contig D provided mixed results.  Contig 34, part of contig D, 
contains a ribosomal cluster with 31% of the total ribosomal genes.  According to Necşulea and Lobry (2007), 
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most of the ribosomal protein coding genes are transcribed in the same direction as DNA replication, this being 
the leading strand.  Due to the fact that 20 ribosomal genes, forming a gene cluster, are transcribed on the plus 
strand of contig 34, it was decided to uphold this contig’s orientation.  Taking this into account, the rest of contig 
D adhered to the method of prediction, except for contig 1.  This was taken as a good starting point of predicting 
strand orientation.  Only two contigs’ strand orientation differed after taking into account the orientation of the 
ribosomal genes and rRNA genes, namely contig 13 and contig 33, both changed from a “no prediction” to a 
“plus prediction”. 
Table 3.8 Distribution of the different categories of essential genes in the Ms02 genome. 
  
Category Total genes Genes on plus strand Genes on minus strand 
Amino acid transport and metabolism 18 7 11 
tRNA genes and related metabolism 62 27 35 
Cell division 24 6 18 
Nucleotide transport and metabolism 18 7 11 
Ribosomal proteins and metabolism 68 45 23 
Lipid metabolism 11 0 11 
Phosphate metabolism 4 1 3 
Inorganic transport and metabolism 8 1 7 
Glycolysis and gluconeogenesis 9 5 4 
Carbohydrate transport and metabolism 18 10 8 
DNA repair 9 4 5 
Pentose phosphate pathway 2 2 0 
Total: 251 115 136 
Percentage:   46% 54% 
3.2.3.4.2. Provisional linkage of contigs based on the gene content on the contig ends 
Using the assumption that certain genes must occur adjacent to one another, the remainder of the contigs were 
investigated to determine if the genes could be used to predict the alignments.  PCR primers were designed on 
those contigs for which primers had not been designed yet.  Three ‘gene sets’ were detected on the contig ends.  
Five contigs contained a Type I Restriction Modification system, or subunit, regarding DNA specificity (contigs 2, 
7, 9, 11, and 44).  Three contigs contained a gene coding for phosphotransferase or cellobiose components 
(contigs 7, 9, and 17).  Two other contigs contained genes involved in deoxyribose and deoxynucleoside 
metabolism (contigs 8 and 14).  However, it was not possible to prove a linkage between any of these contigs.  
This is in line with the observation that mycoplasma genes are not conserved in terms of their position or relative 
order in the genome.  In addition to this, it is suspected that the repetitive nature of the genome further 
complicated positive results.  Figure 3.5 illustrates this point.  A standard amplification PCR was performed using 
forward and reverse primers designed on contig 14 in combination with primer contig_8a.  Numerous products 
resulted in both reactions. 
Stellenbosch University  http://scholar.sun.ac.za
61 
 
 
Figure 3.5 Image of the PCR products obtained after electrophoretic separation depicting the repeats between contig 8 and 
contig 14.  The PCR products were separated on a 1% (w/v) agarose gel with 0.1 µl/ml GelRedTM Nucleic Acid Gel Stain for 
UV visualisation of the DNA.  Lane 1: 1 KB DNA GeneRulerTM DNA ladder mix.  Lane 2: product formed with the primer pair 
contig_8a and contig_14F.  Lane 3: product formed with the primer pair contig_8a and contig_14R. 
3.2.3.4.3. Assembling the single contigs into one contiguous sequence 
Aftre the linkage of the contigs using TAIL-PCR, and the linkage that resulted from focused amplification PCR, 
the contig number was reduced to 14 large contigs.  The 14 contigs were assembled into one large contiguous 
sequence in order to allow gene prediction as a whole.  In determining the sequence in which to link the contigs, 
the information of the above findings was taken into account, i.e. not to link contigs that has preliminary been 
proven not to occur adjacent to each other.  The contigs whose direction was predicted with confidence to be in 
the minus direction were inverted to give the reverse complement (RS) sequences.  Additional sequences (AS) 
that were produced, even though no significant hits were found with other contigs, were also included.  These 
occurrences were unexpected, since most of the additional sequences were quite long.  For instance, the 
produced sequence on contig 6 was 240 bp, on contig 38 it was 350 bp, and on contig 13 it exceeded 500 bp, 
but no alignment with other contigs was detected.  Table 3.9 indicates the sizes of the old contigs as well as the 
newly linked contigs from smallest to largest.  For the above-mentioned reasons, the following sequence was 
used for the final linkage: A-2(AS)-6(AS)-B-C-9-11-12-13(AS)-14(RC)-29(RC)-30(RC)-D-44. 
  
1               2              3 
10 000 bp 
3 000 bp 
1 000 bp 
500 bp 
100 bp 
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Table 3.9 The 14 large contigs obtained from whole-genome GS FLX 
sequencing of Ms02, as well as the linked contigs, using TAIL-PCR. 
Contig ID Contig length (bp) 
Contig00002_AS 1 347 
Contig00011 1 800 
Contig_Ms02_A 2 027 
Contig00044 5 319 
Contig00009 5 851 
Contig00006_AS 25 801 
Contig00012 39 046 
Contig00014_RC 67 524 
Contig00013_AS 72 293 
Contig_Ms02_D_RC 105 763 
Contig00029_RC 111 665 
Contig_Ms02_B 119 099 
Contig00030_RC 127 294 
Contig_Ms02_C_RC 214 166 
3.2.3.4.4. Searching for the origin of replication 
The Ori-Finder detected an ori, including three DNA box motifs, located in the region of 866 359 – 866 821 bp in 
the Ms02 genome, which corresponds to the end of contig 32 just before the alignment with contig 1.  The Ms02 
DnaA box motifs detected are: TTTTCCAAA, TTTGGATAA, and TGTTGAAAA.  The A+T content of the ori is 
68%. 
DoriC is a database containing numerous other oris from a vast array of genomes.  The ori hit most related to 
Ms02 was with M. hyorhinis, with an Expect value of 8e-10.  The sequences have 84% identity and a score of 
89.7.  This sequence occurs in the region of 561 223 – 561 339 bp in the Ms02 genome, which corresponds to 
contig 29, about 10 000 bp into the contig. 
Sequences for both predicted oris can be seen in Addendum B.  The distance between the two predicted ori 
locations gives an indication of the nature of bioinformatic analysis: although largely useful, manual curation and 
experimental proof are still required to finalise the predictions. 
3.2.3.4.5. Nucleotide skews of the Ms02 genome 
The GraphDNA program was used to generate a graphical representation of the raw Ms02 DNA sequence.  This 
allows the graphical analysis of different types of genomic skew, including purine-pyrimidine skew, keto-amino 
skew, G+C skew, and A+T skew (Figure 3.6a – Figure 3.6d). 
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Figure 3.6(a) Graphical representation of the differential G+C distribution along the Ms02 genome as calculated by 
GraphDNA. 
Figure 3.6(b) Graphical representation of the differential A+T distribution of the Ms02 genome as calculated by GraphDNA. 
Figure 3.6(c) Graphical representation of the keto-amino distribution of the Ms02 genome as calculated by GraphDNA. 
Figure 3.6(d) Graphical representation of the purine-pyrimidine distribution of the Ms02 genome as calculated by GraphDNA. 
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A steady increase in the G+C skew is observed (Figure 3.6a).  In this case the G+C skew is indicated by a 
general trend line that increases linearly.  No clear point is detected where a change in the direction of the G+C 
distribution occurred.  The A+T skew is a better demonstration of a change in direction in the distribution of 
nucleotides across the genome, as can be seen in Figure 3.6b.  The predicted ori occurs just as the A+T skew 
starts to decrease (change in direction).  At the start of the graph, the A+T skew starts higher, decreases, and 
then rises again.  If the vantage point of the graph is changed, it will form a clear peak around the ori, with a 
definite change in the direction of the A+T skew.  From these graphs it is clear that the A+T skew is a better 
representation of the predicted ori, as happens in A+T-rich genomes.  The same trend is visible in the purine-
pyrimidine skew and the keto-amino skew, where a turning point is observed at 866 000 bp.  The Ori-Finder 
program predicted the ori to be located around 866 000 bp.  DoriC predicted the ori to be located at 561 000 bp.  
None of the graphs present a turning point at this location, possibly indicating that this is not the correct ori, but 
instead the one predicted by Ori-Finder. 
3.2.3.4.6. Gene predition of the Ms02 genome 
Four different automated gene prediction programs were used to search for ORFs in the newly generated 
contiguous sequence of the Ms02 genome: the ORF Finder available from the NCBI website; GLIMMER from 
the same website; GeneMark; and ZCURVE, an algorithm that forms part of ori finder software.  The results 
were compared and all the ORFs that were located at the joining point between two contigs, or as part of the 
newly generated sequence from the TAIL-PCRs, were submitted to a BLASTx search to determine any 
significant alignments with a known or predicted gene function.  The individual results can be seen in Addendum 
C.  In this manner, 18 ORFs were analysed.  The largest group of ORFs was associated with Type I Restriction 
Modification systems (8/18 ORFs).  The ORFs were analysed as a means of proving the linkages, as determined 
by the TAIL-PCRs.  Linkages that were confirmed with the ORF analysis are: 7-17, 37-39, 8-15, 1-26, and 32-1.  
Additional ORFs that spanned across two contigs that were provisionally linked (but not experimentally) include: 
16-2, 6-7, 11-12, and 26-44.  However, these cannot be seen as a definite indication of a linkage, because of the 
predictive nature of the ORF finding software, and due to the small size of some of these contigs, such as contig 
2 (1347 bp), where an ORF that spans the contig over the ends is somewhat expected. 
3.2.3.4.7. PCR of the final linked contigs 
A PCR was performed, where primers were available, to indicate the true alignments of the final linked contigs.  
As can be seen in Figure 3.7, not many reactions did in fact form a product.  From the 7 reactions that did 
amplify DNA, one was not experimentally proven prior to this.  In lane 11 a clear and intense band formed using 
the primer pair contig_10c and contig_9R.  The size of the amplified product indicates that there is most likely 
another contig between contigs 10 and 9.  The same can be said for the linkage between contigs 32 and 33.  
The size of the amplified product here is well over 3 000 bp, which is odd, since the TAIL-PCR results aligned 
the two contigs with only 8 additional base pairs.  A similar result occured when trying to finalise which contig 
links to contig 33 (Section 3.2.3.2.3).  This might be an indication that this alignment is in fact incorrect, since the 
problem with contig 33 affects so many other alignments, it is possible that another contig is supposed to align 
between contig 32 and contig 33.  The results of this PCR correspond well with the results from the additional 
ORFs detected on the contig ends.  Unfortunately the contigs that contained an ORF located across the ends 
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and that were not previously linked, did not contain primers to determine if the ORF distribution proved the 
existence of a linkage.  An ORF was detected across contigs 16 and 2, although, as can be seen in Lane 2, no 
bands were formed in the corresponding PCR reaction.  This possibly occurred due to the small size of both 
contig 16 and contig 2: 809 bp and 1 347 bp long respectively.  Contig 16 was not annotated previously, due to 
this fact.  Another example is the ORF spanning contigs 6 and 7, although no product was formed in a PCR 
between these two contigs to corroborate the ORF, as can be seen in Lane 3.  Two other incidences like this 
occurred, but without available primers to verify: a slight overlap of an ORF occurs on contig 11 onto contig 12, 
and an ORF that links contig 26 with contig 44. 
 
 
Figure 3.7 Image of the PCR products obtained after electrophoretic separation depicting the alignment between the 
different contigs linked into one.  The PCR products were separated on a 1% (w/v) agarose gel with 0.1 µl/ml GelRedTM 
Nucleic Acid Gel Stain for UV visualisation of the DNA.  Lane 1: 1 KB DNA GeneRulerTM DNA ladder mix.  Lane 2: primer 
pair contig_16c and contig_2c.  Lane 3: primer pair contig_6c and contig_7R.  Lane 4: primer pair contig_7b and contig_17R.  
Lane 5: primer pair contig_31c and contig_37c.  Lane 6: primer pair contig_37R and contig_39c.  Lane 7: primer pair 
contig_39z and contig_8Rc.  Lane 8: primer pair contig_8b and contig_15Fc.  Lane 9: primer pair contig_15R and 
contig_38c.  Lane 10: primer pair contig_4z and contig_41F.  Lane 11: primer pair contig_10c and contig_9R.  Lane 12: 
primer pair contig_9F and contig_11R.  Lane 13: primer pair contig_14F and contig_13Fc.  Lane 14: primer pair contig_33c 
and contig_34R.  Lane 15: primer pair contig_32c and contig_33R.  Lane 16: primer pair contig_1c and contig_32z. 
3.2.4. DISCUSSION 
The Ms02 genome was previously subjected to GS FLX 454 sequencing that resulted in 28 large contiguous 
sequences, ranging from 635 bp to 126 294 bp (Steenmans, 2010).  The estimated genome size was 900 kbp 
(895 119 bp) and was sequenced with 99.78% accuracy.  It was decided to employ the technique of TAIL-PCR 
to attempt assembly of as many as possible of the 28 contigs into larger contigs.  While the TAIL-PCR technique 
proved very effective initially, it soon became apparent that the presence of repeats greatly complicated the 
prediction and alignment of the contigs.  Even though 18 contigs have been linked, resulting in a new total of 
14 contigs, many of the alignments contained contradictory results, and some aligned with more than two other 
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contigs.  This is thought to be due to the difficulty associated with primer design in A+T-rich genomes such as 
mycoplasmas.  It is difficult to design primers without runs or secondary structures.  However, in spite of the 
difficulties that were faced with the TAIL-PCRs in this study, the Ms02 genome’s contiguous sequences were 
reduced by half. 
Attempts to link the contigs based on gene ends proved ineffective, in line with the observation that gene order 
in mycoplasma genomes are not necessarily conserved (Mushegian and Koonin, 1996b; Rocha and Blanchard, 
2000).  Essential genes are predicted to occur on the leading strand, and this proved to be a good starting point 
for predicting the orientation of single contigs in the Ms02 genome (Necşulea and Lobry, 2007).  When this 
method of prediction regarding essential genes and ORF distribution was applied to the contigs that were 
already linked, it correctly predicted the relative directions of the linked contigs of contig A and contig C.  The 
distribution of ribosomal genes was also compatible with these predictions, further supporting this as a 
preliminary mechanism of predicting strand orientation.  Therefore, the distribution of ORFs and essential genes 
on the individual contigs were deemed to be useful in predicting the relative direction of the contigs.  This will 
allow the design of more focussed primers, quickening the assembly process of contiguous sequences. 
The 14 new contiguous sequences now range from the smallest 1 347 bp (contig 2 plus additional sequence) to 
the largest 214 116 bp (contig A).  These sequences were then analysed with different programs to determine 
the extent of the repetitive nature of the Ms02 genome.  Large genome repeats were searched using the CLC 
Combined Workbench, which detected repeats up to 400 bp.  However, manual sequence analysis during the 
alignment and assembly of contigs, and sequences generated with TAIL-PCR, indicated that this might be an 
underestimation of the size of large repeats present in the Ms02 genome.  Further studies and analysis will have 
to be done in order to obtain a better representation of the size of the repeats, as well as the true distribution 
thereof, since the programs did not allow for detection of iterations of the same repeating unit. 
Simple sequence repeats (SSRs) are generally rare in most bacterial genomes, but quite common among 
mycoplasmas (Mrázek, 2006; Mrázek et al., 2007).  SSRs (repeating sequences of 2-6 bp) were searched for by 
using SPUTNIK, which detected 39 different SSRs.  These repeats ranged from 11 bp to 21 bp in final size, and 
consisted of di-, tri- tetra-, and penta-nucleotide repeats.  Mononucleotide repeats were searched for manually 
on the individual contigs.  The mononucleotide repeats of An and Tn were extensive, even with an inclusion start 
value of 8 bp, a repeat size that was deemed to be underrepresented by Metzgar et al. (2002) due to the 
tendency of SSRs to contract in the absence of selection.  Guo and Mrázek (2008) found Tn runs upstream of 
ABC transporter genes, both in M. mycoides and M. capricolum.  In the Ms02 genome, Tn6 runs were found to 
occur within 190-540 bp of ABC transporter genes.  M. hyopneumoniae and M. pulmonis contain short ATn runs 
that are periodically spaced at 11 bp and 12 bp respectively.  This may likely affect the supercoiling ability of the 
DNA molecule (Mrázek, 2006).  The roles of these runs appear to be independent of up- or downstream location 
of genes. 
The mononucleotide repeats contributed to the difficulty of assembly: where contigs were linked with a number 
of bp runs, such as An in the instance of the linkages with contig 33, the exact number of single nucleotide 
repeats is difficult to determine, and when these repeats occur inside a gene, frameshifts may occur.  In order to 
assemble the Ms02 genome more accurately, a good idea would be to resequence using paired-end technology, 
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which would give an indication of the direction and sequence of the contigs, allowing for better linkages and 
focused searches using TAIL-PCR and direct PCRs. 
Nucleotide skews have long been used as a method of predicting the origin of replication in bacterial genomes 
(Lobry, 1996a, 1996b).  Analysis of the different skews of the Ms02 genome indicated the applicability of using 
such skews in ori predictions.  The A+T skew, keto-amino skew, and purine-pyrimidine skew, supported the ori 
prediction as calculated by the Ori-Finder.  In A+T-rich genomes such as mycoplasmas, the A+T skew is often a 
better indication of the ori location than G+C skew, and this has been demonstrated with the Ms02 genome as 
well.  An interesting analysis could result from using Oriloc, which only examines the third codon position to 
determine the skew.  It has been shown that in some species the direction of the skew is opposite to that for the 
third codon position in genes, observed in B. subtilis for the A+T skew and in M. genitalium and M. pneumoniae 
for the A+T and G+C skew (McLean et al., 1998). 
Analysing the ORFs over the contig ends, for those that were linked provisionally and those that were linked with 
the TAIL-PCRs, firstly confirmed the results of the TAIL-PCRs (that resulted in a reduced number of 14 contigs), 
and secondly predicted the additional linkage between contigs 10 and 9, contigs 6 and 7, and contigs 26 and 44.  
There probably exists another contig in between contigs 10 and 9, due to the large product that was formed from 
a focused PCR.  The PCR also exposed a large product formed between contigs 32 and 33, which indicates the 
probability that the predicted linkage is incorrect, and that another contig should be linked to contig 33.  
Further analysis is therefore imperative to prove and establish the correct linkages, not just for this group of 
contigs, but for all of the contigs.  Although this is not a definite indication of a linkage, it is worth exploring to 
determine if the ORFs that were detected, are correct.  However, only the ORFs that occured over two newly 
linked contigs were anlaysed, and not the ORFs that were detected inside the contigs.  Therefore, direct 
comparisons with the previous annotation results cannot be drawn. The previous annotations were performed on 
the ORFs that were detected on individual contigs, thus no ORFs would have occured across two contigs’ ends. 
3.2.5. CONCLUSION 
The Ms02 genome was previously sequenced using GS FLX Roche 454 sequencing technology, which resulted 
in 28 large contiguous sequences.  This study used a technique called TAIL-PCR to reduce the amount of 
contigs to 14 large contigs, contributing to the completion of the genome.  These contigs were then subjected to 
bioinformatic analysis, such as different repeat searches, searching for the origin of replication, and analysing 
the additional open reading frames that were located on the overlapping sequences of the linked contigs.  
The study contributed by providing a richer knowledge of the content of the Ms02 genome by emphasising the 
difficulties that repetitive sequences can cause in assembly and annotation; and illustrating the techniques that 
can be used for assembling genomes. 
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Chapter 4 
4.   
This chapter starts with a discussion on DNA vaccines and how the vector components of the vaccine may 
influence the expression of the recombinant gene.  This is used as an motivation for choosing the three DNA 
vaccine vectors developed in this study.  This is followed by an explanation of the different conditions and 
optimisation strategies used to express recombinant Ms02 OppA protein and the difficulties that accompanied 
the purification of this protein.  Lastly, the experimental procedures and results will be given in an article format. 
4.1. DNA VACCINE VECTORS AND THE CLONING, EXPRESSION AND PURIFICATION 
OF THE Ms02 OppA PROTEIN 
4.1.1. INTRODUCTION 
Mycoplasmas infect a wide range of animal hosts, often colonising the mucosal surfaces of mammals and birds.  
The South African ostrich is susceptible to infection by three distinct ostrich mycoplasmas, provisionally named 
Ms01, Ms02 and Ms03 (Botes et al., 2005a).  These three mycoplasmas cause infection of the upper respiratory 
tract, leading to retarded growth, downgrading of the carcasses, increased treatment costs, and ultimately a loss 
in production.  In addition to the local impact on the South African Ostrich Industry, concerns regarding 
transmission of mycoplasmas to other countries through contaminated meat products, may lead to export 
constraints, resulting in substantial financial losses (Olivier, 2006).  Current methods of controlling mycoplasma 
infections in feedlot ostriches include strict biosecurity practices and a limited range of antibiotics.  Biosecurity 
practices are difficult to maintain successfully and antibiotics should be used sparingly and do not eradicate 
infection (Kleven, 2008). 
Vaccines against the poultry mycoplasmas M. gallisepticum and M. synoviae were tested to determine if a 
response could be elicited in ostriches that would provide protection against the ostrich mycoplasmas (Pretorius, 
2009).  Antibodies that were elicited only reacted against the specific mycoplasma it was vaccinated against, 
and not against the ostrich mycoplasmas.  The conclusion was that due to the low cross-reactivity of the 
antibodies, separate vaccines would have to be developed for the three ostrich mycoplasmas.  Mycoplasmas are 
notoriously difficult to cultivate, and along with other practical problems, make it unfeasible to develop a 
conventional vaccine.  To circumvent the disadvantages associated with traditional vaccines, a new method of 
vaccination was chosen to use in this study: that of DNA vaccination.  DNA vaccination is based on the principle 
that a gene of the pathogenic organism can be cloned into an expression vector and directly injected into the 
host animal.  This results in expression of the antigenic protein and then elicits a protective immune response 
against this foreign protein. 
DNA vaccine development starts with the identification of a vaccine candidate gene.  Proteins involved in 
membrane transport and host cell attachment have been proposed as good vaccine candidate genes, due to 
their strong antigenic properties (Garmory and Titball, 2004).  Sequencing of the Ms02 genome and comparative 
analysis of the predicted open reading frames (ORFs), resulted in the identification of the oppA gene as a 
potential vaccine candidate gene (Steenmans, 2010).  The gene was isolated by PCR from the genomic DNA 
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and modified by site-directed mutagenesis (Steenmans, 2010).  In this study, the modified oppA gene was 
cloned into four different vectors; one prokaryotic expression vector and three different DNA vaccine vectors.  
The choice of a suitable eukaryotic expression vector is the first and foremost critical step in the development of 
a DNA vaccine (Gurunathan, 2000), as the efficacy of the vaccine is dependent on the different components of 
the expression vectors. 
4.1.2. DNA VACCINES: BASIC VECTOR REQUIREMENTS, COMPONENTS THAT INFLUENCE 
EXPRESSION, AND THE THREE DNA VACCINE VECTORS CHOSEN 
DNA vaccines are part of next-generation vaccines, an example of the reverse vaccinology approach.  The shift 
from conventional vaccines toward next-generation vaccines ocurred in parallel with advances in bioinformatics.  
By using the resources available with genome databases, it is now possible to compare and analyse possible 
ORFs within existing annotated genomes, leading to identification and functional annotation of unknown 
hypothetical genes.  In this manner, possible antigens can be identified based on homology searches with other 
known antigens, instead of laboriously expressing and analysing each protein from organisms with incomplete 
and/or unannotated genomes.  Thus, reverse vaccinology refers to the development of a vaccine where one 
starts with identification of antigens in silico, and works backwards toward cultivation in vitro (Rappuoli, 2001). 
4.1.2.1. Basic requirements for a DNA vaccine vector 
The different components of the DNA vaccine vector will determine the level of expression, and subsequently 
the immune response elicited.  Most plasmids that are used as vaccines have a shared set of characteristics, 
including: (i) a bacterial origin of replication with a high copy number for high production of plasmid DNA in 
transformed bacteria; (ii) a selection marker to allow for plasmid selection during bacterial growth; (iii) a strong 
eukaryotic promoter for expression in mammalian cells; (iv) a cloning site downstream of this promoter for 
insertion of the gene(s) of interest (GOI); (v) and lastly a polyadenylation sequence to stabilise and direct 
expression of the mRNA (Garmory et al., 2003; Gurunathan et al., 2000; Webster and Robinson, 1997).  
Sometimes introns are also included in the vector, since a lot of mammalian gene expression is dependent on, 
or increased by, the presence of an intron.  Multicistronic vectors may be created to express more than one 
antigen, or to express an antigen together with an immunostimulatory element (Lewis and Babiuk, 1999). 
4.1.2.2. Vector components that influence expression 
The structure of a vector can be divided into two conceptual parts: the plasmid backbone unit and the 
transcription complex unit. 
4.1.2.2.1. The plasmid backbone unit 
The plasmid backbone unit consists of prokaryotic elements such as an origin of replication, multiple cloning site 
(MCS), a selectable marker, as well as optional immunostimulatory sequences with adjuvant activity.  DNA 
vaccine vectors may contain an origin of replication from viral origin, such as from the Simian virus 40 (SV40) 
and the polyoma virus.  The MCS is designed with unique and convenient restriction sites to allow insertion of 
the GOI, and designed to avoid hairpin formation in the 5’ end of the mRNA, since this reduces the level of 
translation in higher eukaryotes (Fu et al., 1991; Kozak, 1986; Kozak, 1989; Rao et al., 1988).  The selectable 
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marker can either be a drug-resistant marker, enabling cells to detoxify an exogenously added toxic substance, 
or be an auxotrophic marker, enabling cells to synthesise an essential compound not present in the media. 
Krieg et al. (1994) demonstrated that certain DNA sequences induce cytokine secretion and lymphocyte 
activation.  Certain bacterial species-dependant unmethylated cytidine-phosphate-guanosine (CpG) motifs are 
particularly immunostimulatory.  These sequences were found to activate B cells in vitro and act as an adjuvant 
in vivo (Donnelly et al.,1997), as well as to activate monocytes, natural killer cells (NKC) and dentritic cells (DC) 
(van Drunen Littel-van den Hurk et al., 2001).  Elimination of the CpG motifs from the plasmid backbone reduced 
the immunogenicity of the vaccine, an effect that was reversed by co-administering exogenous CpG-containing 
DNA, although not to the magnitude of including the motifs in the plasmid backbone (Klinman, 1998).  Even the 
selectable marker can have an influence.  The human cytomegalovirus (hCMV)-based vectors containing the 
ampicillin resistance gene (ampR) instead of the kanamycin resistance gene (kanR), produced a stronger 
immune response (Sato et al., 1996).  This was thought to be the effect of a certain immunostimulatory 
sequence (ISS), a palindromic CpG hexamer 5’ AACGTT 3’, which is present twice in the ampR gene and 
absent in the kanR gene. 
4.1.2.2.2. The transcription complex unit 
The transcription complex unit (that drives the synthesis of the GOI) contains a promoter/enhancer region, an 
intron with functional splicing sites, the GOI, and a polyadenylation signal. 
Mammalian expression plasmids mostly carry immediate early promoter/enhancer regions from pathogenic 
viruses, due to their high transcription initiation ability in mammalian tissues (Harms and Splitter, 1995).  
The hCMV enhancer/promoter is used most often, due to its induction of strong and consecutive expression in 
various cell types (Boshart et al., 1985; Schmidt et al., 1990; Thomson et al., 1984).  Other 
promoter/enhancement regions include those from the SV40, the Rous Sarcoma Virus (RSV), the murine 
leukemia virus SL3-3, the mouse mammary tumour virus (MMTV), and the human immunodeficiency virus (HIV).  
A study done by Galvin et al. (2000) concluded that the level of humoral and cellular immunity induced by a DNA 
vaccine is directly correlated to the strength of its promoter. 
Intervening sequences (introns) have a positive effect on antigen expression, possibly due to an enhanced rate 
of RNA polyadenylation, or nuclear transport, that is linked to RNA splicing (Huang and Gorman, 1990).  
Most gene vaccination vectors contain the intron A of hCMV.  Chimeric introns, constructed from different donor 
and acceptor sites, can be optimised at the branchpoint site to match consensus sequences of splicing ,and lead 
to an increase in the level of expression (Senapathy et al., 1990). 
High levels of gene expression are dependent on efficient termination and polyadenylation of RNA transcripts.  
Polyadenylation, the addition of 200-250 adenosine residues to the 3’ end of the RNA transcript, contributes to 
the stability and translation of the transcript (Bernstein and Ross, 1989; Jackson and Standart, 1990). 
For DNA vaccine development, the GOI should be inserted into the vaccine vector to have the maximum 
immune response.  Boyle et al. (1998) showed that both cellular and humoral immune responses were 
enhanced when using an antigen-targeting strategy, by vaccinating with DNA than encodes for an antigen-ligand 
fusion protein.  Another factor to take into consideration is the target of the gene product.  Different cellular 
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compartments will elicit different immune responses, for instance secreted or membrane-bound proteins induce 
antibodies more effectively than cytosolic antigens.  On the other hand, cytotoxic T cell responses are greatly 
improved by cytosolic degradation and subsequent presentation on the MHC class I (Robinson and Pertmer, 
2000). 
4.1.2.3. The DNA vaccine vectors pCI-neo, VR1012 and VR1020 
In this study the three mammalian expression vectors: pCI-neo, and two Vical vectors, VR1012 and VR1020 
were used for DNA vaccine development.  All three contain an expression cassette under control of the hCMV-IE 
enhancer/promoter, an intron, and a polyadenylation signal to regulate expression.  To date only VR1020 has 
been approved by the FDA for human use. 
In the pCI-neo vector (Figure 4.1), the chimeric intron is composed of the 5’ donor site of the first intron from the 
human β-globin gene, as well as the branch and 3’ acceptor site from an intron of an immunoglobulin heavy 
chain variable region gene (Bothwell et al., 1981).  The sequences were modified to match the consensus 
sequences for splicing (Senapathy et al., 1990).  Both the Vical vectors contain intron A from hCMV. 
The pCI-neo vector contains the ampR gene, conferring resistance to ampicillin, while the two Vical vectors 
contain the kanR gene, conferring resistance to kanamycin.  This allows for plasmid selection during growth in 
bacteria.  Based on a study by Sato et al. (1996), this difference could cause the pCI-neo vector to produce a 
stronger immune response than the Vical vectors. 
The VR1012 and VR1020 vectors contain a hCMV untranslated region, which contains intron A and a bovine 
growth hormone terminator element.  VR1020 also contains a secretion signal, the human tissue plasminogen 
activator (tPA) signal peptide sequence.  This is situated at the amino terminus of the expressed protein to 
facilitate secretion of the expressed recombinant protein to the outside of the cell, when the foreign gene is 
inserted downstream of and in-frame with the tPA signal.  Smooker et al. (1999) demonstrated that their VR1020 
construct, and not the VR1012 construct, directed expression so that the protein was exported from the cell.  
They found that when immunising mice with a Fasciola hepatica glutathione-S-transferase, an increased 
humoral response was achieved when the VR1020 vector was used, if compared to the VR1012 vector. 
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Figure 4.1 The mammalian expression vector pCI-neo (Promega), as an example to illustrate the important vector 
components.  In addition, the two restriction sites that were used for insertion of the oppA gene are indicated with striped 
arrows. 
4.1.3. Ms02 OppA PROTEIN EXPRESSION AND PURIFICATION 
The oppA gene, part of the oligopeptide permease system, was chosen as a possible DNA vaccine candidate 
gene in previous studies for the other two ostrich mycoplasmas.  The three DNA vaccine vectors pCI-neo, 
VR1012 and VR1020, were chosen to test the antigenicity of the oppA gene in different DNA plasmid vectors.  
For Ms02, expression of the plasmid was to be determined by using a cell culture system (see Chapter 5).  
In other studies performed in this laboratory, the Ms01 and Ms03 vaccine vectors were tested, or are still being 
tested, for their efficacy in eliciting an immune response in ostriches.  Purified OppA protein is needed to test the 
serological responses of the ostriches.  It is also needed to produce rabbit antibodies against the recombinant 
protein which can be used to test for protein expression in a cell culture system.  Expression of the OppA protein 
was performed by using a GST-tag expression system to allow for affinity chromatography purification that 
utilises immobilised glutathione. 
After realising that the expression and purification conditions previously used for the Ms01 and Ms03 GST-OppA 
proteins in Escherichia coli did not work for the Ms02 GST-OppA protein, an attempt was made to optimise the 
expression conditions, with the objective of improving the production of soluble protein.  Different approaches 
towards soluble protein expression were tested; on the one hand to maximise the expression of soluble protein, 
and on the other hand to solubilise the protein after expression.  In order to maximise the expression of soluble 
protein, different cell types were used for expression, and different inducer concentrations, growth temperatures 
and time points for inducing and harvesting were tested.  Before induction, an additional heat-shock incubation 
step was included, based on the postulate that inducing the expression of heat-shock proteins to chaperone the 
OppA protein into correct folding might prevent protein aggregation. 
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4.1.3.1. Expression of the Ms02 GST-OppA protein 
All of the expression optimisations were performed in E. coli BL21(DE3) cells (Novagen) and Single Step (KRX) 
cells (Promega).  The KRX cells are inducable with rhamnose and subjected to catabolite repression by glucose, 
which allows for more precise control of the recombinant protein expression, while the BL21 cells are induced 
with isopropyl β-D-1-thiogalactopyranoside (IPTG) and are more prone to leaky expression, but is an all-purpose 
strain often used for its high level of protein expression.  In order to determine the optimal conditions for 
maximum protein expression, different conditions were tested using 10 ml culture volumes.  Two different 
temperatures were tested, i.e. 26°C and 37°C.  Two different induction conditions were tested at each 
temperature.  Inducer concentrations were tested based on the respective manufacturers’ suggestions for 
optimising recombinant protein expression.  For the KRX cell culture, the cultures were induced either with 1 mM 
IPTG and 0.05% L-rhamnose, or with 4 mM IPTG and 0.1% L-rhamnose, while the BL21 cultures were induced 
with IPTG at concentrations of either 1 mM or 4 mM.  Even though the KRX cells are induced with rhamnose, 
IPTG is added because of the lac operator that occurs in the pGEX-4T-1 vector, as suggested by the 
manufacturers.  It was determined that the best conditions to use were a temperature of 37°C and an IPTG 
concentration of 1 mM (with the 0.05% L-rhamnose for the KRX cell cultures).  These conditions were then used 
to determine the optimal time point to harvest the cells.  The culture volumes were increased to 50 ml and cell 
samples were taken every 2 h for 24 h.  The results indicated that the optimal approach would be to use the 
BL21 cells for expression and to harvest the cells 4 h after induction.  However, when the small test cultures 
were scaled up in order to achieve a larger amount of cells, and thus proteins, it was found that the conditions 
were not optimal for the larger volume.  Even when adjusting the time to harvest to 6 h, taking into account that 
the larger volume means less aeration and slower growth, the proteins still appeared to be mostly insoluble.  
Since the literature suggested that one should either induce at a low cell density for a longer period of time, or a 
high cell density for a shorter period of time (Guan and Dixon, 1991; Liobikas et al., 2006), a simple experiment 
was performed to determine the applicability of this statement to these experiments.  Two flasks of 100 ml Luria-
Bertani (LB) medium were inoculated with BL21 cell cultures.  One culture was allowed to grow for 2 h before 
inducing the cells with IPTG, and then the cells were harvested after 6 h.  The other culture was grown for 6 h 
before induction, and the cells harvested after 3 h.  The expression profiles were analysed with sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE), which proved that the protein was more soluble when 
induced at a high cell density for a shorter time period.  Still, using these expression conditions, but further 
adhering to the basic protocol for sample preparation as described in Sigma’s manual on the Glutathione-
Agarose product (G4510) (as followed successfully for the Ms01 and Ms03 GST-OppA proteins), did not result in 
purified protein.  The supernatant was too viscous to load onto the glutathione-agarose column, which can result 
from the nucleic acids that is released upon cell lysis.  The viscosity forced batch purification instead of eluting 
fractions, which resulted in a protein isolate that had high levels of impurities.  In addition to these complications, 
the visualisation of proteins on an SDS gel is an inaccurate representation of the state of proteins in the sample.  
Since all the proteins are denatured before loading onto the gel, it is possible that many were aggregated and 
inclusion body proteins were falsely thought to be soluble.  Therefore, it was found that further experiments were 
required in order to optimise the purification of the OppA protein. 
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4.1.3.2. Purification of the Ms02 GST-OppA protein 
Both E. coli BL21(DE3) and Single Step (KRX) cells were used to try to express soluble protein and isolate the 
protein according to the protocol that was used successfully for isolating the Ms01 and Ms03 GST-OppA 
proteins.  This was performed according to Sigma’s instructions on their glutathione-agarose column resin.  
While being able to isolate the GST protein as a control using the same protocol, it was confirmed after 
numerous attempts that the Ms02 GST-OppA protein was not soluble under these conditions.  Protein 
denaturants such as guanidinium hydrochloride (GuHCl), SDS, urea, and β-mercapto-ethanol were tested to 
determine their efficacy in disrupting protein aggregation.  Using GuHCl at a concentration of 6 M in the buffer 
increased the solubility of the protein, but the supernatant was too viscous to enable effective column loading.  
After considering the sample preparation for loading proteins on an SDS gel, the same conditions were scaled 
up and tested on a larger cell suspension.  A buffer consisting of 0.125 M Tris-HCl, 4% (w/v) SDS, and 10% (v/v) 
β-mercapto-ethanol, was used for denaturation and the cell suspension was boiled in this solution.  
Unfortunately, though the results appeared promising on a small scale, the buffer cell suspension was unable to 
separate sufficiently during centrifugation to allow collection of the supernatant (that contained the soluble 
protein). 
Coincidently it was discovered that by repeating the preparation steps of normal SDS sample preparation, i.e. 
the freeze/thaw cycles and sonication, the protein appeared to be more visible on the SDS gel.  It was concluded 
that a possible explanation for lack of protein in the soluble fractions were due to incomplete lysis of the cells, 
thus not allowing release of the protein into the external buffer.  To increase the release of proteins out of the 
cells, it was decided to employ lysozyme to digest the bacterial cell wall.  To this end, lysozyme was added at a 
concentration of 1 µl (10 mg/ml) for every 100 µl cell suspension.  After an ice incubation step, the original 
protocol as per Sigma was performed.  This resulted in the first successful isolation of protein.  Analysis with 
SDS-PAGE indicated the eluted protein to be impure, as the fractions contained either multiple different proteins, 
or damaged/truncated proteins, indicated by the multiple protein bands visible on the SDS gel.  An explanation 
was ventured as to this result: damage to the cell walls caused by the lysozyme also caused numerous 
proteolytic enzymes to be released, resulting in degraded protein.  To inhibit the proteases, one tube of HaltTM 
Protease Inhibitor Single-Use Cocktail EDTA-free (Thermo Scientific) per 10 ml cell suspension was added 
together with the lysozyme.  The result was a narrower peak of protein in the fractions, as well as a marked 
reduction in the amount of additional bands, as visualised on the SDS gel.  The protocol was finally repeated 
with separate incubation steps for the lysozyme and the protease inhibitors, and resulted in a satisfactory pure 
isolated protein.  The concentrations achieved in the peak fractions were deemed sufficient and although the 
protein was not completely pure (it still contained degradation products), the results were deemed acceptable to 
continue. 
In this study the Ms02 oppA gene was cloned into three mammalian DNA vaccine vectors, namely pCI-neo, 
VR1012 and VR1020, to test the expression of the gene in a eukaryotic cell system and to provide three ostrich 
Ms02 vaccines for future efficacy tests.  The gene was also cloned into the prokaryotic expression vector pGEX-
4T-1 in order to express the recombinant protein for subsequent purification.  The purified protein was then used 
to generate antibodies by injecting pure protein into a rabbit and collecting its sera. 
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4.2. THE PRODUCTION OF THREE Ms02 oppA GENE CONTAINING RECOMBINANT 
DNA VACCINE VECTORS, PURE Ms02 OppA PROTEIN, AND ANTI-OppA 
ANTIBODIES 
4.2.1. INTRODUCTION 
Respiratory diseases in ostriches cause significant economical losses to the South African Ostrich Industry every 
year.  Three ostrich-specific mycoplasmas are responsible for infection of the upper respiratory tract of ostriches, 
namely Ms01, Ms02 and Ms03 (Botes et al., 2005a).  Mycoplasmas are small, cell wall-less bacteria known for 
their ability to cause pathogenesis in a wide variety of hosts (Minion, 2002; Prescott et al., 2002).  Their small, 
rudimentary genome contains only the essential genes needed for independent reproduction, but they are 
dependent on their hosts for nutrients such as amino acids, fatty acids, vitamins, nucleic acid precursors, and 
other biosynthetic compounds necessary for their survival (Bradbury, 2005; Prescott et al., 2002).  
The mycoplasma’s parasitic lifestyle also causes damage to the host due to the sequestering of these 
compounds, production of free radicals, and general damage to the host cells. 
Mycoplasma infection in ostriches is characterised by reduced feed consumption, depression and tardiness of 
the ostriches, sneezing, coughing, and nasal exudates, ultimately causing decreased viability, downgrading of 
carcasses and death (Olivier, 2006).  The ostrich industry suffers dramatic production losses each year.  
Currently, there are no effective antibiotics or registered vaccines available against the three ostrich 
mycoplasmas.  Low or no cross-reactivity between the three ostrich mycoplasmas and poultry mycoplasmas 
also indicated that a vaccine will have to be specific to each ostrich mycoplasma (Pretorius, 2009).  Thus an 
urgent need exists to develop a vaccine against each of the three ostrich mycoplasmas. 
In this study the Ms02 oppA gene, previously identified to be a possible vaccine candidate gene, was cloned into 
three different eukaryotic DNA vaccine vectors.  The gene was also expressed in a prokaryotic expression 
system, the recombinant protein isolated, and rabbit antibodies generated against the Ms02 OppA protein.  
This provided all the necessary components for future vaccine efficacy testing in ostriches. 
4.2.2. EXPERIMENTAL PROCEDURES 
4.2.2.1. Cloning of the Ms02 oppA gene into the pGEM®-T Easy vector 
A pGEM®-T Easy vector (Promega) that contained the modified Ms02 oppA gene (pGEM®-T Easy_OppA), was 
provided by Shandré Steenmans, Department of Biochemistry, Stellenbosch University.  The gene was 
previously subjected to site-directed mutagenesis in order to change 10 TGA codons to TGG.  This was done to 
prevent premature truncation of the protein, since mycoplasmas use TGA to code for tryptophan (a codon that is 
recognised by most other organisms as a stop codon).  Appropriate restriction endonuclease recognition sites 
were incorporated into the modified oppA gene for subcloning into the mammalian expression vector pCI-neo 
(Promega).  In this study, the gene was amplified to add different restriction endonuclease recognition sites to 
enable subcloning into the other two DNA vaccine vectors, VR1012 and VR1020 (Vical Inc. San Diego, CA, 
USA), as well as into the prokaryotic expression vector pGEX-4T-1 (GE Healthcare, UK). 
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4.2.2.1.1. Primer design 
Primers that contained the appropriate restriction endonuclease (RE) recognition sites were designed using the 
computer software package Primer Designer (v. 1.01, Scientific and Educational Software), and synthesised by 
Integrated DNA Technologies (IDT), Iowa City, USA.  RE were chosen, firstly according to each expression 
vector, and secondly not to contain similar recognition sites as in the Ms02 oppA gene itself.  To this end, two 
sets of primers were designed, with a forward and a reverse primer per set.  For one set, each contained a 
BamHI recognition site,  and for the other, a SalI recognition site (Table 4.1). 
Table 4.1 Nucleotide sequences of the primers used to RE recognition sequences into the Ms02 oppA gene, indicated in 
italics.  The recognition cut sites are indicated with arrows, and the initiation codon (ATG) and termination codon (TAA) of the 
oppA gene are indicated in bold. 
Primer name Primer sequence (5'→3') Tm (°C) Endonuclease 
Ms02_OppA_SalR G↓TCGACTTATTTAGATGAGTTTTCTTCT 53.2 SalI 
Ms02_OppA_SalF G↓TCGACATGAAATTGAAAAAAAGATTTAAT 52.6 SalI 
Ms02_OppA_BamR G↓GATCCTTATTTAGATGAGTTTTCTTCT 53.0 BamHI 
Ms02_OppA_BamF G↓GATCCATGAAATTGAAAAAAAGATTTAAT 52.4 BamHI 
4.2.2.1.2. Amplification of the oppA gene to add RE sites 
Using the pGEM®-T Easy_OppA vector construct, the gene was amplified to add the BamHI and SalI 
endonuclease recognition sites.  Three different constructs were generated.  To enable cloning into the pGEX-
4T-1 vector, a BamHI recognition site was added to the 5’ end of the Ms02 oppA gene, while at the 3’ end a SalI 
recognition site was added.  The vector VR1012 required a reverse of these sites, thus a 5’ Sall recognition site 
and a 3’ BamHI recognition site were added.  For vector VR1020, a BamHI recognition site was added to both 
the 5’ and 3’ ends of the oppA gene.  In brief, each PCR contained 10 µl of 5x High Fidelity reaction buffer, 
1 µl of 1 U/µl HiFi proofreading Taq DNA polymerase, 1.5 µl of 10 mM deoxynucleotide triphosphates (dNTPs), 
and 0.5 µl of 25 mM MgCl2 (all from Kapa Biosystems, RSA), as well as 1.5 µl of each respective primer 
(20 pmol/µl), 5 ng of purified DNA, and enough Milli-Q® water to bring the final volume to 50 µl.  The 
amplification of the gene was carried out in a 2720 Thermal Cycler (v. 2.09, Applied Biosystems Ltd., 
Warrington, UK), and entailed an initial denaturation step at 95°C for 2 min, followed by 25 cycles of 
denaturation at 98°C for 20 s, annealing at 50°C for 15 s and extension at 68°C for 90 s.  A final extension step 
was performed at 68°C for 5 min.  Next, the PCR product was analysed on a 1% (w/v) agarose gel (Molecular 
Grade Agarose D1-LE, Whitehead Scientific), in 1x TAE buffer (40 mM Tris-acetate and 2 mM EDTA, pH 8.0), to 
establish that a single PCR product was formed.  The gel was cast with 0.1 µl/ml GelRedTM Nucleic Acid Gel 
Stain (Biotium, Hayward, CA), to enable ultraviolet (UV) visualisation of the DNA.  For each 10 µl of amplified 
product, 1 µl of loading buffer (50% glycerol, 1 g/l bromophenol blue, 0.5 mM EDTA pH 8.0, and 100 mM Tris-
acetate, pH 8.0) was added before loading the samples.  A 1 KB GeneRulerTM DNA ladder mix (Fermentas) was 
used to ensure the product was the correct size.  The remainder of the amplified gene was then purified, using 
the DNA Clean & ConcentratorTM-5 kit (Zymo Research) according to the manufacturer’s instructions.  The DNA 
was eluted with 10 µl (60°C) Milli-Q® water.  The concentration of the purified product was determined 
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spectrophotometrically using a Novell NanoDrop® ND-1000 (v. 3.5.1).  The concentration (ng/µl) and purity were 
noted (A260/A230 and A260/A280). 
4.2.2.1.3. Polyadenylation of the purified PCR product to enable ligation into the pGEM®-T Easy vector 
The purified PCR product was used as a template for polyadenylation to create overhangs for cloning, using the 
pGEM®-T Easy Vector System kit (Promega) as described in the manual.  Each 10 µl reaction mixture contained 
1 µl of 10x reaction buffer, 0.8 µl of 25 mM MgCl2, 1 µl of 5 U/µl Super-Therm Taq DNA polymerase, (all from 
JMR-Holdings, USA) 0.4 µl of 2 mM dATP (Bioline), and 4 µl purified blunt-ended PCR product.  The reaction 
was incubated at 70ºC for 25 min and purified, using the DNA Clean Concentrator™-5 kit according to the 
manufacturer’s instructions. 
4.2.2.1.4. Ligation of the oppA gene into the pGEM®-T Easy vector 
The ligation reaction contained 2 µl of the purified polyadenylated PCR product, 5 µl of 2x ligation buffer, 50 ng 
of pGEM®-T Easy vector, 1 µl of 3 U/µl T4 DNA Ligase, and enough Milli-Q® water to take the final volume to 
10 µl.  The reactions were incubated overnight at 4°C, before proceeding to bacterial transformation.  In 
accordance with the manufacturer’s instructions, controls were included and consisted of: (a) a background 
reaction mixture containing no insert; and (b) a positive control reaction containing a control insert, provided with 
the pGEM® -T Easy Vector Kit. 
4.2.2.1.5. Transformation of Escherichia coli JM-109 cells with the recombinant pGEM®-T Easy plasmid 
The pGEM®-T Easy plasmid, containing the modified Ms02 oppA gene, was transformed into E. coli JM-109 
competent cells (1 x 107 cfu/µg DNA) (Promega), using the pGEM®-T Easy Vector System kit according to the 
manufacturer’s instructions.  Two microliters of each ligation reaction were added to 50 µl of E. coli JM-109 
competent cells.  After 20 min of ice incubation, the cells were subjected to heat shock in a 42°C water bath for 
45 s and returned to the ice for 2 min, before 950 µl room temperature LB-medium was added to the cells.  
The cells were then allowed to recover for 90 min at 37°C, while being shaken on an IKA® KS 260 Basic orbital 
shaker at 220 rpm.  Luria-Bertani (LB) broth plates with 15 g/L agar were supplemented with 100 µg/ml ampicillin 
(Sigma-Aldrich) at 1 µl/ml, 0.1 M (IPTG) (Bioline) at 1.6 µl/ml, and 50 mg/ml X-Gal (Bioline) at 0.8 µl/ml.  The cell 
culture was then plated onto the prepared LB/agar plates to enable blue/white-colony screening, and incubated 
for 16 h at 37°C before analyses of colony formation.  
4.2.2.1.6. Diagnostic PCR to confirm insertion of the oppA gene into the pGEM®-T Easy plasmid 
White colonies are indicative of plasmids with inserted DNA and were used in a diagnostic PCR for confirmation 
of the insert.  The two primers, T7-promoter and SP6 (Table 4.2), were used in 10 µl reactions, each containing 
1 µl of 10x Reaction buffer, 0.1 µl of 5 U/µl Super-Therm Taq DNA polymerase, and 0.6 µl of 25 mM MgCl2 (all 
from JMR-Holdings), as well as 0.4 µl of 5 mM dNTPs (Bioline), 0.5 µl of each primer (20 pmol/µl), and 6.9 µl of 
Milli-Q® water.  Approximately half of each of the chosen white colonies were scraped with sterile toothpicks and 
mixed in separate reaction tubes containing the reaction mixture, to serve as the DNA template for the PCR.  
The amplifications were carried out in a 2720 Thermal Cycler as follows: initial denaturation of 10 min at 94ºC, 
followed by 25 cycles of 94ºC for 30 s, 55ºC for 30 s, and 72ºC for 30 s, with a final extension step at 72ºC for 
7 min.  The resultant product was electrophoresed on a 1% (w/v) agarose gel (Section 3.2.2.4). 
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Table 4.2 Nucleotide sequences of the primers used with the respective cloning vectors. 
Vector Primer name Primer sequence (5'→ 3') 
pGEM®-T Easy 
T7-promoter 5’-TAATACGACTCACTATAGGG-3’ 
SP6 5’-ATTTAGGTGACACTATAGAA-3’ 
pGEX-4T-1 
pGEX-F 5’-GGGCTGGCAAGCCACGTTTGGTG-3’ 
pGEX-R 5’-CCGGGAGCTGCATGTGTCAGAGG-3’ 
pCI-neo  
T7EEV 5’-AGGGCTAGAGTACTTAATACG-3’ 
T3 5’-AATTAACCCTCACTAAAGGG-3’ 
VR1012 
VR1012-F 5’-CGCGCCACCAGACATAATAG-3’ 
VR1012-R 5’-AACAACAGATGGCTGGCAAC-3’ 
VR1020 
VR1020-F 5’-CGTCGACAGAGCTGAGATCCTACAG-3’ 
VR1020-R 5’-GACACCTACTCAGACAATGCGATGC-3’ 
4.2.2.1.7. Isolation of the pGEM® -T Easy vector-insert construct 
The remainder of those colonies confirmed to contain the insert were scraped with a sterile toothpick and 
inoculated into 5 ml LB broth, supplemented with 5 µl (100 mg/ml) ampicillin, and incubated for 16 h at 37°C, 
while being shaken at 220 rpm on an orbital shaker.  Invisorb® Spin Plasmid Mini Two (Invitrogen) was used to 
purify the plasmid from the culture, with slight modifications to the manufacturer’s instructions.  To elute the 
plasmid DNA, 50 µl of pre-warmed 60°C Milli-Q® water was added directly onto the filter and incubated for 
10 min at room temperature.  A final centrifugation step for 1 min at 10 000 x g eluted the purified plasmid.  
The concentration and purity was determined spectrophotometrically and visualised on an agarose gel (Section 
3.2.2.2 and Section 3.2.2.4). 
4.2.2.1.8. Sequencing of the plasmid inserts  
The purified plasmids were used as the DNA template in a sequencing reaction to confirm successful insertion of 
the Ms02 oppA gene, as well as to validate that no mutations (other than those introduced by site-directed 
mutagenesis), were introduced.  Six internal primers (Table 4.3), and the two outside primers T7-promoter and 
SP6 (Table 4.2), were used to create overlapping sequences in order to assemble the entire 2 997 bp of the 
gene.  The reactions were executed with the ABI BigDye® Terminator Cycle Sequencing kit (v. 3.1, Applied 
Biosystems).  Each sequencing reaction consisted of 2 µl Terminator mix, 2 µl Half-Dye mix (Bioline), 3 µl primer 
(3.3 pmol/µl), and 300 ng plasmid DNA, up to a total reaction volume of 10 µl.  Cycle sequencing consisted of 
35 cycles of 96ºC for 10 s, 52ºC for 30 s, 60ºC for 4 min, followed by a final extension step at 60ºC for 10 min.  
The reactions were performed in a 2720 Thermal Cycler.  The sequencing reaction products were then analysed 
with an ABI® 3130 Genetic Analyser (Applied Biosystems) at the Central Analytical Facility (CAF), the DNA 
sequencing facility of the University of Stellenbosch (RSA).  Resulting sequences were manually aligned in 
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BioEdit® Sequence Alignment Editor (v. 7.0.5.2, Hall) and inspected for mutations, as well as for the correct 
restriction endonuclease recognition sites.  Freeze cultures of the positive plasmids were made, by carefully 
mixing 250 µl of the overnight cell culture and 750 µl of an 80% sterile glycerol solution, and stored at -80°C. 
Table 4.3 Nucleotide sequences of the six internal primers used to sequence the Ms02 oppA gene. 
Primer name Primer sequence (5'→ 3') bp-position  Tm (°C) 
Ms02_OppA_T7R 5’-CAGGTCTAATTCTGAATCTTACTTCTGAGG-3’ 732-762 56 
Ms02_OppA_PP2F 5’-CAGCACGAAGGTCAAACATATAGCTATTAC-3’ 625-655 57 
Ms02_OppA_PP2R 5’-TCCTTGTGTATATGAGTGTAGAAGTTGATC-3’ 1483-1513 56 
Ms02_OppA_PP3F 5’-CAGTTGAAGTACTTCTAAACAAACATCACC-3’ 1364-1394 56 
Ms02_OppA_PP3R 5’-AAGTTGTGGAACACCTAAGTAGTAGTTACC-3’ 2242-2272 57 
Ms02_OppA_SP6F 5’- TTTCAGTAAGAGATTACTTAGCAGATAGAT-3’ 2084-2114 54 
4.2.2.2. Subcloning of the Ms02 oppA gene into the mammalian expression vector pCI-neo 
A pGEM®-T Easy plasmid that contained the modified Ms02 oppA gene was provided by Steenmans (2010).  
It had a MluI recognition sequence on the 5’ end and an AccI recognition sequence on the 3’ end of the gene.  
In order to subclone the gene into the pCI-neo vector, the gene was excised from the pGEM®-T Easy plasmid 
and the pCI-neo vector linearised with AccI and MluI. 
4.2.2.2.1. RE excision of the pGEM®-T Easy_OppA plasmid and the pCI-neo vector with AccI 
The pGEM®-T Easy plasmid containing the Ms02 oppA gene and the pCI-neo vector were both first treated with 
the AccI endonuclease.  Each 20 µl reaction contained 2 µl of 10x RE buffer, 0.2 µl of 10 mg/ml acetylated 
bovine serum albumin (BSA), 1 µg of the vector, 500 ng of the plasmid, and 1.7 µl of 6 U/µl AccI (Promega).  
The pGEM®-T Easy_OppA plasmid was incubated for 2 h at 37°C, while the pCI-neo vector was incubated for 1 
h at 37°C.  After incubation, the reactions were purified with the DNA Clean & Concentrator™-5 kit to remove the 
AccI enzyme and the digestion products. 
4.2.2.2.2. RE excision of the purified products with MluI 
The purified products were then subjected to digestion with the RE MluI in a 20 µl reaction, containing 8.8 µl 
Milli-Q® water, 2 µl 10x RE buffer, 0.2 µl (10 mg/ml) acetylated BSA, 8 µl DNA (80 ng/µl), and 1 µl of 10 U/µl MluI 
(Promega).  Both reactions were incubated at 37ºC for 1 h, followed by inactivation of the enzyme for 15 min at 
65ºC.  To prevent reattachment of the pCI-neo vector, the digestion reaction was treated with shrimp alkaline 
phosphate (SAP) in a 30 µl reaction, containing 3 µl 10x SAP buffer, 16 µl DNA (80 ng/µl), and 1.3 µl of 
1 U/µl SAP (Promega).  Incubation for 15 min at 37°C was followed by inactivation for 15 min at 65°C.  The oppA 
excised pGEM®-T Easy plasmid and the pCI-neo SAP reactions were then purified with the DNA Clean & 
Concentrator™-5 kit according to the manufacturer’s instructions. 
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4.2.2.2.3. Construction of the pCI-neo vector to contain the Ms02 oppA gene 
In order to construct the pCI-neo vector with the excised Ms02 oppA gene, the pCI-neo Mammalian Expression 
Vector kit (Promega) was used in a 10 µl ligation reaction, containing the purified oppA gene, 100 ng SAP-
treated pCI-neo vector, 1 µl 10x ligation buffer, and 1 µl of 3 U/µl T4 DNA Ligase.  A vector:insert ratio of 3:1 and 
1:1 was calculated using the equation as seen in Figure 4.2.  A negative control without DNA was also included.  
The ligation reactions were incubated overnight at 4°C and used directly in the transformation of E. coli JM-109 
competent cells (Section 4.2.2.1.5).  Positive clones that contained the recombinant pCI-neo vector were 
identified and confirmed in a diagnostic PCR.  The primer pair T7EEV (Table 4.2) and Ms02_OppA_PP2R 
(Table 4.3) was used to verify the presence of the insert in the correct orientation.  The colonies that were 
confirmed to be positive were cultivated and the plasmids isolated (Section 4.2.2.1.6 to Section 4.2.2.1.7). 
 
Figure 4.2 The equation used to calculate the amount of insert required (in ng), where x represents the chosen ratio.  
The ratio may be varied in order to determine the optimal ligation reaction.
 
4.2.2.2.4. Sequencing of the Ms02 oppA gene inserted into the pCI-neo vector 
The entire 2 997 bp gene insertion of the recombinant pCI-neo plasmid was sequenced to confirm that 
successful cloning without any mutations was achieved.  In addition to the 6 internal primers (Table 4.3), the 
outside primer pair T7EEV and T3 (Table 4.2) were employed in 8 separate sequencing reactions.  
The sequencing reactions were performed as previously described, using the ABI BigDye® Terminator Cycle 
Sequencing kit (Section 4.2.2.1.8).  The products were analysed with an ABI® 3100 Genetic Analyser and the 
resulting sequences manually aligned in BioEdit® Sequence Alignment Editor. 
4.2.2.3. Cloning of the Ms02 oppA gene into the eukaryotic expression vector VR1012 
To enable cloning of the Ms02 oppA gene into the VR1012 vector, the pGEM®-T Easy_OppA plasmid with a SalI 
recognition site on the 5’ end and a BamHI recognition site on the 3’ end were used to excise the oppA gene.  
Simultaneous digestion with the two enzymes was performed on the two vectors and the purified, digested DNA 
products ligated in a standard reaction. 
4.2.2.3.1. RE excision of the pGEM®-T Easy_OppA plasmid and the VR1012 vector with BamHI and SalI 
Both the pGEM®-T Easy_OppA plasmid and the VR1012 vector were subjected to simultaneous endonuclease 
excision with BamHI and SalI (both from Fermentas).  The VR1012 vector reaction contained 5 µl of 10x RE 
buffer, 0.5 µl (10 mg/ml) acetylated BSA, 2.5 µl of each enzyme, 1.25 µg vector, and Milli-Q® water up to a total 
reaction volume of 50 µl.  The pGEM®-T Easy_OppA reaction contained 4 µl of 10x RE buffer, 0.4 µl (10 mg/ml) 
acetylated BSA, 2 µl of each enzyme, 1 µg DNA (pGEM®-T Easy plasmid containing the oppA gene), and Milli-
Q® water up to a total reaction volume of 40 µl.  Both reactions were incubated at 37°C for 30 min and 
inactivated for 10 min at 80°C.  The products were then purified using the DNA Clean & Concentrator™-5 kit 
according to the manufacturer’s instructions.  The digested VR1012 vector was treated with SAP in a 30 µl 
reaction, containing 3 µl 10x SAP buffer, 8 µl (160 ng/µl) DNA, 1.3 µl of 1 U/µl SAP, and Milli-Q® water to a final 
( ) ( )
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volume of 30 µl.  Incubation for 15 min at 37°C was followed by 15 min inactivation at 65°C.  Before proceeding, 
the product was purified with the DNA Clean & Concentrator™-5 kit according to the manufacturer’s instructions. 
4.2.2.3.2. Construction of the VR1012 vector to contain the Ms02 oppA gene 
The linearised VR1012 vector and the excised Ms02 oppA gene were ligated in a reaction containing 1 µl of the 
VR1012 vector, 3 µl of the excised oppA gene, 1 µl of a 10x ligation buffer, and 1 µl of 3 U/µl T4 DNA Ligase.  
The reactions were incubated overnight at 4°C and transformation of E. coli JM-109 competent cells was 
performed as previously described, except that 4 µl of the ligation reaction was used per transformation.  
Colonies were chosen to verify the presence of insert in a diagnostic PCR, with the primer pair VR1012-F (Table 
4.2) and Ms02_OppA_PP2R (Table 4.3).  Positive colonies were cultivated in LB-medium and the plasmids were 
isolated (Section 4.2.2.1.6 to Section 4.2.2.1.7). 
4.2.2.3.3. Sequencing of the Ms02 oppA gene inserted into the VR1012 vector 
To verify successful in-frame cloning of the Ms02 oppA gene into the VR1012 vector, the entire 2 997 bp gene 
was sequenced in 8 separate sequencing reactions.  In addition to the six internal primers (Table 4.3), the 
outside primers VR1012-F and VR1012-R (Table 4.2) were also included.  Sequencing of the product and 
analysis of the resultant sequences were performed as described previously.  Freeze cultures were prepared of 
the cultures containing the correct plasmids (Section 4.2.2.1.8). 
4.2.2.4. Cloning of the Ms02 oppA gene into the eukaryotic secretion expression vector VR1020 
Cloning of the Ms02 oppA gene into the VR1020 vector required the gene to have a BamHI recognition site on 
both ends.  Due to the fact that the same RE recognition sequence occurred on both sides of the gene, the 
possibility of reverse insertion existed.  Since an internal primer was used with an external primer in the 
diagnostic PCR, a clone with the gene in the correct orientation could be identified. 
4.2.2.4.1. RE excision of the pGEM®-T Easy_OppA plasmid and the VR1020 vector with BamHI 
The pGEM®-T Easy_OppA plasmid and the VR1020 vector were subjected to endonuclease excision with 
BamHI.  The VR1020 vector reaction contained 4 µl of 10x RE buffer, 0.4 µl (10 mg/ml) acetylated BSA, 4 µl of 
BamHI, 4 µg of the vector, and Milli-Q® water up to a total reaction volume of 40 µl.  The pGEM®-T Easy_OppA 
plasmid reaction contained 4 µl of 10x RE buffer, 0.4 µl (10 mg/ml) acetylated BSA, 4 µl of BamHI, 1 µg DNA 
(pGEM®-T Easy plasmid containing the oppA gene), and Milli-Q® water up to a total reaction volume of 40 µl.  
Both reactions were incubated at 37°C for 30 min, inactivated for 5 min at 80°C, and subsequently purified using 
the DNA Clean & Concentrator™-5 kit according to the manufacturer’s instructions.  The digested VR1020 
vector was treated with SAP in a 30 µl reaction containing 3 µl 10x SAP buffer, 7 µl (160 ng/µl) DNA, 1 µl of 1 
U/µl SAP, and Milli-Q® water to a final volume of 30 µl.  The reaction was incubated for 15 min at 37°C, 
inactivated for 15 min at 65°C and then purified with the DNA Clean & Concentrator™-5 kit according to the 
manufacturer’s instructions. 
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4.2.2.4.2. Construction of the VR1020 vector to contain the Ms02 oppA gene 
The linearised SAP-treated VR1020 vector and the excised oppA gene were then ligated in a 10 µl reaction, 
containing 1 µl of the VR1020 vector, 1 µl of a 10x ligase buffer and 1 µl of 3 U/µl T4 DNA Ligase.  
A vector:insert ratio of 3:1 and 1:1 was calculated as described before (Figure 4.2), as well as a reaction that 
contained the maximum possible insert.  The reactions were incubated overnight at 4°C and transformation of 
E. coli JM-109 competent cells was performed.  Colonies were chosen to verify the presence of the inserted 
gene in a diagnostic PCR, with the primer pair VR1020-F (Table 4.2) and Ms02_OppA_PP2R (Table 4.3).  
By using an external primer in combination with an internal primer, clones with inserts in the correct orientation 
were identified.  Positive colonies were cultivated in LB-medium and the plasmids were isolated (Section 
4.2.2.1.5 to Section 4.2.2.1.7). 
4.2.2.4.3. Sequencing of the Ms02 oppA gene inserted into the VR1020 vector 
To verify successful in-frame cloning of the oppA gene into the VR1020 vector, the entire 2 997 bp gene was 
sequenced in 8 separate sequencing reactions.  In addition to the six internal primers (Table 4.3), the outside 
primers VR1020-F and VR1020-R (Table 4.2) were also included.  Sequencing of the product and analysis of 
the results were performed as described previously.  Positive plasmids were stored as previously described 
(Section 4.2.2.1.8). 
4.2.2.5. Subcloning of the Ms02 oppA gene into the prokaryotic expression vector pGEX-4T-1 
To subclone the Ms02 oppA gene into the pGEX-4T-1 vector, a BamHI recognition site was added to the 5’ end 
and a SalI recognition site added to the 3’ end of the oppA gene.  This allowed for excision of the gene from the 
pGEM®-T Easy_OppA vector and linearisation of the pGEX-4T-1 vector, allowing subsequent ligation. 
4.2.2.5.1. RE excision of the pGEM®-T Easy_OppA plasmid and the pGEX-4T-1 vector with BamHI and SalI 
The pGEM®-T Easy_OppA plasmid and the pGEX-4T-1 vector were subjected to simultaneous endonuclease 
excision with BamHI and SalI.  The pGEX-4T-1 reaction contained 4 µl of 10x RE buffer, 0.4 µl (10 mg/ml) 
acetylated BSA, 2 µl of each enzyme, 1 mg of the vector, and Milli-Q® water up to a total reaction volume of 40 
µl.  The pGEM®-T Easy_OppA reaction contained 4 µl of 10x RE buffer, 0.4 µl (10 mg/ml) acetylated BSA, 500 
ng DNA (pGEM®-T Easy plasmid containing the oppA gene), and Milli-Q® water to make up the volume to 40 µl.  
Both reactions were incubated at 37°C; the pGEX-4T-1 reaction for 15 min and the pGEM®-T Easy reaction for 
60 min.  An inactivation step of 10 min at 65°C preceded purification of the product with the DNA Clean & 
Concentrator™-5 kit, according to the manufacturer’s instructions.  The digested pGEX-4T-1 vector was treated 
with SAP to remove a phosphate group from the 5’ and 3’ ends of the vector in order to prevent reattachment.  
The reaction consisted of 3 µl 10x SAP buffer, 8 µl (160 ng/µl) DNA, 1.3 µl of 1 U/µl SAP, and Milli-Q® water to a 
final volume of 30 µl.  Incubation for 15 min at 37°C was followed by inactivation for 15 min at 65°C.  Again, the 
product was purified with the DNA Clean & Concentrator™-5 kit according to the manufacturer’s instructions. 
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4.2.2.5.2. Construction of the pGEX-4T-1 vector to contain the Ms02 oppA gene 
The linearised SAP-treated pGEX-4T-1 vector and the excised Ms02 oppA gene were then ligated in a reaction 
containing 1 µl of the pGEX-4T-1 vector, 5 µl of a 2x ligation buffer and 1 µl of 3 U/µl T4 DNA Ligase.  
An insert:vector ratio of 5:1 and 3:1 were used to calculate the amount of the oppA gene to add.  The reactions 
were incubated overnight at 4°C.  Transformation of E. coli JM-109 competent cells was performed.  To test 
which colonies contained the insert, a diagnostic PCR was performed, using the primer pair pGEX-F (Table 4.2) 
and Ms02_OppA_T7R (Table 4.3).  Positive colonies were inoculated in LB-medium and the plasmids were 
isolated (Section 4.2.2.1.5 to Section 4.2.2.1.7). 
4.2.2.5.3. Sequencing of the Ms02 oppA gene inserted into the pGEX-4T-1 vector 
To verify successful in-frame cloning of the Ms02 oppA gene into the pGEX-4T-1 vector, 8 sequencing reactions 
were performed with the six internal primers and the two outside primers pGEX-F and pGEX-R (Table 4.2).  The 
entire gene was sequenced to confirm the absence of mutations and the resultant sequences were aligned 
manually with BioEdit® Sequence Alignment Editor.  Freeze cultures were prepared of the positive colonies 
(Section 4.2.2.1.8). 
4.2.2.5.4. Transformation of E. coli BL21(DE3) competent cells with the pGEX-4T-1_OppA vector 
The pGEX-4T-1 vector containing the Ms02 oppA gene was transformed into E. coli BL21(DE3) competent cells 
(Novagen).  Of the competent cells, 100 µl were mixed with 0.18 µl (14.05 M) β-mercapto-ethanol and incubated 
on ice for 10 min, with gentle swirls every 2 min.  To this, 5 µl of the pGEX-4T-1_OppA vector was added, 
incubated on ice for 30 min, followed by 45 s heat-shock at 42°C.  The heat-shocked cells were cooled on ice for 
2 min.  SOC medium was preheated to 37°C and added to the cell mixture to a final volume of 1 ml.  The cells 
were allowed to recover for 1 h at 37°C, while being shaken on an IKA® KS 260 Basic orbital shaker at 220 rpm.  
The cultures were then plated on prepared LB/agar plates, supplemented with 100 µg/ml ampicillin at 1 µl/ml, 
and cultivated for 16 h at 37°C.  After confirmation of positive transformants, using the pGEX-F and pGEX-R 
primer pair in a diagnostic PCR (Table 4.2), cultures were made by inoculating the positive colonies into 5 ml LB-
medium supplemented with 5 µl (100 mg/ml) ampicillin.  The cultures were incubated at 37°C for 16 h, while 
being shaken on an IKA® KS 260 Basic orbital shaker at 220 rpm.  
4.2.2.5.5. Transformation of Single Step (KRX) competent cells with the pGEX-4T-1_OppA vector 
The pGEX-4T-1 vector containing the oppA gene was transformed into Single Step (KRX) competent cells 
(Promega) according the manufacturer’s instructions.  Of the KRX competent cells, 50 µl were mixed with 5 µl of 
the pGEX-4T-1_OppA vector and incubated on ice for 10 min.  The cells were heat-shocked for 20 s at 42°C and 
immediately returned to the ice for 2 min.  To this, 450 µl preheated SOC media was added and the cells 
incubated for 1 h at 37°C, while being shaken on an IKA® KS 260 Basic orbital shaker at 220 rpm.  The cultures 
were then plated on LB/amp/IPTG/X-gal plates prepared as described before (Section 4.2.2.1.5).  A diagnostic 
PCR was performed using the pGEX-F and pGEX-R primer pair (Table 4.2).  The positive colonies were cultured 
and stored for future use (Section 4.2.2.1.8). 
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4.2.2.6. Expression of the recombinant Ms02 OppA protein using the pGEX-4T-1 prokaryotic 
expression system 
The Ms02 OppA protein was expressed as a GST-fusion protein with the following conditions after numerous 
attempts to optimise the expression of soluble OppA protein.  For a complete discussion on the different 
attempts and associated problems, refer to Section 4.1.3. 
4.2.2.6.1. Expression of the Ms02 GST-OppA protein in E. coli BL21(DE3) and Single Step (KRX) cells 
The two respective cell freeze cultures, that contained the recombinant pGEX-4T-1 vector with the Ms02 oppA 
gene, were streaked onto LB/agar plates that were supplemented with 100 mg/ml ampicillin at 1 µl/ml.  
The plates were incubated for 16 h at 37°C before colony formation was analysed.  The transformed colonies 
were tested in a diagnostic PCR, using the primer pair Ms02_OppA_PP2F and Ms02_OppA_PP3R (Table 4.3).  
To express the oppA gene, starter cultures were made by inoculating multiple positive colonies from each cell 
type in their respective flasks, containing 20 ml LB-medium supplemented with 20 µl (100 mg/ml) ampicillin and 
400 µl (20%) glucose.  The cultures were incubated for 14 h at 37°C, before it was diluted in 400 ml Terrific 
Broth (TB)-medium (360 ml TB, 40 ml (1 M) phosphate buffer, pH 7.8, 400 µl (100 mg/ml) ampicillin, and 6 ml 
(20%) glucose).  The medium was divided in four 100 ml flasks to ensure proper aeration and incubated for 6 h 
at 37°C, while being shaken at 220 rpm.  The cultures were then induced.  The flasks that contained the BL21 
culture were induced with 1 ml (0.1 M) IPTG, while the flasks with the KRX culture were induced with 1 ml 
(0.1 M) IPTG and 500 µl (20%) L-rhamnose.  The cultures were allowed to express for 3 h, before the cells were 
harvested by centrifugation for 10 min at 10 000 x g and resuspended in 1x TEN50 (50 mM NaCl2, 20 mM 
Tris-acetate, and 1 mM EDTA) buffer, supplemented with 0.2 mM DTT, 0.1% (v/v) Triton-X-100 and 10% (v/v) 
glycerol.  Samples of the cell supension were stored for subsequent use in SDS-PAGE analysis.  To prepare the 
protein for subsequent protein isolation, the cell suspension was subjected to three freeze/thaw cycles, cycling 
between 37°C and -80°C, and five cycles of sonication for 20 s followed by 20 s on ice.  The cell lysate were 
then mixed with 1 µl of a 10 mg/µl lysozyme solution (Sigma-Aldrich) per 100 µl cell suspension, and incubated 
on ice for 30 min, with occasional mixing.  To the lysozyme-treated cell suspension, 1 tube of HaltTM Protease 
Inhibitor Single-Use Cocktail EDTA-free (Thermo-Scientific) per 10 ml cell suspension was added and again 
incubated on ice for 30 min, with occasional mixing.  The soluble fractions were then separated from the 
insoluble fractions by centrifugation at 10 000 x g for 20 min. 
4.2.2.6.2. Visualisation of the expressed proteins using SDS-PAGE 
To analyse the expression profile, an SDS-PAGE was performed.  The harvested cells were lysed with 3 cycles 
of freezing at -80°C for 5 min, and thawing at 37°C until completely thawed.  To ensure complete lysis of 
individual cells in order to release the intracellular proteins into the medium, the cell lysate was then forced four 
times through a 0.33 mm insulin needle.  To prepare the cells for loading onto the SDS gel, 20 µl of cell lysis 
product, 12 µl of 0.1 % (m/v) bromophenol blue, and 20 µl of reducing loading buffer (0.125 M Tris-HCl, 4% (m/v) 
SDS, 20% (v/v) glycerol, and 10% (v/v) β-mercapto-ethanol, pH 6.8) were mixed and boiled for 2 minutes and 
immediately placed on ice.  Twenty microliters of the samples were then loaded onto a reducing SDS gel, 
composed of 4.5% stacking and 12% resolving gel, and electrophoresed at a constant 20 mA.  To visualise the 
protein bands, the gel was stained with staining buffer (0.125% (w/v) Coomassie Brilliant Blue R250, 50% (v/v) 
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methanol, and 10% (v/v) acetic acid) for 1 h at 37°C, while being agitated at 4 rpm.  This was followed by 1 h of 
destaining with Destain I solution (50% (v/v) methanol and 10% (v/v) acetic acid) at 37°C, while being agitated at 
4 rpm.  To ensure complete destaining, the gel was left overnight in Destain II solution (5% (v/v) methanol and 
7% (v/v) acetic acid) at room temperature on a rotary table (20 rpm). 
4.2.2.7. Detection of the Ms02 GST-OppA protein and its purification 
Western blot analysis was used to confirm that the expressed protein, as seen on the SDS gel, is in actual fact 
the Ms02 OppA GST-fusion protein.  Confirmation was achieved before proceeding with protein isolation, 
however, it could only be confirmed that a GST-tagged protein of the expected size was present, because an 
anti-GST antibody was used as the primary antibody.  Pure protein was required to generate OppA antibodies, 
as well as for use in possible future serological tests. 
4.2.2.7.1. Western blot analysis of the expressed proteins using an anti-GST antibody 
The western blot was performed with an anti-GST antibody as the primary antibody.  First, to determine the 
optimal amount of protein needed so as not to overload the gel, different dilutions of the 24 h control GST cell 
sample was separated with SDS-PAGE (Section 4.2.2.6.2).  After determining the optimal concentrations to use, 
three different dilutions were prepared, and were transferred to a 0.45 µm nitrocellulose membrane (Schleicher 
and Schuel, Sigma-Aldrich).  The transfer occurred by electrophoresis in electrode buffer (50 mM Tris-HCl, 200 
mM glycine, and 20% (v/v) methanol, pH 8.3) for 16 h at a constant of 120 mA.  Casein buffer (154 mM NaCl, 
0.5% (w/v) casein, 10 mM Tris-HCl, and 0.02% (w/v) thiomersal, pH 7.6) was used to block the membrane for 
20 min at room temperature, while being agitated.  The goat anti-GST antibody (GE Healthcare) was diluted 
10 000 times with casein buffer in a volume sufficient to cover the nitrocellulose membrane.  The membrane 
(covered with the primary antibody dilution) was then incubated for 1 h at 37°C while being agitated at 6 rpm.  
The nitrocellulose membrane was then washed three times with PBS-Tween (137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4·2H2O, 2 mM KH2PO4, and 0.1% (v/v) Tween-20, pH 7.2) for 5 min each at room temperature, 
while being agitated, to remove excess unbound antibody.  Horse-radish peroxidase (HRP)-conjugated rabbit 
anti-goat antibody (Sigma-Aldrich) was diluted 5 000 times with casein buffer, added to the nitrocellulose 
membrane and incubated for 1 h at 37°C, while being agitated at 6 rpm.  The nitrocellulose membrane was 
washed again, with an additional final wash of PBS without Tween-20 (15 min at room temperature) to remove 
excess Tween-20.  The substrate, consisting of 0.05% (w/v) 4-chloro-1-naphtol, 16% (v/v) ice cold methanol, ice-
cold 1x PBS, and 0.025% (v/v) cold H2O2, was added to the nitrocellulose membrane and allowed to develop for 
30 min at room temperature, while being agitated.  To prevent over-development, the nitrocellulose membrane 
was washed with Milli-Q® water after bands could be visualised.  After the results were established the protocol 
was repeated using the Ms02 GST-OppA protein under the same conditions to confirm the presence of a GST-
tagged protein of the expected size, before proceeding with isolation of the protein. 
4.2.2.7.2. Purification of the Ms02 GST-OppA protein 
Affinity chromatography was employed to purify the Ms02 GST-OppA protein from the cell suspension of the 
expression culture.  The glutathione-agarose resin (Sigma-Aldrich) was prepared according to the 
manufacturer’s instructions.  The protein sample was prepared as described previously to obtain soluble protein 
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in the supernatant (Section 4.1.3.2).  Purification of the protein, from the soluble sample onwards, then 
proceeded according to the manufacturer’s instructions.  The protein was eluted with elution buffer (10 mM 
reduced glutathione and 50 mM Tris-HCl, pH 9.4), and 20 eluted fractions were collected in 1 ml volumes.  The 
fractions were analysed with SDS-PAGE and the concentrations were measured spectrophotometrically with the 
Bradford protein determination assay.  In short, a standard dilution series of concentrations in the range of 0 to 
175 µg/ml, made with bovine serum albumin (BSA) (Roche), was used to determine the protein concentration in 
each fraction (in a Greiner Bio-One 96-well microtitre plate).  Of the protein fractions, 5 µl was diluted in 250 µl 
Bradford reagent (8.5% (w/v) phosphoric acid, 0.01% (w/v) Coomassie Brilliant Blue G-250, and 4.7% (v/v) 
ethanol), incubated for 5 min at room temperature, and the absorbance measured at 620 nm with a Labsystems 
Multiskan MS spectrophotometer.  The BSA standards were used to generate a standard curve to calculate the 
protein concentrations of the fractional samples.  An 8% resolving denaturing SDS gel was used to visualise the 
fractions and to determine the quality of the isolated protein. 
4.2.2.8. Rabbit antibody production raised against the Ms02 GST-OppA protein 
The Ms02 GST-OppA fusion protein was used to generate rabbit antibodies.  The antibodies were to be used to 
determine if the recombinant DNA plasmid, pCI-neo, can express the OppA protein in eukaryotic cell culture.  
In future ostrich vaccination trials, the OppA fusion protein can be used as an antigen to determine ostrich 
immune responses toward the Ms02 DNA vaccines. 
4.2.2.8.1. Antibodies raised against Ms02 GST-OppA purified protein in rabbits 
In order to produce antibodies against the Ms02 GST-OppA protein, a rabbit was immunised with the protein, 
and the blood sera from the rabbit were collected.  First, the protein was adsorbed onto acid-treated naked 
Salmonella minnesota bacteria (Bellstedt et al., 1987) in a 1:5 ratio and dried using a rotary evaporator, the 
SpeedyVac Concentrator (Savant).  The precipitated protein-bacteria complex was suspended in PBS to a final 
concentration of 0.4 mg/ml total protein.  A rabbit was immunised with 200 µg (0.5 ml) of the protein-bacteria 
complex on days 0, 3, 6, 13, 16, 20, 27, 31 and 35.  A test bleed of 2 ml was drawn on days 0 and 28 and a 
large bleed of 20 ml on day 42 for sera collection. 
4.2.2.8.2. Enzyme-Linked Immunosorbent Assay to test rabbit antibody titres 
The protein concentration as determined in Section 4.2.2.7.2 was used to coat Nunc© 96-well microtitre plates 
with 1, 2 or 5 µg of the purified GST-OppA protein.  The protein was diluted in 100 µl carbonate buffer 
(50 mM NaHCO3, pH 9.6).  The plate was incubated overnight at 4°C and blocked with 200 µl casein buffer 
(154 mM NaCl, 0.5% (w/v) casein, and 10 mM Tris-HCl, pH 7.6) for 1 h at 37°C.  The wells were washed three 
times with PBS-Tween (PBS with 0.1% (v/v) Tween-20, pH 7.2).  Rabbit serum from day 42 was diluted 1:20 in 
casein buffer that contained 0.05% (v/v) Tween-20, and 200 µl of the diluted serum added to the first well.  
In each of the other wells, 100 µl casein-Tween buffer was added.  By pipetting 100 µl of the first well into the 
next, mixing the content and pipetting 100 µl of the mixed content into the next well, and so on, a dilution series 
of up to 10 240 times was created.  This was followed by incubation at 37°C for 1 h.  The wells were washed 
again three times with PBS-Tween.  The secondary antibody, a goat anti-rabbit antibody (Sigma-Aldrich), was 
diluted 1:500 in casein-Tween, 100 µl added to each well, and the plate incubated at 37°C for 1 h.  This was 
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followed by three wash steps.  The tertiary antibody, a horse-radish peroxidase (HRP)-conjugated rabbit anti-
goat antibody (Sigma-Aldrich), was diluted 1:10 000 in casein-Tween and 100 µl added to each well.  This was 
followed by a final incubation step at 37°C for 1 h, and three wash steps with PBS-Tween.  Substrate solution, 
consisting of 0.1 M citrate buffer (pH 5) and 0.05% (w/v) 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) 
(ABTS), were prepared fresh and incubated at room temperature for 10 min.  Just before use, 0.05% (v/v) cold 
H2O2 was added to the substrate solution, and 100 µl of this solution was added to each well.  Absorbance was 
measured with a Labsystems Multiscan Original spectrophotometer, at 405 nm at five minute intervals for 30 
min.  In between measurements, the plate was incubated at 37°C. 
4.2.2.8.3. Western blot analysis to confirm the antibody activity 
To confirm the presence of Ms02 GST-OppA antibodies in the rabbit sera, and to test the cross-reactivity with 
the three ostrich mycoplasma GST-OppA proteins, a western blot analysis was performed as previously 
described, but with different antibodies (Section 4.2.2.7.1).  The purified GST-OppA proteins from Ms01, Ms02 
and Ms03, as well as isolated GST protein, were tested with the rabbit sera.  Following the initial blocking step, 
three different dilutions of the rabbit sera were tested against purified Ms02 GST-OppA protein, namely 1:1 000, 
1:2 500 and 1:5 000.  To determine the cross-reactivity of the antibody with Ms01 and Ms03 GST-OppA proteins, 
a 1:2 500 rabbit antibody dilution was used against the three different purified GST-OppA proteins.  A secondary 
antibody, goat anti-rabbit (Sigma-Aldrich), was diluted 1:2 500 in casein buffer to cover the membrane and 
incubated for 1 h at 37°C.  The membrane was washed with PBS-Tween as described earlier.  The HRP-
conjugated rabbit anti-goat antibody was diluted 1:5 000 and allowed to incubate for 1 h with the membrane at 
37°C.  Substrate was added as described earlier (Section 4.2.2.8.3). 
4.2.3. RESULTS 
4.2.3.1. PCR amplification of the Ms02 oppA gene to add RE recognition sequences 
The Ms02 oppA gene was successfully amplified with PCR from the recombinant pGEM®-T Easy plasmid, using 
the primers designed with recognition sequences for the restriction endonucleases BamHI and SalI.  
Three different amplified gene products were created: one with a BamHI recognition site on the 5’ and 3’ end of 
the oppA gene; one with a SalI recognition site on the 5’ end and a BamHI recognition site on the 3’ end; and 
one with the two sites reversed.  The amplification products were of the predicted size of 3 009 bp (2 997 bp 
oppA gene + 2 x 6 bp of the RE cut sites).  Figure 4.3 shows an agarose gel with the amplified gene product at 
just above 3 000 bp. 
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Figure 4.4 Image depicting the products of the diagnostic PCR performed on the transformed E. coli cells to contain the 
modified pGEM®-T Easy plasmid.  The products were separated on a 1% (w/v) agarose gel cast with 0.1 µl/ml GelRedTM 
Nucleic Acid Gel Stain for UV visualisation of the DNA.  Lane 1: 1 KB DNA GeneRulerTM ladder mix. Lane 2-12: amplified 
product from the pGEM®-T Easy plasmid containing BamHI recognition sites at both ends of the oppA gene for subcloning 
into the VR1020 vector.  Lane 13-23: amplified product from the pGEM®-T Easy plasmid containing a SalI recognition site at 
the 5’ end and a BamHI recognition site at the 3’ end of the oppA gene for subcloning into the VR1012 vector. 
4.2.3.3. Subcloning of the Ms02 oppA gene into the mammalian expression vector pCI-neo 
RE digestion of the pGEM®-T Easy plasmid and the pCI-neo vector with AccI and MluI was successful and was 
verified by agarose gel electrophoresis.  Cloning of the oppA gene into the pCI-neo vector resulted in numerous 
colonies, but using the primer pair T7EEV and Ms02_OppA_PP2R in a diagnostic PCR indicated poor ligation 
efficiency.  Three plasmids containing the oppA gene were isolated from the bacteria and sequenced.  Only two 
contained the full-length gene, were confirmed to be mutation-free, and stored for subsequent use. 
4.2.3.4. Subcloning of the Ms02 oppA gene into the eukaryotic expression vector VR1012 
The VR1012 expression vector and the pGEM®-T Easy plasmid containing a 5’ SalI and a 3’ BamHI RE cut site 
were digested with the two respective endonucleases.  The ligation reactions were analysed with agarose gel 
electrophoresis and, due to the lack of intensity of the band corresponding with the expected size of the plasmid 
containing the insert, the amount of ligated product used per transformation reaction was increased.  
Transformation resulted in numerous colonies, of which a satisfactory amount was diagnosed to contain the 
oppA gene, using the primer pair VR1012-F and Ms02_OppA_PP2R.  Sequencing confirmed the presence of 
the oppA gene and the absence of mutations, and the successful plasmid was stored for subsequent use. 
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4.2.3.5. Subcloning of the Ms02 oppA gene into the eukaryotic secretion expression vector VR1020 
RE digestion of the relevant pGEM®-T Easy plasmid and the VR1020 expression vector was performed with the 
endonuclease BamHI.  Multiple colonies were obtained with the transformation.  A diagnostic PCR, using the 
primer pair VR1020-F and Ms02_OppA_PP2R, identified two colonies that contained the oppA gene.  
The plasmids were isolated and subjected to sequencing.  After confirming one plasmid to be free of mutations, 
it was stored for future use. 
4.2.3.6. Subcloning of the Ms02 oppA gene into the prokaryotic expression vector pGEX-4T-1 
In order to subclone the oppA gene into the prokaryotic expression vector pGEX-4T-1, the endonucleases 
BamHI and SalI were used to digest the pGEM®-T Easy plasmid containing a BamHI cutting site at the 5’ end 
and a SalI cutting site on the 3’ end of the oppA gene, as well as to linearise the pGEX-4T-1 vector.  Successful 
transformation was proven by means of a diagnostic PCR, using the primer pair pGEX-F and Ms02_OppA_T7R.  
Three colonies were identified, their plasmids isolated and sequenced and, when established mutation-free, 
stored for subsequent use in protein expression. 
4.2.3.7. Transformation of the pGEX-4T-1_OppA vector into E. coli BL21(DE3) competent cells and 
Single Step (KRX) competent cells 
The pGEX-4T-1 vector containing a mutation-free insert of the oppA gene was successfully cloned into E. coli 
BL21(DE3) competent cells and Single Step (KRX) competent cells.  A diagnostic PCR with the primer pair 
Ms02_OppA_PP2F and Ms02_OppA_PP3R identified all the colonies that were tested to be positive for the 
oppA gene.  Cultures were made of selected positive colonies for expression of the recombinant OppA protein. 
4.2.3.8. Expression of the Ms02 GST-OppA protein for purification 
The Ms02 GST-OppA protein was successfully expressed, by growing cells to a high density and performing 
induction for a short time before the cells were harvested.  Comparing the expression profiles of the two cell 
types, E. coli BL21(DE3) and Single Step (KRX) cells, the BL21 cells were chosen based on their faster growing 
capacity.  Expression tests in the two cell types indicated that expression occured faster in the BL21 cells, 
although the KRX cells expressed a higher amount of protein over an extended period of time.  BL21 cell 
colonies on agar plates were consistently larger, and the protein expression peaked earlier than the KRX cell 
cultures.  Figure 4.5 indicates the first 15 h of the BL21 cell culture expression, for both the pGEX_control vector 
(with no insert) and the pGEX_OppA vector (with Ms02 oppA gene insert).  The recombinant protein is predicted 
to be 146 kDa (120 kDa OppA protein plus the 26 kDa GST protein).  A clear increase in the amount of 
expressed protein at the predicted size is visible in the pGEX_OppA cell samples, with the absence of a protein 
of the same band size in the control cell samples.  In addition, the presence of the GST protein is clearly visible 
in the pGEX_control cell samples, and the same protein is reduced in the pGEX-OppA cell suspension.  This is 
an indication of the expression of a GST-tagged protein. 
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Figure 4.9 Measurement of the rabbit antibodies elicited against the Ms02 GST-OppA protein.  Serum was collected on day 
0, day 28 and day 42.  Serum samples were diluted between 20 and 10 240 times and the absorbance recorded at 405 nm.  
The values were used to calculate the antibody titre values over the 42 day period for each of the different protein 
concentrations to illustrate the rabbit immune response against the GST-OppA protein. 
 
Figure 4.10 The antibody response in the rabbit against the Ms02 GST-OppA protein over a 42 day period as determined 
using the ELISA method.  The serum was diluted and used to bind to 1, 2 or 5 µg of Ms02 GST-OppA protein utilised as the 
coating antigen. 
4.2.3.13. Production of rabbit antibodies against the Ms02 GST-OppA protein 
The rabbit sera collected on day 42 were diluted and successfully used in a western blot analysis, indicating the 
response of the antibodies against the Ms02 GST-OppA protein.  Two bands were observed in all three dilutions 
(Figure 4.12a), the sizes supporting the theory that the GST protein tag is removed and that the protein exist as 
GST-tagged, and without the GST tag.  No binding to the GST protein was observed, thus the rabbit did not form 
antibodies against the GST moiety itself.  The possibility of truncated proteins also has to be considered, since 
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The pCI-neo_OppA vector was also quite difficult to obtain: in approximately 100 colonies, only three tested 
positive for the gene insert, and from these three, only one was ultimately useful. 
The pGEX-4T-1 vector used in this study employs the Glutathione-S-transferase (GST) gene fusion system: 
a multipurpose system that enables the expression, purification and detection of recombinant proteins using the 
Schistosoma japonicum GST protein tag.  This GST protein is then expressed at the amino terminus of the 
recombinant protein.  Even though this system has been used successfully for expressing a wide variety of 
soluble proteins in the bacterial cytoplasm, as well as several mycoplasma genes (Robino et al., 2007; Rosati et 
al., 2000), expressing the Ms02 GST-OppA protein proved to be quite different to the usual protocol followed.  
Numerous optimisation strategies were investigated, first to try and improve the expression of soluble protein, 
and second to improve solubilisation after expression.  Tactics employing denaturing agents such as GuHCl and 
β-mercapto-ethanol, extreme pH conditions, and lower induction temperatures, were investigated.  In the end, 
protein was optimally expressed just by increasing the cell density before induction.  In other words, the cells 
were grown for a longer period of time before induction, and then cells were harvested shortly after to limit the 
expression time.  This resulted in expression of the optimal amount of soluble protein, yielding a protein band of 
just below 150 kDa.  The predicted size of the Ms02 OppA protein is 120 kDa, thus, adding the 26 kDa of the 
GST moiety, this would result in a recombinant protein of 146 kDa.  Western blot analysis with an anti-GST 
probe indicated the presence of a GST-tagged protein in the pGEX_OppA cell samples (under 150 kDa), and a 
GST protein (at just below the 30 kDa marker protein band) in the control samples with no gene insert.  
This proved that successful expression was achieved. 
Purification of the protein was achieved with affinity chromatography.  Purification of the Ms02 GST-OppA 
protein proved to be another hurdle that took some optimisation to overcome.  The optimum conditions to 
produce soluble protein were determined to involve a lysozyme incubation step, followed by a protease inhibitor 
incubation step.  This allowed the cells to be thoroughly lysed and to release the protein.  The protease inhibitor 
was added after it was noticed that the isolated protein seemed to be degraded.  Multiple bands were visible on 
the SDS gel and it was thought that this was due to the release of proteases when the cells were lysed with 
lysozyme.  Adding the protease inhibitor, after a 30 min incubation step with the lysozyme, resulted in purified 
OppA protein of a satisfying quality and quantity.  Even though it is sometimes advisable to remove the fusion 
protein tag, it was decided that the relative size of the GST moiety with regards to the OppA protein was of 
lesser importance.  It was decided to proceed with the rabbit immunisations using the Ms02 OppA fusion protein. 
A rabbit was immunised with the purified Ms02 GST-OppA protein and its antibody activity proven with ELISA.  
Western blot analysis using the rabbit serum as a primary antibody indicated that the rabbit antibodies reacted 
only to the purified Ms02 GST-OppA protein, and not to the GST protein.  In addition, the antibodies also did not 
bind to purified Ms01 and Ms03 GST-OppA proteins.  The Ms02 and Ms01 genomes are more closely related to 
each other than the Ms03 genome (refer to Chapter 2, Figure 2.1) and possible cross-reactivity of the Ms02 and 
Ms01 OppA antibodies could be expected.  Previous studies in our laboratory did detect the Ms03 protein with 
Ms02 antibodies, but in that instance the antibodies were tested against the whole mycoplasma organism and 
not just the purified protein.  In addition, the Ms01 antibodies reacted only to the Ms01 organism, and the Ms03 
antibodies only to the Ms03 organism.  The ability of rabbit anti-Ms03 OppA antibodies to react to Ms01 GST-
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OppA protein, but not the Ms02 GST-OppA protein, were illustrated in the course of an Honours study in this 
laboratory (Collop, 2011).  It is possible in that study that the Ms02 protein sample used in the western blot 
analysis was not ideal, since it was not a purified sample, but a cell sample with expressed protein.  At the time 
of the Ms03 experiment, there were still problems with the Ms02 protein expression, and a possible explanation 
is that in that particular cell sample, the Ms02 protein was not present, or not in a usable form.  However, in this 
study no cross-reactivity was detected from the Ms02 OppA antibody with the other mycoplasma proteins.  This 
requires further investigations into the cross-reactivity of the antibodies: both towards the purified proteins and 
the whole organisms.  This serves to illustrate the necessity to develop a vaccine specific to each mycoplasma, 
since cross reactivity is too low, or as in this case, absent. 
During the course of the study, it was discovered that the GST moiety is lost from the recombinant protein either 
during the protein isolation procedure, or soon afterwards.  This was indicated by western blot analysis, where 
the anti-GST antibody would detect one large band at 150 kDa, and a small band at the GST protein size of 26 
kDa, but the rabbit anti-OppA antibodies would detect two bands at the 150 kDa marker, one slightly below the 
other.  It is possible that the Ms02 GST-OppA protein was present both with the GST moiety and without the 
GST moiety.  The size difference supports this theory: a difference that could account for the 26 kDa GST 
protein.  This occurence was also noted by Brandt (2012), who detected the separate GST protein and the Ms01 
GST-OppA protein, both on an SDS gel as well as with a western blot performed with the anti-GST antibody.  
The possibility of truncated proteins exists, due to the strong codon bias of E. coli, but truncated proteins would 
have resulted in multiple detected bands, and not just the two proteins as were detected.  Therefore truncation 
was not considered to be the cause of the double band observation.  One could ascertain the identity of the two 
protein bands by mass spectrometry.  However, this would ential the cumbersome process of excising the bands 
directly from the SDS gel and purifying the two proteins.  The pGEX-4T-1 vector linker sequence contains a 
thrombin cleavage site to enable removal of the GST-tag.  Natural proteases that are present in the cell could 
influence the stability of the recombinant protein through non-specific cleavage at the thrombin cleavage site.  
The GST-OppA protein would therefore its GST-tag quite rapidly, resulting in a detectable GST protein with the 
anti-GST antibody, and two proteins with the anti-OppA antibody. 
4.2.5. CONCLUSION 
This study produced three DNA vaccine vectors each containing the Ms02 oppA gene: pCI-neo, VR1012 and 
VR1020.  These DNA vaccine vectors can now be used in ostrich vaccine trials to determine the efficacy thereof.  
Purified Ms02 GST-OppA protein and antibodies against the protein were also produced.  The purified protein 
may be used as a booster vaccine, since studies indicated the efficacy of first vaccinating with a DNA vaccine, 
then following up with a protein booster vaccine.  In addition to this, the purified protein can be used as antigen 
in future serological tests to develop ELISA assays to test for ostrich immune responses.  These proteins and 
antibodies are also useful to test the expression efficiency of DNA vaccine vectors in eukaryotic cell systems.  
Testing of the expression efficiency of pCI-neo, containing the Ms02 oppA gene, in such a cell system, will be 
discussed in the next chapter.  
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Chapter 5 
5.   
This chapter contains a broad overview on animal cell culture, transfection, the cell expression system, and its 
applications.  This is followed by the experimental procedures and results of the preliminary study on the 
expression of the pCI-neo_OppA vector in a cell culture system. 
5.1. A SHORT INVESTIGATION INTO CELL CULTURES AND TRANSFECTION 
5.1.1. INTRODUCTION 
The term cell culture refers to the complex process by which cells, mostly single-cellular eukaryotes, are grown 
under experimental conditions.  At the end of the 19th century, Wilhelm Roux took a portion of the medullary 
plate from a chicken embryo and maintained it in a saline solution for a few days on a flat glass plate, 
demonstrating the ability of cells to survive outside of the donor organism.  Thus the practice of using cell 
cultures arose more than a hundred years ago, but it was the need for viral vaccines in the 1950s and the onset 
of recombinant protein technology in the 1970s and 1980s that accelerated the design and improvement of 
mammalian cell culture bioprocesses (Kretzmer, 2002).  In 1955, Harry Eagle mixed naturally occurring cells 
with a solution of synthetic nutrients and proved that pure cell lines can be preserved for an indefinite period of 
time.  The first mass-produced product using cell culture technology was the injectable polio vaccine developed 
by Jonas Salk.  Proteins are currently the foremost licensed biopharmaceutical product, with 70% being 
produced in mammalian cells (Carta and Jungbauer, 2010; Wurm, 2004).  There are two types of cell lines: 
primary cell lines and continuous cell lines.  Primary cells, such as from a mammalian embryo, cannot survive 
outside of the original organism indefinitely, while continuous cell lines (sometimes known as immortal cell 
cultures), such as those originating from tumours, can survive indefinitely outside of the organism. 
5.1.2. ANIMAL CELL CULTURE 
Animal cells can be used to produce therapeutic proteins, subunit vaccines, diagnostic products, and viral 
vaccines.  Other applications include gene and cell therapy, regenerative medicine research, as well as in vitro 
research and toxicology studies (Pham et al., 2006).  For production of complicated eukaryotic proteins, 
mammalian cells are the preferred choice due to post-translational modifications needed to obtain active protein 
(Wurm, 2004).   
Animal cells are more vulnerable than bacteria and fungi cells that are routinely used in experiments.  The cells 
are more prone to damage and grow more slowly, which requires extremely sterile working conditions, and are 
dependant on several variables such as pH, temperature, osmolality and gas concentrations (Freshney et al., 
2005).  Another characteristic of animal cells is that their metabolism in culture is different than in the organism 
of origin: an increase in glycolytic flux and a resulting increase in the amount of lactose formed (due to inability to 
metabolise glucose completely), are observed.  The lactate build-up leads to high acidity levels and a rise in 
osmolality.  Even under fully aerobic conditions, the build-up of toxic metabolites inhibits cell growth and 
expression of the recombinant protein (Nelson and Cox, 2004). 
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Certain requirements for the ideal cell culture system arise out of the need to maximise protein expression, 
including control of temperature, pH, gas exchange, adequate supply of nutrients in the culture medium, and 
steps to avoid cell contamination.  Furthermore, the cell line itself is a crucial choice: it should be able to 
transfect easily, and be able to transcribe, translate and process the recombinant protein.  An additional 
advantage is if the protein is secreted into the medium, because this simplifies the extraction and purification 
process when proteins are produced for therapeutic purposes (Pham et al., 2006). 
5.1.2.1. Cell line cross-contamination 
Studies suggest that up to 20% of the cells used in culture are either misidentified or contaminated with another 
cell line.  Contamination has far reaching effects on the quality of research and the production of therapeutic 
products.  Cells have to be authenticated early in passaging (splitting the cells into subcultures) to identify any 
possible contaminations, and contamination tests have to be repeated before freezing cell line stocks, as well as 
every two months during active culturing.  Thus the emphasis with all cell manipulations falls on sterility, to avoid 
contamination with bacteria, yeast, or other cell lines.  Antibiotics and antifungals can also be added as an extra 
measure of prevention.  Mycoplasma contamination often goes undetected because mycoplasma growth is not 
turbid, a trait that is rather associated with bacterial and fungal growth (Rottem, 2003).  Therefore, cultures need 
to be tested regularly for mycoplasma contamination. 
5.1.2.2. Manipulation and maintenance of cells 
An effective system requires a stable and consistent number of cells.  This can be achieved by passaging at 
regular intervals.  Passaging avoids the senescence associated with prolonged high cell density and the cells 
can be cultured for longer periods of time.  Several problems arise as cells increase in the medium, such as 
nutrient depletion of the growth medium and accumulatation of apoptotic cells.  Contact inhibition may also 
occur, where cell to cell contact can cause cells to stop dividing, as well as stimulate cell differentiation.  
Too much cell passaging may decrease the transfection efficiency, alhough this also differs between different 
cell types.  NIH-3T3 cells demonstrated increased transfection efficiency when 56 passages were compared with 
2 passages.  CHO cells demonstrated stable transfection efficiency from 2 to 26 passages (Jacobsen et al., 
2004). 
5.1.3. TRANSFECTION 
Transfection refers to the deliberate introduction of nucleic acids or proteins into eukaryotic cells.  
Genetic material such as DNA and RNA, or proteins such as antibodies, can be transfected in the cells by 
opening pores in the cell membrane to allow uptake of the material. 
To make use of gene therapy, the introduced DNA has to enter the nuclei of the target cells.  Mulligan and Berg 
(1980) were the first to report successful transfection of cells with recombinant DNA plasmid, using the calcium 
phosphate transfection method.  By 1980, a liposome-mediated transfection method was developed (Fraley et 
al., 1980).  Later in the same decade a polylysine (PLL)-based transfection method was developed (Wu and Wu, 
1987).  In 1995 Boussif et al. demonstrated a polyethyleneimine (pEI) based delivery system.   
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The ever-expanding variety of delivery systems, cell lines, and variety of protocol conditions make a direct 
comparison between different gene delivery studies almost impossible (van Gaal et al., 2011). 
The different methods of transfection can be broadly classified as chemical (Orrantia and Chang, 1990), 
non-chemical (Escriou et al., 1998; Maasho et al., 2004), particle-based (Bertram, 2006), and viral (Fisher et al., 
1996; Jones and Hartl, 1998; Vandenberghe et al., 2006). 
5.1.3.1. Transfection efficiency 
Transfection efficiency is incfluenced by the DNA/reagent complex formation, the incubation time of the DNA 
with the transfection reagent, and the dose of transfection.  The complex formation of the DNA and the 
transfection reagent is influenced by numerous factors, including the ratio of reagent to DNA, the media pH and 
ionic strength, the order of mixing of the reagent, media, and DNA before the transfection (reviewed in van Gaal 
et al., 2011; Riss and Moravec, 2004).  In order to develop a successful production process, the correct 
expression plasmid, host cell, culture medium, DNA quality, and transfection vehicle have to be selected 
(Graham et al., 1977; Pham et al., 2006).  Optimising these factors will ensure the desired level of transfection, 
expression and cellular productivity. 
5.1.4. CELL EXPRESSION SYSTEM 
There are four basic steps in creating a mammalian cell expression system for recombinant protein production.  
First, the vector is constructed to include the gene(s) of interest (GOI) (refer to Basic requirements for a DNA 
vaccine vector in Chapter 4, Section 4.1.2.1, for more detail).  Then preliminary expression is performed for 
evaluation purposes.  Third, stable clones are developed from the cell line, and lastly, the medium should be 
optimised to provide the nutrients for the production clone.  Therefore, there are many parameters that have to 
be taken into account to optimise gene delivery to the nucleus.  The transfection efficiency is dependent on 
factors such as medium composition, cell passaging and seeding, and the protocol used in terms of media 
volume, incubation time, and other parameters (Promega Protocols and Applications Guide). 
5.2. PRELIMINARY INVESTIGATIONS INTO THE EXPRESSION OF THE Ms02 oppA 
GENE IN THE pCI-neo DNA VACCINE VECTOR USING A EUKARYOTIC CELL 
SYSTEM 
5.2.1. INTRODUCTION 
The principle of DNA vaccination is based on the expression of the chosen vaccine candidate gene in the 
eukaryotic host.  Good vaccine candidate genes are the genes that encode for attachment proteins involved in 
cytadherence, as well as proteins located on the surface of the pathogen, and proteins involved with essential 
cellular functions.  Once an appropriate antigenic gene is chosen, the gene is cloned into a DNA vaccine vector 
and injected into the host.  Inside the host cells, the plasmid is then expressed, resulting in the production of the 
recombinant antigenic protein.  Since the protein is recognised as foreign by the host’s immune system, 
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an immune response is launched against the protein.  In this manner the host produces antibodies and memory 
cells against the antigen, enabling it to protect itself against infection by the pathogenic organism.  
Different DNA vaccine vectors have different expression profiles, thus resulting in different levels of the elicited 
immune response.  Ostrich DNA vaccine trials where the ostrich sera are tested in serological assays, such as 
enzyme-linked immunosorbent assays (ELISAs), measure the immune response against the expressed protein 
that was produced in the ostrich host.  In cases where no immune response is detected, it does not necessarily 
indicate the absence of an ostrich immune response, but could indicate that the vector did not express correctly 
in the ostrich (or other eukaryotic host).  Therefore, in order to corroborate vaccine trials, it is necessary to 
confirm protein expression in a eukaryotic system, so that future vaccination trials are conducted with the prior 
knowledge that the vaccine vector does express correctly in eukaryotic cells.  One way to confirm protein 
expression is to investigate the expression profile of the plasmid in a cell culture system.  Antibodies against the 
protein indicate the presence of the recombinant protein, thus confirming expression of the DNA vaccine vector. 
In order to develop a DNA vaccine against the ostrich mycoplasma Ms02, the oppA gene was cloned into three 
DNA vaccine vectors, namely pCI-neo, VR1012 and VR1020 (Chapter 4).  Purified OppA protein was injected 
into rabbits to generate OppA antibodies (Section 4.2.2.8).  In this study, the pCI-neo DNA vaccine vector was 
used to transfect mammalian cells.  The OppA antibodies were used to detect possible expression of the 
recombinant protein in the cell culture system.  
5.2.2. EXPERIMENTAL PROCEDURES 
5.2.2.1. Preparation of the pCI-neo_OppA vector to be used in transfection 
In order to prepare the DNA for transfection into the mammalian cells, it was first necessary to increase the 
amount of vector available.  To obtain a large volume of cell culture that contain the pCI-neo_OppA vector, 
a freeze culture of E. coli JM-109 cells (Promega), containing the vector, was streaked onto Luria-Bertani (LB) 
plates with 15 g/L agar, supplemented with 1 µl/ml (100 µg/ml) ampicillin (Sigma-Aldrich).  The plates were 
incubated for 16 h at 37°C before colony formation was analysed. 
5.2.2.1.1. Diagnostic PCR to confirm the presence of the pCI-neo_OppA vector 
Before starter cultures were made for the isolation, a diagnostic PCR was performed to ensure the picked 
colonies did contain the pCI-neo_OppA vector.  From the plates, 8 colonies were picked to serve as a DNA 
template in a diagnostic PCR.  Approximately half of each of the chosen colonies were scraped with a sterile 
toothpick and mixed in respective reaction tubes containing 1 µl of 10x Reaction buffer, 0.1 µl of 5 U/µl 
Super-Therm Taq DNA polymerase, 0.6 µl of 25 mM MgCl2 (all from JMR-Holdings, USA), as well as 0.4 µl of 
5 mM dNTPs (Bioline), 0.5 µl of each primer (20 pmol/µl), and 6.9 µl of Milli-Q® water.  The forward primer 
T7EEV (5’-AGGGCTAGAGTACTTAATACG-3) and the reverse primer T3 (5’-AATTAACCCTCACTAAAGGG-3’) 
were used to amplify the gene insert.  The amplifications were carried out in a 2720 Thermal Cycler Version 2.09 
(Applied Biosystems Ltd., Warrington, UK) as follows: initial denaturation of 10 min at 94ºC, followed by 
25 cycles of 94ºC for 30 s, 55ºC for 30 s, and 72ºC for 30 s, with a final extension step at 72ºC for 7 min.  
The PCR products were analysed on an 1% (w/v) agarose gel as described in Chapter 3, Section 3.2.2.4. 
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5.2.2.1.2. Large scale isolation of the pCI-neo_OppA vector 
Four single positive colonies were then inoculated into respective Erlenmeyer flasks containing 10 ml LB-
medium, supplemented with 10 µl (100 µg/ml) ampicillin and incubated on an IKA® KS 260 Basic orbital shaker 
for 8 h at 37°C, while being agitated at 220 rpm.  After the 8 h growth, each 10 ml culture was then diluted in 100 
ml fresh LB/amp-medium and allowed to grow for a further 12 h at 37°C, while being agitated at 220 rpm.  
The cells were harvested by centrifugation at 6 000 x g for 10 min (4°C) and the supernatant was discarded as 
effectively as possible.  Thereafter the NucleoBond® Xtra Maxi kit (Macherey-Nagel, Germany) was used to 
purify the vector according to the manufacturer’s instructions, save a few differences.  In short, the cell pellet was 
resuspended in 18 ml Resuspension buffer (RES-EF) + RNaseA by pipetting up and down so that no clumps 
remained.  To lyse the cells, 18 ml Lysis buffer (LYS-EF) was added to the suspension and the tube inverted 
5 times by hand, followed by a 5 min incubation step at room temperature.  During the incubation step, the 
NucleoBond® Xtra Column with the inserted column filter was equilibrated by applying 35 ml Equilibration buffer 
(EQU-EF) onto the rim of the column filter.  After this step, care was taken that the column did not run dry.  
To neutralise the lysis buffer, 18 ml Neutralisation buffer (NEU-EF) was added and the lysate gently mixed by 
inverting 15 times, followed by 5 min incubation on ice.  Before applying the lysate to the equilibrated column 
filter, the suspension was inverted 3 times, ensuring a homogenous mixture to avoid clogging the filter.  The filter 
was washed with 15 ml Equilibration buffer (FIL-EF) to wash out the remaining lysate.  The column filter was 
then discarded and the column washed with 90 ml Wash buffer (ENDO-EF), and allowed to empty by gravitation.  
This was followed by another wash step with 45 ml Wash buffer (ENDO-EF).  The DNA was then eluted with 
15 ml Elution buffer (ELU-EF) and collected in a 50 ml centrifuge tube.  The elution was filtered through the 
NucleoBond® Finalizer (a DNA-binding column) and the flow-through discarded.  The NucleoBond® Finalizer was 
washed with 70% ethanol, after which care was taken to dry the NucleoBond® Finalizer as completely as 
possible by plunging down a few times with the plunger with the NucleoBond® Finalizer attached.  To elute the 
vector, 400 µl H2O-EF was pressed through the NucleoBond® Finalizer, transferred back into the syringe and 
pressed through again.  This was repeated twice again with 400 µl fresh H2O-EF.  
5.2.2.1.3. Determination of the quality and quantity of the pCI-neo_OppA vector 
The concentration and quality of the isolated vector were determined spectrophotometrically with the Novell® 
Nanodrop ND-1000 (v 3.5.1) at 260 nm.  Concentration (ng/µl) and purity (A260/A230 and A260/A280) were 
measured.  The vector was loaded onto an agarose gel in order to ascertain the topology and purity (Section 
3.2.2.4). 
5.2.2.1.4. Restriction enzyme treatment of the pCI-neo_OppA vector with MluI and AccI 
The pCI-neo_OppA vector was constructed as described in Chapter 4, Section 4.2.2.2.  The vector had a MluI 
recognition sequence on the 5’ end and an AccI recognition sequence on the 3’ end of the Ms02 oppA gene.  
The vector was first subjected to digestion with the restriction endonuclease (RE) MluI in two 20 µl reactions 
each containing Milli-Q® water, 2 µl 10x RE buffer, 0.2 µl (10 mg/ml) acetylated bovine serum albumin (BSA), 1 
µg of the vector, and 1 µl of 10 U/µl of MluI (Promega).  Both the reactions were incubated at 37ºC for 1 h, 
followed by purification with the DNA Clean & Concentrator™-5 kit (Zymo Research) according to the 
manufacturer’s instructions.  One of the reactions was then treated with the AccI endonuclease.  The 20 µl 
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reaction contained 2 µl of 10x RE buffer, 0.2 µl (10 mg/ml) acetylated BSA, 8 µl of the purified DNA, and 1.7 µl of 
6 U/µl AccI (Promega), and Milli-Q® water to make up the volume.  After 1 h incubation at 37°C, the product was 
purified with the DNA Clean & Concentrator™-5 kit.  In order to analyse the digestion products, 10 µl of each of 
the reactions were separated on a 1% (w/v) agarose gel, together with 2 µl of the uncut pCI-neo_OppA vector 
(Section 3.2.2.4). 
5.2.2.2. Cell culture  
The cell line MDA (human breast carcinoma cells) was kindly provided by Ms CJ Langeveldt from the Donita 
Africander’s Reasearch Group, Department of Biochemistry, University of Stellenbosch (RSA).  Cultures were 
maintained in 75 cm3 culture flasks (Greiner Bio-One Int., Austria) in high glucose (4.5 g/ml) Dulbecco’s Modified 
Eagle Medium (DMEM) (Sigma-Aldrich), supplemented with 10% heat inactivated fetal calf serum (FCS), 100 (1 
U/ml) penicillin (Sigma-Aldrich) and 100 µg/ml streptomycin (Sigma-Aldrich) at 37°C in an atmosphere of 90% 
humidity and 5% CO2.  Cells were plated at 1.25 x 105 cells per well in 12-well plates (Greiner Bio-One) the day 
before transfection. 
5.2.2.3. Transfection with the pCI-neo_OppA vector 
In order to transfect the cells, the FuGENE® 6 Transfection Reagent (Promega) was used, a propriety blend of 
lipids and other components.  The non-liposomal lipids and polymers form complexes with DNA, with the 
potential to form micelles.  Performing transfection under aqueous conditions enables the lipophilic portion of the 
ampiphilic compound to form the micelle core within which the exogenous nucleic acids are ensconced.  
Four different vector amounts were transfected, namely 0.5 µg, 1.0 µg, 1.5 µg and 2.0 µg.  Each was done in 
triplicate.  For every µg of vector DNA, 4.5 µl FuGENE® 6 was added.  The transfection reagent was added first 
to a serum-free medium, before it was added to the DNA.  After mixing, the transfection reagent/medium/DNA 
was incubated for 30 min.  During this time, the media on the adherent cells were aspirated and replaced with 
1 ml supplemented medium.  The appropriate amount of plasmid mixture was added to the wells, the plate 
swirled to mix, and returned to the incubator.  Two 12-well plates were transfected.  The cells were then 
harvested from one plate after 24 h and from the other plate after 48 h.  The media from the cells were stored at 
-20°C.  The cells were washed by adding 1 ml PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4·2H2O, and 
2 mM KH2PO4, pH 7.2) to each well, with care taken not to disturb the cells on the bottom of the well.  After the 
PBS was aspirated, 80 µl SDS lysis buffer (0.125 M Tris-HCl, 4% (m/v) sodium dodecyl sulfate (SDS), 20% (v/v) 
glycerol, 10% (v/v) β-mercapto-ethanol, pH 6.8), with added 0.1% (m/v) bromophenol blue) was added to each 
well.  The buffer was mixed thoroughly inside the well with the pipette tip to ensure all the cells were loosened 
and suspended in the buffer, thus ensuring complete lysis.  The cell samples were then incubated at 97°C for 
10 min before storage at -80°C. 
5.2.2.4. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis 
SDS-PAGE was used to analyse the expression profiles of the cells, as well as detect whether any proteins were 
present in the media.  For this purpose, samples were loaded onto a denaturing SDS gel composed of a 4.5% 
stacking and an 8% resolving gel, and electrophoresed at a constant of 20 mA.  The media samples needed to 
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be prepared first, as the cell samples already contained the reducing treatment buffer and the loading dye, 
added during the cell harvesting procedure.  In order to prepare the media samples for SDS-PAGE, 30 µl of 
medium was added to 30 µl of SDS lysis and the mixture boiled for 2 min before being placed on ice.  In the 
same manner, 20 µl of the purified Ms02 GST-OppA protein was prepared, as well as 30 µl of a previously 
expressed pGEX_OppA cell culture as control samples.  
5.2.2.5. Western blot analysis 
For detection of the expressed Ms02 OppA protein in the cell cultures, the same antibodies and basic procedure 
were used as described in Chapter 4, Section 4.2.2.8.3.  A few optimisations were performed in order to 
increase the signal-to-noise ratio, mainly regarding the blocking buffer.  An SDS-PAGE was performed as 
described above.  The separated proteins were transferred to a 0.45 µm nitrocellulose membrane (Schleicher 
and Schuel, Sigma-Aldrich) in an electrode buffer (50 mM Tris-HCl, 200 mM glycine and 20% (v/v) methanol, pH 
8.3) for 16 h at a constant of 120 mA.  After the transfer, the membrane was stained with Ponceau S (2% (w/v) 
Ponceau S in 30% trichloroacetic acid and 30% sulfosalicylic acid) to ensure that sufficient transfer was 
achieved.  Staining was allowed to occur for 5 min at room temperature while being agitated, followed by 
destaining for 2 min with Milli-Q® water before the membrane was investigated, and a final destaining for 10 min.  
The membrane was then blocked for 2 h at room temperature, while being agitated, in TBST blocking buffer 
(20 mM Tris-acetate, 150 mM NaCl, and 0.1% (v/v) Tween-20), with 5% (w/v) fat free milk powder (Elite, 
available from any convenience store).  The rabbit serum was diluted 1:500 in TBST blocking buffer and 
incubated with the membrane for 1 h at 37°C at 4 rpm.  This was followed by 3 wash steps of 10 min each with 
TBST at room temperature, while being agitated.  The secondary antibody, goat anti-rabbit antibody (Sigma-
Aldrich) was diluted 1:2000 in TBST blocking buffer and the covered membrane incubated for 1 h at 37°C, while 
being agitated.  This was followed by 3 wash steps as described above.  Lastly, the horse-radish peroxidase 
(HRP)-conjugated rabbit anti-goat antibody (Sigma-Aldrich) was diluted 1:2 000 in TBST blocking buffer and 
incubated as before, followed by the 3 wash steps.  An additional 3 washes were performed with TBS buffer 
without the Tween-20 to remove the excess Tween-20 from the membrane.  Ice-cold substrate, consisting of 
0.05% (w/v) 4-chloro-1-naphtol, 16% (v/v) ice cold methanol, ice cold TBS and 0.025% (v/v) cold H2O2, was 
added to the nitrocellulose membrane and allowed to develop for 30 min at room temperature, while being 
agitated.  After band development was observed, the membrane was washed with Milli-Q® water to prevent 
over-development. 
For the Western dot blot analysis, the membrane was dotted with approximately 25 µl media, but in separate 
steps.  Every 15 min, 5 µl of the medium from the 4 different transfections, was added drop-wise onto the 
membrane.  After the last 5 µl medium was added, the membrane was allowed to dry for at least one hour.  
Thereafter, the membrane was incubated overnight in TBST blocking buffer at 4°C.  The rest of the protocol 
remained the same. 
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5.2.3. RESULTS 
5.2.3.1. Diagnostic PCR to confirm the presence of the pCI-neo_OppA vector 
To prepare a starter culture for the large scale isolation of the pCI-neo_OppA vector, freeze cultures of the 
E. coli JM-109 cells containing the vector was first streaked out on LB/agar plates.  A diagnostic PCR was 
performed to identify colonies that contained the vector with the insert.  From the eight colonies tested, only one 
did not contain the pCI-neo_OppA vector (Figure 5.1).  It was decided to use colonies 1-4 for starter cultures.  
 
 
Figure 5.1 Image of the products from the diagnostic PCR on the cultures containing the pCI-neo_OppA vector.  The 
products were separated on a 1% (w/v) agarose gel, cast with 0.1 µl/ml GelRedTM Nucleic Acid Gel Stain for UV visualisation 
of the DNA.  Lane 1: 1 KB DNA GeneRulerTM DNA ladder mix.  Lane 2-9: PCR product of colonies 1-8. 
5.2.3.2. Isolation of the pCI-neo_OppA vector 
The pCI-neo_OppA vector was isolated from a culture volume of 400 ml, which resulted in 1 736 ng/µl vector in 
an elution volume of 800 µl.  The vector was subjected to restriction enzyme digestion to indicate the sizes.  
The conformation of plasmid DNA influences its migration during agarose separation.  Five different 
conformations can occur.  In order of slowest migration to fastest: nicked open-circular DNA (one strand cut); 
relaxed circular DNA (fully intact, but no supercoiled structures); linear DNA (either both strands have been cut, 
or the DNA exists in a linear form in vivo); supercoiled (DNA is fully intact with an integral twist, resulting in a 
compact form); and supercoiled denatured (slightly less compact than supercoiled, due to unpaired regions that 
may be caused by excessive alkalinity during plasmid preparation).  Supercoiled DNA migrates faster than linear 
or open DNA due to its tight conformation.  In order to indicate the size of the pCI-neo_OppA vector, it was cut 
with only one restriction enzyme (resulting in linear DNA), and with both restriction nucleases (resulting in the 
excised oppA gene and the linear vector without the gene), seen in Figure 5.2.  The pCI-neo vector on its own is 
1       2        3      4      5     6        7       8      9 
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5472 bp in length, the Ms02 oppA gene is 2 997 bp in length, thus accounting for an approximate added size of 
8 500 bp.  Thus the larger band as seen lane 5, that corresponds to the band seen in lane 4, represents the 
incomplete digestion (linearisation) of the vector, followed by a band that represents the linear vector without the 
oppA gene, and lastly the excised oppA gene itself. 
 
 
Figure 5.2 Image depicting the different conformations of the pCI-neo_OppA vector after electrophoretic separation.  The 
nicked plasmid is indicated with an arrow.  The products were separated on a 1% (w/v) agarose gel cast with 0.175 µg/ml 
ethidium bromide for UV visualisation of the DNA.  Lane 1 and 7: 5 µl of 1 KB DNA GeneRulerTM DNA ladder mix.  Lanes 2 
and 6 were left empty.  Lane 3: uncut pCI-neo_OppA vector.  Lane 4: pCI-neo_OppA vector cut with only MluI.  Lane 5: pCI-
neo_OppA vector cut with MluI and AccI. 
5.2.3.3. SDS-PAGE of the transfected cells and media 
An SDS-PAGE was performed to determine whether any proteins in the media or transfected cells corresponded 
to the size of the purified OppA protein.  Figure 5.3 is an SDS gel illustrating the OppA protein sizes, both as a 
purified fusion protein and as part of an expressed cell suspension.  The media from the transfected cells were 
compared and, according to the protein sizes as observed on the SDS gel, it is possible that there was OppA 
protein present.  The OppA protein would be expressed without the GST protein, since the GST tag is a result of 
expression in the prokaryotic expression vector pGEX-4T-1.  Thus the size of the mammalian expressed protein 
should correspond to the smaller size as visible in the Ms02 GST-OppA protein sample, the argument being that 
the smaller OppA protein is a result of the removal of the GST protein tag from the OppA protein.  A light protein 
band in the media samples as separated in the SDS gel is visible that corresponds to the size of the smaller 
protein band (above 102 kDa).  However, the amount of protein in the SDS sample is too low to allow definite 
conclusions, and the amount of sample loaded onto an SDS gel cannot be increased, due to the size of the 
wells. 
1         2       3       4       5       6       7  
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Figure 5.3 Media from the transfected eukaryotic MDA cells compared with Ms02 GST-OppA protein as a purified protein 
and as part of a prokaryotic cell expression sample.  The proteins were separated on an 8% SDS gel.  Lane 1: Full-range 
Rainbow marker. Lane 2: purified Ms02 GST-OppA protein.  Lane 3: pGEX_OppA cell suspension sample.  Lane 4: 0.5 µg 
transfected cell medium48h.  Lane 5: 2.0 µg transfected cell medium48h.  The Ms02 GST-OppA protein is indicated on the SDS 
gel with an arrow. 
5.2.3.4. Western blot analysis 
5.2.3.4.1. Ponceau S stain of the separated proteins 
Ponceau S is a stain used to stain all of the proteins after transfer to a nitrocellulose membrane.  In Figure 5.4, 
an image of such a stain can be seen.  In this instance, both the transfected cells and the media were separated 
on an 8% denaturing SDS gel, together with purified GST-OppA protein as a positive control, and transferred to 
the nitrocellulose membrane.  From the image it is clear that the SDS gel did not run uniformly, and that the 
proteins did not run in a straight line.  During electrophoresis of the SDS gel, the observed front that is usually 
blue, changed colour as the proteins separated on the gel.  When the media were concentrated and separated 
on an SDS gel, the samples were skewed and blotchy, as is also visible in the figure below.  This was only 
observed when the media were separated: when only the cells were separated the same effect was not 
observed.  This led to the conclusion that components of the media may possibly interfere with the normal 
separation on the SDS gel, and this could lead to a further influence on the western blot analysis. 
The GST-OppA protein is indicated on the membrane with an arrow.  The second protein band, which then 
represents the Ms02 OppA protein without the GST protein, is barely visible, and the same size band is also 
barely visible in the media samples.  This is a promising result, and first a western dot blot was attempted on the 
media. 
1           2          3        4        5  
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Figure 5.4 Ponceau S stain of the nitrocellulose membrane containing eukaryotic expressed proteins from the transfected 
MDA cells and media compared to the purified Ms02 GST-OppA protein.  The proteins were seperated and transferred from 
an 8% SDS gel.  Lane 1: Full-range Rainbow marker.  Lane 2: purified GST-Ms02 OppA protein.  Lane 3: 0.5 µg transfected 
cell24h.  Lane 4: 0.5 µg transfected cell medium24h.  Lane 5: 2.0 µg transfected cell24h.  Lane 6: 2.0 µg transfected cell 
medium24h.  The Ms02 GST-OppA protein is indicated on the SDS gel with an arrow. 
5.2.3.4.2. Western blot with the anti-OppA antibody 
An SDS gel loaded with the samples from 24 h as well as 48 h indicated that the amount of proteins (intensity of 
the bands on the SDS gel) were more after 48 h (results not shown).  Therefore, it was decided to test only the 
48 h cell harvest for protein expression. 
The dot blot seemed to indicate the presence of OppA protein in the media.  Direct comparisons between the 
intensity of the blots according to their concentrations of transfected vector cannot be made, due to the varying 
amount of medium that was dotted onto the membrane.  The experiment was done as a preliminary and quick 
method of detecting the presence of proteins.  No reactions were detected in the dot blot with the lysed cell 
samples (results not shown).  
 
Figure 5.5 Western dot blot analysis on the media of the transfected cells harvested at 48 h.  The concentrations of the 
pCI-neo_OppA vector that were used in the transfection of the MDA cells are indicated below its respective dot. 
In Figure 5.6, the image of the western blot after SDS-PAGE separation can be seen.  Only the purified Ms02 
GST-OppA protein reacted with the anti-OppA rabbit antibodies (lane 2).  However, bands were visible in the 
medium samples at a size just larger than 52 kDa, indicated by the arrows.  This is thought to be due to 
non-specific binding, which would be explain by the western dot blot analysis.  The sizes of the bands detected 
with the western blot corresponds to the size of the major protein present in the media samples, clearly visible in 
1          2          3          4          5          6 
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Ponceau S, although the bands were less visible.  No bands of the same size were detected in the cell samples, 
but the cell samples contained significantly lower numbers and amount of proteins than the media samples.  
However, the western blot performed on the cells and media after separation in an SDS-PAGE did not result in 
any detectable bands, except for detection of a band of just larger than 52 kDa in size.  It is thought that this was 
what accounted for the dot blot protein detection, and that the binding activity detected was only due to non-
specific binding.  From the start it was clear that the amount of protein in the lysed cell samples was too small to 
allow definite conclusions based on the SDS analysis.  Due to the limitations of an SDS gel, a larger sample 
volume cannot be loaded and the recombinant protein may not be visible, and overloading the gel has negative 
consequences.  This may be corrected for by using later harvesting times to enrich the transfection samples with 
OppA protein.  Dialysis could also be considered, both for the protein samples and the media samples, to ensure 
a sample that is less contaminated with salts and small, unwanted proteins. 
The western blot analysis of the proteins was performed on a colorimetric basis, a technique that is low in 
sensitivity.  Other western blot techniques, utilizing chemiluminescence, may provide a better option for the 
detection of the OppA protein, due to the increased sensitivity of the technique.  Preliminary optimisations with 
the chemiluminescent technique indicated a low signal-to-noise ratio, something that was improved when the 
blocking buffer was changed to contain a different form of casein, as well as a higher concentration of casein.  
However, there was still too high background to allow any definite conclusions.  This method could be explored 
further, due to its numerous advantages. 
The eubacterial secretion signal that is responsible for directing proteins across the cell membrane, is also 
present in mycoplasma proteins (Henrich et al., 1999).  Studies have shown that prokaryotic signal peptides are 
active in eukaryotic cells, directing the protein towards the medium in transfection studies (Hall et al., 1990; 
Williamson et al., 1994).  The signal peptide sequence of the Ms02 oppA gene was not removed prior to cloning 
into the DNA vaccine vectors, since studies showed that genes containing a signal peptide are more 
immunogenic than the same genes without a signal peptide, irrespective of whether it is a eukaryotic or 
prokaryotic signal peptide (Baldwin et al., 1999; Drew et al., 2000; Haddad et al., 1998; Kammath et al., 1999).  
This could indicate that the expressed OppA protein in a cell culture system may be directed out of the cell and 
into the medium.  However, the prokaryotic signal may not have been functional in these mammalian cells.  
The two other DNA vaccines, VR1012_OppA and VR1020_OppA also need to be tested.  The VR1020 vector 
contains a eukaryotic signal peptide, and should eliminate doubt regarding pCI-neo’s prokaryotic signal peptide 
efficiency.  The Vical vectors are also slightly smaller than the pCI-neo vector (both approximately 500 bp), 
and could transfect more easily. 
Different cells may also be transfected.  Although no ostrich cell cultures are available yet to transfect, 
an acceptable choice would be to use bird cells, such as chicken cells.  The KCEL cell line was established from 
chicken embryonic lung, which might have been a better choice (Kadoi, 2010).  Due to import constraints 
throughout this study’s time period, it was not possible to obtain chicken cells, and the transfection was therefore 
carried out in human cells. 
Another factor to consider is stable transfection, where the antibiotic resistance genes of the vaccine vectors can 
be employed to ensure optimal transfection.  In transient transfection, employed in this study, the efficacy 
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of transfection is one of the limiting factors, since transfection efficiency is dependant on the number of cells that 
are taken up and express the protein.  Transfection efficiency should also be determined, for instance by using 
reporter genes. 
5.2.5. CONCLUSION 
In this study an attempt was made to prove expression of the OppA protein as a result of transfection with 
pCI-neo_OppA DNA vaccine vector in a eukaryotic cell system.  The failure to detect any expressed protein 
could be due to a lack of expression, because of a nonfunctional signal sequence, or the levels of expression 
are too low for detection with the presently used detection system.  However, there are still numerous 
optimisation strategies that could be explored: different cell lines need to be tested, later harvesting times could 
be necessary, and a different western blot detection technique, such as chemiluminescence, should be 
investigated as well. 
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Chapter 6 
6.   
6.1. CONCLUSIONS AND FUTURE PERSPECTIVES 
Most of the Ms02 genome was previously sequenced and preliminary annotated.  The assembly of the 
generated sequences resulted in 28 large contiguous sequences, which were reduced to 14 in this study.  
A PCR technique developed by Liu and Whittier (1995) called Thermal Asymmetric Interlaced Polymerase Chain 
Reaction (TAIL-PCR) was used to accomplish the partial linkage of the large Ms02 contigs.  Knowing the gene 
content as determined by the previous preliminary annotations, predictions were also made as to the orientation 
and linkages of the 14 contigs that were produced.  This was done in order to attempt to locate the origin of 
replication and to establish if the TAIL-PCR linkages were correct, by subjecting the linked Ms02 genome 
sequence to open reading frame (ORF) analysis.  ORFs that were located across two linked contigs, or on the 
additional sequences that were produced by sequencing the TAIL-PCR products, were further investigated and 
used in a BLASTx search to determine their gene annotations.  This resulted in three predictions of linkages 
between contigs that were not linked using the TAIL-PCR technique.  This warrants further investigation, as well 
as completion of the rest of the genome sequence.  One observation during the assembly of the genome was 
the extent of repeats present, a common feature of mycoplasmas.  Thus the genome was also subjected to 
repetitive sequence analysis, from large repeats to microsatellites to mononucleotide repeats.  
Further investigations are required to obtain a true representation of the repetitive nature of the Ms02 genome, 
but thus far it has been shown to affect the assembly of the contigs.  Therefore, it is also suggested to repeat the 
sequencing of the Ms02 genome with paired-end technology, which will allow mapping of the resultant 
sequences, and so one would be able to orientate the contigs to their positions relative to one another. 
This study produced three DNA vaccine vectors by cloning the Ms02 oppA gene into pCI-neo, VR1012, and 
VR1020, frequently used DNA vaccine vectors, for future vaccine efficacy trials.  In order to obtain purified OppA 
protein, the gene was also cloned into the prokaryotic expression vector pGEX-4T-1.  The protein was 
expressed with a GST-tag to allow for affinity purification.  After purified fusion protein was obtained, it was used 
to immunise a rabbit in order to obtain anti-OppA antibodies.  These antibodies can be used for the detection of 
OppA in other studies. 
The pCI-neo vector was used in a preliminary study to detect expression of the OppA protein in a cell culture 
system.  MDA cells were transfected with the pCI-neo_OppA vector and the transfected cells were harvested at 
24 h and 48 h.  Due to the presence of the prokaryotic secretion signal in the Ms02 oppA gene, the possibility 
existed that the protein could be exported out of the cell and would therefore reside in the medium.  
However, expression of the protein could not be shown.  Using a colorimetric western blot on the cell samples 
did not result in any detectable reaction between the cell sample and the anti-OppA rabbit antibodies produced 
in this study.  It is concluded that the transfection studies should be repeated in different cell types, as well as 
repeated with the other two vaccine vectors.  Different detection methods of the transfected expressed protein 
should also be investigated, such as the use of chemiluminescent western blotting. 
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Future studies should also include ostrich vaccine trials, since an interesting observation by Fynan et al. (1993) 
indicates that efficiency of transfection does not necessarily determine the efficiency of vaccination.  Ideally, one 
would like to develop a single vaccine for all three of the ostrich mycoplasmas; however, the cross-reactivity thus 
far is too low to use the vaccine developed for one of the ostrich mycoplasmas to protect against the other two 
as well.  Options to overcome this include identifying other possible vaccine candidate genes and developing 
a multivalent (multi-component) vaccine to induce immunity simultaneously against all three mycoplasmas.  
Other possibilities include the use of a delivery system of the vaccine to the host.  The ostrich mycoplasmas 
affect the upper respiratory tract of the ostriches; as such mucosal immunity might be optimal in preventing 
infection.  Using carriers such as Salmonella may prove to be beneficial in developing quick, localised immunity.  
When successful vaccines have been developed, the concept of DNA-protein prime-boost regiments should be 
investigated.  By vaccinating with a DNA vaccine and boosting with protein, the immune response elicited 
is longer and more pronounced than otherwise.  The recombinant OppA protein produced in this study could 
therefore be of particular value for use as a booster protein, after priming with the DNA vaccines developed 
in this study. 
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Addendum A 
Analysis of the distribution of essential genes and ORFs across the contigs of the Ms02 genome 
Table A. Previous annotation results illustrated for each contig, with the essential gene and ORF distribution, to predict the direction of the contig. *NEI: Not enough 
information.  Contig 16, 37 and 39 were not included, since they were not annotated previously. 
      
Essential genes Total genes 
  
Contiguous sequence Size (Kbp) ORFs total + strand - strand + percentage + strand - strand + percentage Predicted direction 
contig00001 17530 17 6 2 75 14 3 82 + 
contig00002 1268 1 / / / 1 / 100 NEI* 
contig00003 1204 1 / / / / 1 0 NEI* 
contig00004 24502 27 1 10 9 10 17 37 - 
contig00006 25664 6 / / / 3 3 50 NEI* 
contig00007 86160 43 3 9 25 10 33 23 - 
contig00008 54571 49 7 10 41 18 31 37 - 
contig00009 5851 8 / 2 0 / 8 0 NEI* 
contig00010 12270 14 4 4 50 6 8 43 NEI* 
contig00011 1800 2 / 1 0 / 2 0 NEI* 
contig00012 39046 28 1 2 33 20 8 71 NEI* 
contig00013 71894 60 12 8 60 24 36 40 NEI* 
contig00014 67524 37 4 14 22 6 31 16 - 
contig00015 75929 61 17 6 74 40 21 66 + 
contig00017 2262 2 / / / 2 / 100 NEI* 
contig00026 9174 2 / / / 1 1 50 NEI* 
contig00029 111665 81 8 22 27 29 52 36 - 
contig00030 127294 115 12 32 27 40 75 35 - 
contig00031 27764 13 / 1 0 6 7 46 NEI* 
contig00032 37340 31 3 8 27 10 21 32 - 
contig00033 4870 2 2 / 100 2 / 100 NEI* 
contig00034 36348 42 31 / 100 38 4 90 + 
contig00038 1089 2 / / / / 2 0 NEI* 
contig00041 43856 27 3 6 33 12 15 44 - 
contig00044 5319 4 1 1 50 4 / 100 NEI* 
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Addendum B 
Sequences of the origin of replication of the Ms02 genome 
Ori-Finder 
Ori sequence as detected by the Ori-Finder.  The three DnaA boxes are indicated in bold and capital letters.  
The sequence is located 866359-866821 bp in the Ms02 genome. 
taaacctattttttgtttttctttttggatgtaagaagtttcgatgtcatttagaagcctcccgatcttaacctgctcattta
ttgaaggattcattataggcattgtgtgtagtacatcttcctttattacgaatcttcttgctttagctcctgtttctctattg
aaaaaaataaatttatgtcagtaatttgataagaaaaagTTTTCCAAAaagtcgttggaaatatcatgcgttttaaaaacata
gtaaagtgaagaagttactcctgtaattcctgttttatttctctttattgacccgtacaagaacccTTTGGATAAtgaTGTTG
AAAAaatgaaactgttcggttcaactaatcaataacctttcattgtttcttttgaaggagtcatatcttgatcaaaaaagtct
gattgcctaacaacaccgtattttgcagtgctagttagtgtaatcgag  
DoriC 
Ori sequence as detected by the DoriC finder located 561223-561339 bp in the Ms02 genome.  DoriC is a 
database containing numerous oris.  The following sequence has an 84% identity with M. hyorhinis HUB-1 
chromosome. 
ttttctacctttagctcttctagcagctaaaacttttctaccgttagcagttttcattcttgctctaaaaccgtgaaccttag
cgtgtttacgtttgtttggttggtatgttctttt 
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Addendum C 
Table of the ORFs that occur over the newly linked contiguous sequences of the Ms02 
genome 
Table C. The first most significant hits obtained from BLASTx searches on the Ms02 genome in the NCBI 
database, employing the mitochondrial genetic code. 
Query range Contig Accession number Description Bit 
score 
E-value 
13…1137 3 YP_003515791.1 
Type I R/M system specificity 
subunit [Mycoplasma 
agalactiae] 
270 1e-25 
2014…3204 16_2 YP_003515788.1 
Type I R/M system specificity 
subunit [Mycoplasma 
agalactiae] 
182 3e-14 
29114…30391 6_7 YP_003515788.1 
Type I R/M system specificity 
subunit [Mycoplasma 
agalactiae] 
254 2e-23 
113762…115246 7_17 ZP_08703696.1 
PTS system lactose/cellobiose 
family IIC subunit 
[Mycoplasma anatis 1340]  
1228 7e-164 
115246…116337 7_17 ZP_08703694.1 Outer surface protein [Mycoplasma anatis 1340] 1095 5e
-147
 
146983…147924 37_39 YP_003515788.1 
Type I R/M system specificity 
subunit [Mycoplasma 
agalactiae]  
139 5e-09 
202935…203603 8_AS ZP_10029432.1 Beta-phosphoglucomutase [Mycoplasma canis UF31]  624 5e
-80
 
203853…204833 AS_15 YP_003560335.1 
Hypothetical protein 
MCRO_0736 [Mycoplasma 
crocodyli MP145]  
457 1e-52 
280435…281040 38_AS YP_004683700.1 ISMbov4 transposase [Mycoplasma bovis Hubei-1]  643 2e
-80
 
305562…306290 41_start ZP_14232350.1 Asparaginyl-tRNA synthetase [Mycoplasma canis UF33]  118 2e
-06
 
347720…349663 41_AS ZP_08703784.1 Transketolase [Mycoplasma anatis 1340]  2623 0 
361746…362387 10_AS YP_004790383.1 
Type I restriction modification 
DNA specificity protein 
[Mycoplasma putrefaciens 
KS1]  
140 8e-10 
368936…370081 end_11_12 YP_003515788.1 
Type I R/M system specificity 
subunit [Mycoplasma 
agalactiae] 
180 1e-16 
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Table C. The first most significant hits obtained from BLASTx searches on the Ms02 genome in the NCBI 
database, employing the mitochondrial genetic code. 
Query range Contig Accession number Description Bit 
score 
E-value 
884164…884514 1_26 ZP_02931917.1 
DNA gyrase, B subunit 
[Ureaplasma urealyticum 
serovar 13 str. ATCC 33698]  
77 0.048 
893663…894826 26_44 YP_003515791.1 
Type I R/M system specificity 
subunit [Mycoplasma 
agalactiae]  
274 8e-26 
146972…145299 AS_37 YP_002961132.1 
Transposase IS1634AM 
[Mycoplasma conjunctivae 
HRC/581] 
1441 0 
203699…203821 AS YP_004137136.1 
Hypothetical protein 
MfeM64YM_0762 
[Mycoplasma fermentans 
M64]  
110 2e-08 
866822...866980 32_1 ZP_20412978.1 
Type I R/M system specificity 
subunit domain protein, partial 
[Mycoplasma sp. G5847]  
63 0.071 
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